WO2006019965A2 - Dipeptidyl peptidase inhibitors - Google Patents

Dipeptidyl peptidase inhibitors Download PDF

Info

Publication number
WO2006019965A2
WO2006019965A2 PCT/US2005/025070 US2005025070W WO2006019965A2 WO 2006019965 A2 WO2006019965 A2 WO 2006019965A2 US 2005025070 W US2005025070 W US 2005025070W WO 2006019965 A2 WO2006019965 A2 WO 2006019965A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
phenyl
group
aminomethyl
amino
Prior art date
Application number
PCT/US2005/025070
Other languages
French (fr)
Other versions
WO2006019965A3 (en
Inventor
Jun Feng
Steven Gwaltney
Betty Lam
Zhiyuan Zhang
Original Assignee
Takeda San Diego, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda San Diego, Inc. filed Critical Takeda San Diego, Inc.
Publication of WO2006019965A2 publication Critical patent/WO2006019965A2/en
Publication of WO2006019965A3 publication Critical patent/WO2006019965A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Definitions

  • the invention relates to compounds that may be used to inhibit dipeptidyl peptidases as well as compositions of matter and kits comprising these compounds.
  • the present invention also relates to methods for inhibiting dipeptidyl peptidases as well as treatment methods using compounds according to the present invention.
  • Dipeptidyl Peptidase IV (IUBMB Enzyme Nomenclature EC.3.4.14.5) is a type ⁇ membrane protein that has been referred to in the literature by a wide a variety of names including DPP4, DP4, DAP-IV, FAP ⁇ , adenosine deaminase complexing protein 2, adenosine deaminase binding protein (AD Abp), dipeptidyl aminopeptidase IV; Xaa-Pro- dipeptidyl-aminopeptidase; Gly-Pro naphthylamidase; postproline dipeptidyl aminopeptidase PV; lymphocyte antigen CD26; glycoprotein GPIlO; dipeptidyl peptidase PV; glycylproline aminopeptidase; glycylproline aminopeptidase; X-prolyl dipeptidyl aminopeptidase; pep X; leukocyte antigen CD26; glyc
  • DPP-W Dipeptidyl Peptidase PV is referred to herein as "DPP-W.”
  • DPP-PV is a non-classical serine aminodipeptidase that removes Xaa-Pro dipeptides from the amino terminus (N-terminus) of polypeptides and proteins. DPP-PV dependent slow release of dipeptides of the type X-GIy or X-Ser has also been reported for some naturally occurring peptides.
  • DPP-PV is constitutively expressed on epithelial and endothelial cells of a variety of different tissues (intestine, liver, lung, kidney and placenta), and is also found in body fluids. DPP-FV is also expressed on circulating T-lymphocytes and has been shown to be synonymous with the cell-surface antigen, CD-26. DPP-PV has been implicated in a number of disease states, some of which are discussed below.
  • DPP-PV is responsible for the metabolic cleavage of certain endogenous peptides (GLP-I (7-36), glucagon) in vivo and has demonstrated proteolytic activity against a variety of other peptides (GHRH, NPY, GLP-2, VIP) in vitro.
  • GLP-I (7-36) is a 29 amino-acid peptide derived by post-translational processing of proglucagon in the small intestine.
  • DPP-IV has been shown to be the primary degrading enzyme of GLP-I (7-36) in vivo.
  • GLP-I (7-36) is degraded by DPP-IV efficiently to GLP-I (9-36), which has been speculated to act as a physiological antagonist to GLP-I (7-36).
  • Inhibiting DPP-IV in vivo is therefore believed to be useful for potentiating endogenous levels of GLP-I (7-36) and attenuating the formation of its antagonist GLP-I (9-36).
  • DPP-IV inhibitors are believed to be useful agents for the prevention, delay of progression, and/or treatment of conditions mediated by DPP-IV, in particular diabetes and more particularly, type 2 diabetes mellitus, diabetic dislipidemia, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose (IFG), metabolic acidosis, ketosis, appetite regulation and obesity.
  • ITT impaired glucose tolerance
  • IGF impaired fasting plasma glucose
  • metabolic acidosis ketosis
  • appetite regulation and obesity appetite regulation and obesity.
  • DPP-IV expression is increased in T-cells upon mitogenic or antigenic stimulation (Mattem, T., et al., Scand. J. Immunol, 1991, 33, 737).
  • DPP-IV inhibitors based on boroProline, (Flentke, G. R., et al., Proc. Nat. Acad.
  • CD45 is known to be an integral component of the T-cell signaling apparatus. It has been reported that DPP-IV is essential for the penetration and infectivity of HIV-I and HIV-2 viruses in CD4+ T-cells (Wakselman, M., Nguyen, C, Mazaleyrat, J.-P., Callebaut, C, Krust, B., Hovanessian, A. G., Inhibition of HIV-I infection of CD 26+ but not CD 26-cells by a potent cyclopeptidic inhibitor of the DPP-IV activity of CD 26. Abstract P.44 of the 24.sup.th European Peptide Symposium 1996).
  • lung endothelial cell DPP-IV is an adhesion molecule for lung-metastatic rat breast and prostate carcinoma cells (Johnson, R. C, et al., J. Cell. Biol, 1993, 121, 1423). DPP-IV is known to bind to fibronectin and some metastatic tumor cells are known to carry large amounts of fibronectin on their surface. Potent DPP-IV inhibitors may be useful as drugs to prevent metastases of, for example, breast and prostrate tumors to the lungs.
  • DPP-FV expression has also been found in human skin fibroblast cells from patients with psoriasis, rheumatoid arthritis (RA) and lichen planus (Raynaud, F., et al., J. Cell. Physiol, 1992, 151, 378). Therefore, DPP-IV inhibitors may be useful as agents to treat dermatological diseases such as psoriasis and lichen planus.
  • High DPP-IV activity has been found in tissue homogenates from patients with benign prostate hypertrophy and in prostatosomes. These are prostate derived organelles important for the enhancement of sperm forward motility (Vanhoof, G., et al., Eur. J. Clin.
  • DPP-IV inhibitors may also act to suppress sperm motility and therefore act as a male contraceptive agent.
  • DPP-IV inhibitors have been implicated as novel for treatment of infertility, and particularly human female infertility due to Polycystic ovary syndrome (PCOS, Stein-Leventhal syndrome) which is a condition characterized by thickening of the ovarian capsule and formation of multiple follicular cysts. It results in infertility and amenorrhea.
  • PCOS Polycystic ovary syndrome
  • DPP-IV is thought to play a role in the cleavage of various cytokines (stimulating hematopoietic cells), growth factors and neuropeptides.
  • Stimulated hematopoietic cells are useful for the treatment of disorders that are characterized by a reduced number of hematopoietic cells or their precursors in vivo. Such conditions occur frequently in patients who are immunosuppressed, for example, as a consequence of chemotherapy and/or radiation therapy for cancer. It was discovered that inhibitors of dipeptidyl peptidase type IV are useful for stimulating the growth and differentiation of hematopoietic cells in the absence of exogenously added cytokines or other growth factors or stromal cells.
  • DPP-IV in human plasma has been shown to cleave N-terminal Tyr-Ala from growth hormone-releasing factor and cause inactivation of this hormone. Therefore, inhibitors of DPP-IV may be useful in the treatment of short stature due to growth hormone deficiency (Dwarfism) and for promoting GH-dependent tissue growth or re- growth.
  • DPP-IV can also cleave neuropeptides and has been shown to modulate the activity of neuroactive peptides substance P, neuropeptide Y and CLIP (Mentlein, R., Dahms, P., Grandt, D., Kruger, R., Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV, Regul. Pept., 49, 133, 1993; Wetzel, W., Wagner, T., Vogel, D., Demuth, H.-U., Balschun, D., Effects of the CLIP fragment ACTH 20-24 on the duration of REM sleep episodes, Neuropeptides, 31, 41, 1997).
  • DPP-IV inhibitors may also be useful agents for the regulation or normalization of neurological disorders.
  • the present invention relates to compounds that have activity for inhibiting DPP-IV. It is noted that these compounds may also have activity for inhibiting other S9 proteases and thus may be used against these other S9 proteases as well as DPP-IV.
  • the present invention also provides compositions, articles of manufacture and kits comprising these compounds.
  • a pharmaceutical composition that comprises a DPP-IV inhibitor according to the present invention as an active ingredient.
  • Pharmaceutical compositions according to the invention may optionally comprise 0.001%- 100% of one or more DPP-IV inhibitors of this invention.
  • These pharmaceutical compositions may be administered or coadministered by a wide variety of routes, including for example, orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, or intrathecally.
  • the compositions may also be administered or coadministered in slow release dosage forms.
  • the invention is also directed to kits and other articles of manufacture for treating disease states associated with DPP-IV.
  • a kit comprising a composition comprising at least one DPP-IV inhibitor of the present invention in combination with instructions.
  • the instructions may indicate the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition.
  • the kit may also comprise packaging materials.
  • the packaging material may comprise a container for housing the composition.
  • the kit may also optionally comprise additional components, such as syringes for administration of the composition.
  • the kit may comprise the composition in single or multiple dose forms.
  • an article of manufacture comprises a composition comprising at least one DPP-IV inhibitor of the present invention in combination with packaging materials.
  • the packaging material may comprise a container for housing the composition.
  • the container may optionally comprise a label indicating the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition.
  • the kit may also optionally comprise additional components, such as syringes for administration of the composition.
  • the kit may comprise the composition in single or multiple dose forms.
  • the compounds, compositions, kits and articles of manufacture are used to inhibit DPP-IV.
  • the compounds, compositions, kits and articles of manufacture are used to treat a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state.
  • a compound is administered to a subject wherein DPP-
  • IV activity within the subject is altered, preferably reduced.
  • a prodrug of a compound is administered to a subject that is converted to the compound in vivo where it inhibits DPP-IV.
  • a method of inhibiting DPP-IV comprises contacting DPP-IV with a compound according to the present invention.
  • a method of inhibiting DPP-IV comprises causing a compound according to the present invention to be present in a subject in order to inhibit DPP-IV in vivo.
  • a method of inhibiting DPP-IV comprises administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits DPP-IV in vivo.
  • the compounds of the present invention may be the first or second compounds.
  • a therapeutic method comprises administering a compound according to the present invention.
  • a method of inhibiting cell proliferation comprises contacting a cell with an effective amount of a compound according to the present invention.
  • a method of inhibiting cell proliferation in a patient comprises administering to the patient a therapeutically effective amount of a compound according to the present invention.
  • a method of treating a condition in a patient which is known to be mediated by DPP-IV, or which is known to be treated by DPP-IV inhibitors comprising administering to the patient a therapeutically effective amount of a compound according to the present invention.
  • a method for using a compound according to the present invention in order to manufacture a medicament for use in the treatment of disease state which is known to be mediated by DPP-IV, or which is known to be treated by DPP-IV inhibitors.
  • a method for treating a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state comprising: causing a compound according to the present invention to be present in a subject in a therapeutically effective amount for the disease state.
  • a method for treating a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state comprising: administering a first compound to a subject that is converted in vivo to a second compound such that the second compound is present in the subject in a therapeutically effective amount for the disease state.
  • the compounds of the present invention may be the first or second compounds.
  • a method for treating a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state comprising: administering a compound according to the present invention to a subject such that the compound is present in the subject in a therapeutically effective amount for the disease state.
  • a method for treating a cell proliferative disease state comprising treating cells with a compound according to the present invention in combination with an anti-proliferative agent, wherein the cells are treated with the compound according to the present invention before, at the same time, and/or after the cells are treated with the anti-proliferative agent, referred to herein as combination therapy.
  • combination therapy is intended to cover when agents are administered before or after each other (sequential therapy) as well as when the agents are administered at the same time.
  • diabetes more particular type 2 diabetes mellitus, diabetic dislipidemia, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose (IFG), metabolic acidosis, ketosis, appetite regulation, obesity, immunosuppressants or
  • the present invention is intended to encompass all pharmaceutically acceptable ionized forms (e.g., salts) and solvates (e.g., hydrates) of the compounds, regardless of whether such ionized forms and solvates are specified since it is well known in the art to administer pharmaceutical agents in an ionized or solvated form. It is also noted that unless a particular stereochemistry is specified, recitation of a compound is intended to encompass all possible stereoisomers (e.g., enantiomers or diastereomers depending on the number of chiral centers), independent of whether the compound is present as an individual isomer or a mixture of isomers.
  • pharmaceutically acceptable ionized forms e.g., salts
  • solvates e.g., hydrates
  • prodrugs may also be administered which are altered in vivo and become a compound according to the present invention.
  • the various methods of using the compounds of the present invention are intended, regardless of whether prodrug delivery is specified, to encompass the administration of a prodrug that is converted in vivo to a compound according to the present invention.
  • certain compounds of the present invention may be altered in vivo prior to inhibiting DPP-IV and thus may themselves be prodrugs for another compound.
  • Such prodrugs of another compound may or may not themselves independently have DPP-IV inhibitory activity.
  • Alicyclic means a moiety comprising a non-aromatic ring structure. Alicyclic moieties may be saturated or partially unsaturated with one, two or more double or triple bonds. Alicyclic moieties may also optionally comprise heteroatoms such as nitrogen, oxygen and sulfur. The nitrogen atoms can be optionally quaternerized or oxidized and the sulfur atoms can be optionally oxidized.
  • alicyclic moieties include, but are not limited to moieties with C3 - C8 rings such as cyclopropyl, cyclohexane, cyclopentane, cyclopentene, cyclopentadiene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptene, cycloheptadiene, cyclooctane, cyclooctene, and cyclooctadiene.
  • "Aliphatic" means a moiety characterized by a straight or branched chain arrangement of constituent carbon atoms and may be saturated or partially unsaturated with one, two or more double or triple bonds.
  • Alkenyl represented by itself means a straight or branched, unsaturated, aliphatic radical having a chain of carbon atoms having at least one double bond between adjacent carbon atoms.
  • Cx alkenyl and C ⁇ . ⁇ alkenyl are typically used where X and Y indicate the number of carbon atoms in the chain.
  • C 2-6 alkenyl includes alkenyls that have a chain of between 2 and 6 carbons.
  • Alkoxy means an oxygen moiety having a further alkyl substituent.
  • the alkoxy groups of the present invention can be optionally substituted.
  • Alkyl represented by itself means a straight or branched, saturated or unsaturated, aliphatic radical having a chain of carbon atoms, optionally with oxygen (See “oxaalkyl”) or nitrogen atoms (See “aminoalkyl”) between the carbon atoms.
  • Cx alkyl and Cx -Y alkyl are typically used where X and Y indicate the number of carbon atoms in the chain.
  • C 1-6 alkyl includes alkyls that have a chain of between 1 and 6 carbons (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-bvftyl, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylallyl, ethynyl, 1-propynyl, 2-propynyl, and the like).
  • 1 and 6 carbons e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-bvftyl, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylallyl, ethynyl, 1-prop
  • Alkyl represented along with another radical means a straight or branched, saturated or unsaturated aliphatic divalent radical having the number of atoms indicated or when no atoms are indicated means a bond (e.g., (C 6-10 )aryl(C 1-3 )alkyl includes, benzyl, phenethyl, 1-phenylethyl, 3-phenylpropyl, 2-thienylmethyl, 2-pyridinylmethyl and the like).
  • "Alkylene" unless indicated otherwise, means a straight or branched, saturated or unsaturated, aliphatic, divalent radical.
  • Cx alkylene and C ⁇ . ⁇ alkylene are typically used where X and Y indicate the number of carbon atoms in the chain.
  • Alkylidene means a straight or branched saturated or unsaturated, aliphatic radical connected to the parent molecule by a double bond.
  • Cx alkylidene and C ⁇ . ⁇ alkylidene are typically used where X and Y indicate the number of carbon atoms in the chain.
  • Alkynyl represented by itself means a straight or branched, unsaturated, aliphatic radical having a chain of carbon atoms having at least one triple bond between adjacent carbon atoms.
  • Cx alkynyl and C ⁇ . ⁇ alkynyl are typically used where X and Y indicate the number of carbon atoms in the chain.
  • C 2-6 alkynyl includes alkynyls that have a chain of between 2 and 6 carbons.
  • the compounds of the invention containing amino moieties may include protected derivatives thereof.
  • Suitable protecting groups for amino moieties include acetyl, tert-butoxycarbonyl, benzyloxycarbonyl, and the like.
  • Aminoalkyl means an alkyl, as defined above, except where one or more substituted or unsubstituted nitrogen atoms (-N-) are positioned between carbon atoms of the alkyl.
  • an (C 2 . 6 ) aminoalkyl refers to a chain comprising between 2 and 6 carbons and one or more nitrogen atoms positioned between the carbon atoms.
  • Animal includes humans, non-human mammals (e.g., dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like) and non-mammals (e.g., birds, and the like).
  • non-human mammals e.g., dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like
  • non-mammals e.g., birds, and the like.
  • Aromatic means a moiety wherein the constituent atoms make up an unsaturated ring system, all atoms in the ring system are sp 2 hybridized and the total number of pi electrons is equal to 4n+2.
  • An aromatic ring may be such that the ring atoms are only carbon atoms or may include carbon and non-carbon atoms (see Heteroaryl).
  • Aryl means a monocyclic or polycyclic ring assembly wherein each ring is aromatic or when fused with one or more rings forms an aromatic ring assembly. If one or more ring atoms is not carbon (e.g., N, S), the aryl is a heteroaryl. Cx aryl and C ⁇ . ⁇ aryl are typically used where X and Y indicate the number of atoms in the ring.
  • Bicycloalkyl means a saturated or partially unsaturated fused bicyclic or bridged polycyclic ring assembly.
  • Bicycloaryl means a bicyclic ring assembly wherein the rings are linked by a single bond or fused and at least one of the rings comprising the assembly is aromatic. Cx bicycloaryl and C ⁇ . ⁇ bicycloaryl are typically used where X and Y indicate the number of carbon atoms in the bicyclic ring assembly and directly attached to the ring. [0059] “Bridging ring” as used herein refers to a ring that is bonded to another ring to form a compound having a bicyclic structure where two ring atoms that are common to both rings are not directly bound to each other.
  • Non-exclusive examples of common compounds having a bridging ring include boraeol, norbornane, 7- oxabicyclo[2.2. l]heptane, and the like.
  • One or both rings of the bicyclic system may also comprise heteroatoms.
  • Carbamoyl means the radical -OC(O)NR a R b where R a and R b are each independently two further substituents where a hydrogen or carbon atom is attached to the nitrogen.
  • Carbocycle means a ring consisting of carbon atoms.
  • Carbocyclic ketone derivative means a carbocyclic derivative wherein the ring contains a -CO- moiety.
  • Carbonyl means the radical -CO-. It is noted that the carbonyl radical may be further substituted with a variety of substituents to form different carbonyl groups including acids, acid halides, aldehydes, amides, esters, and ketones.
  • Carboxy means the radical -CO 2 -. It is noted that compounds of the invention containing carboxy moieties may include protected derivatives thereof, i.e., where the oxygen is substituted with a protecting group. Suitable protecting groups for carboxy moieties include benzyl, tert-butyl, and the like.
  • Cyano means the radical -CN.
  • Cycloalkyl means a non-aromatic, saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly.
  • Cx cycloalkyl and C ⁇ . ⁇ cycloalkyl are typically used where X and Y indicate the number of carbon atoms in the ring assembly.
  • C 3-10 cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,5-cyclohexadienyl, bicyclo[2.2.2]octyl, adamantan-1-yl, decahydronaphthyl, oxocyclohexyl, dioxocyclohexyl, thiocyclohexyl,
  • Cycloalkylene means a divalent saturated or partially unsaturated, monocyclic or polycyclic ring assembly. Cx cycloalkylene and C ⁇ . ⁇ cycloalkylene are typically used where X and Y indicate the number of carbon atoms in the ring assembly.
  • Disease specifically includes any unhealthy condition of an animal or part thereof and includes an unhealthy condition that may be caused by, or incident to, medical or veterinary therapy applied to that animal, i.e., the "side effects" of such therapy.
  • fused ring refers to a ring that is bonded to another ring to form a compound having a bicyclic structure where the ring atoms that are common to both rings are directly bound to each other.
  • Non-exclusive examples of common fused rings include decalin, naphthalene, anthracene, phenanthrene, indole, furan, benzofuran, quinoline, and the like.
  • Compounds having fused ring systems may be saturated, partially saturated, carbocyclics, heterocyclics, aromatics, heteroaromatics, and the like.
  • Halo means fluoro, chloro, bromo or iodo.
  • Halo-substituted alkyl as an isolated group or part of a larger group, means
  • alkyl substituted by one or more "halo" atoms, as such terms are defined in this
  • Halo-substituted alkyl includes haloalkyl, dihaloalkyl, trihaloalkyl, perhaloalkyl and the like (e.g. halo-substituted (C 1-3 )alkyl includes chloromethyl, dichloromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, perfluoroethyl,
  • Heteroatom refers to an atom that is not a carbon atom. Particular examples of heteroatoms include, but are not limited to nitrogen, oxygen, and sulfur.
  • Heteroatom moiety includes a moiety where the atom by which the moiety is attached is not a carbon.
  • Heterobicycloalkyl means bicycloalkyl, as defined in this Application, provided that one or more of the atoms within the ring is a heteroatom.
  • hetero(C 9-12 )bicycloalkyl as used in this application includes, but is not limited to, 3-aza- bicyclo[4.1.0]hept-3-yl, 2-aza-bicyclo[3.1.0]hex-2-yl , 3-aza-bicyclo[3.1.0]hex-3-yl, and the like.
  • Heterocycloalkylene means cycloalkylene, as defined in this Application, provided that one or more of the ring member carbon atoms is replaced by a heteroatom.
  • Heteroaryl means a cyclic aromatic group having five or six ring atoms, wherein at least one ring atom is a heteroatom and the remaining ring atoms are carbon.
  • heteroaryl groups of this invention include, but are not limited to, those derived from furan, imidazole, isothiazole, isoxazole, oxadiazole, oxazole, 1,2,3-oxadiazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrroline, thiazole, 1,3,4-thiadiazole, triazole and tetrazole.
  • Heteroaryl also includes, but is not limited to, bicyclic or tricyclic rings, wherein the heteroaryl ring is fused to one or two rings independently selected from the group consisting of an aryl ring, a cycloalkyl ring, a cycloalkenyl ring, and another monocyclic heteroaryl or heterocycloalkyl ring.
  • bicyclic or tricyclic heteroaryls include, but are not limited to, those derived from benzo[b]furan, benzo[b]thiophene, benzimidazole, imidazo[4,5-c]pyridine, quinazoline, thieno[2,3-c]pyridine, thieno[3,2- b]pyridine, thieno[2,3-b]pyridine, indolizine, imidazo[l,2a]pyridine, quinoline, isoquinoline, phthalazine, quinoxaline, naphthyridine, quinolizine, indole, isoindole, indazole, indoline, benzoxazole, benzopyrazole, benzothiazole, imidazo[l,5-a]pyridine, pyrazolo [ 1 ,5-a]pyridine, imidazo [ 1 ,2-a]pyrimidine, imidazo [ 1 ,2-c]pyrimidine, imidazo[
  • the bicyclic or tricyclic heteroaryl rings can be attached to the parent molecule through either the heteroaryl group itself or the aryl, cycloalkyl, cycloalkenyl or heterocycloalkyl group to which it is fused.
  • the heteroaryl groups of this invention can be substituted or unsubstituted.
  • Heterobicycloaryl means bicycloaryl, as defined in this Application, provided that one or more of the atoms within the ring is a heteroatom.
  • hetero(C 4-10 )bicycloaryl as used in this Application includes, but is not limited to, 2-amino- 4-0X0-3 ,4-dihydropteridin-6-yl, tetrahydroisoquinolinyl, and the like.
  • Heterocycloalkyl means cycloalkyl, as defined in this Application, provided that one or more of the atoms forming the ring is a heteroatom selected, independently from N, O, or S.
  • heterocycloalkyl examples include piperidyl, A- morpholyl, 4-piperazinyl, pyrrolidinyl, perhydropyrrolizinyl, 1,4-diazaperhydroepinyl, 1,3- dioxanyl, 1,4-dioxanyl and the like.
  • Haldroxy means the radical -OH.
  • Iminoketone derivative means a derivative comprising the moiety -C(NR)-, wherein R comprises a hydrogen or carbon atom attached to the nitrogen.
  • Isomers mean any compound having an identical molecular formulae but differing in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed
  • stereoisomers Stereoisomers that are not mirror images of one another are termed
  • enantiomers or sometimes “optical isomers.”
  • a carbon atom bonded to four nonidentical substituents is termed a “chiral center.”
  • a compound with one chiral center has two enantiomeric forms of opposite chirality.
  • a mixture of the two enantiomeric forms is termed a “racemic mixture.”
  • a compound that has more than one chiral center has 2 n ⁇ enantiomeric pairs, where n is the number of chiral centers.
  • chiral center may exist as ether an individual diastereomer or as a mixture of diastereomers, termed a "diastereomeric mixture.”
  • a stereoisomer may be characterized by the absolute configuration of that chiral center.
  • Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center.
  • Enantiomers are characterized by the absolute configuration of their chiral centers and described by the R- and S-sequencing rules of Cahn, Ingold and Prelog.
  • Niro means the radical -NO 2 .
  • Oxaalkyl means an alkyl, as defined above, except where one or more oxygen atoms (-O-) are positioned between carbon atoms of the alkyl.
  • oxygen atoms -O-
  • oxaalkyl refers to a chain comprising between 2 and 6 carbons and one or more oxygen atoms positioned between the carbon atoms.
  • Oxoalkyl means an alkyl, further substituted with a carbonyl group. The carbonyl group may be an aldehyde, ketone, ester, amide, acid or acid chloride.
  • “Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use.
  • “Pharmaceutically acceptable salts” means salts of inhibitors of the present invention which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity.
  • Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, o-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid
  • Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic bases.
  • Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydroxide.
  • Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, JV-mefhylglucamine and the like.
  • Prodrug means a compound that is convertible in vivo metabolically into an inhibitor according to the present invention.
  • the prodrug itself may or may not also have DPP-IV inhibitory activity.
  • an inhibitor comprising a hydroxy group may be administered as an ester that is converted by hydrolysis in vivo to the hydroxy compound.
  • esters that may be converted in vivo into hydroxy compounds include acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates, quinates, esters of amino acids, and the like.
  • an inhibitor comprising an amine group may be administered as an amide that is converted by hydrolysis in vivo to the amine compound.
  • Protected derivatives means derivatives of inhibitors in which a reactive site or sites are blocked with protecting groups. Protected derivatives are useful in the preparation of inhibitors or in themselves may be active as inhibitors. A comprehensive list of suitable protecting groups can be found in T.W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999.
  • Substituted or unsubstituted means that a given moiety may consist of only hydrogen substituents through available valencies (unsubstituted) or may further comprise one or more non-hydrogen substituents through available valencies (substituted) that are not otherwise specified by the name of the given moiety.
  • isopropyl is an example of an ethylene moiety that is substituted by -CH 3 .
  • a non-hydrogen substituent may be any substituent that may be bound to an atom of the given moiety that is specified to be substituted.
  • substituents include, but are not limited to, aldehyde, alicyclic, aliphatic, alkyl, alkylene, alkylidene, amide, amino, aminoalkyl, aromatic, aryl, bicycloalkyl, bicycloaryl, carbamoyl, carbocyclyl, carboxyl, carbonyl group, cycloalkyl, cycloalkylene, ester, halo, heterobicycloalkyl, heterocycloalkylene, heteroaryl, heterobicycloaryl, heterocycloalkyl, oxo, hydroxy, iminoketone, ketone, nitro, oxaalkyl, and oxoalkyl moieties, each of which may optionally also be substituted or unsubstituted.
  • Sulfinyl means the radical -SO-. It is noted that the sulfinyl radical may be further substituted with a variety of substituents to form different sulfinyl groups including sulfinic acids, sulfinamides, sulfinyl esters, and sulfoxides.
  • “Sulfonyl” means the radical -SO 2 -. It is noted that the sulfonyl radical may be further substituted with a variety of substituents to form different sulfonyl groups including sulfonic acids, sulfonamides, sulfonate esters, and sulfones. [0093] “Therapeutically effective amount” means that amount which, when administered to an animal for treating a disease, is sufficient to effect such treatment for the disease.
  • Thiocarbonyl means the radical -CS-. It is noted that the thiocarbonyl radical may be further substituted with a variety of substituents to form different thiocarbonyl groups including thioacids, thioamides, thioesters, and thioketones.
  • Treatment or “treating” means any administration of a compound of the present invention and includes:
  • a C 1 alkyl indicates that there is one carbon atom but does not indicate what are the substituents on the carbon atom.
  • a C 1 alkyl comprises methyl (i.e., -CH 3 ) as well as -R a RbR c where R a , Rb, and R c may each independently be hydrogen or any other substituent where the atom attached to the carbon is a heteroatom or cyano.
  • CF 3 , CH 2 OH and CH 2 CN for example, are all C 1 alkyls.
  • the present invention relates to compounds, compositions, kits and articles of manufacture that may be used to inhibit dipeptidyl peptidases IV (referred to herein as
  • DPP-IV (EC.3.4.14.5 also known as DPP4, DP4, DAP-IV, adenosine deaminase complexing protein 2, adenosine deaminase binding protein (AD Abp) or CD26) is a 766 residue, 24OkDa protein that is a highly specific membrane bound non-classical serine aminodipeptidase.
  • DPP-IV has a serine type mechanism of protease activity, cleaving off dipeptides from the amino-terminus of peptides with proline or alanine at the penultimate position. In addition the slow release of dipeptides of the type X-GIy or X-Ser is reported for some naturally occurring peptides.
  • DPP-IV is constitutively expressed on epithelial and endothelial cells of a variety of different tissues (intestine, liver, lung, kidney and placenta), and is also found in body fluids. DPP-IV is also expressed on circulating T- lymphocytes and has been shown to be synonymous with the cell-surface antigen, CD-26.
  • the wild-type form of full length DPP-IV is described in GenBank Accession Number NM_001935 ("Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2.
  • DPP-IV is a member of the S9 family of serine proteases, more particularly the S9B family.
  • Other members of the S9 family include, but are not limited to:
  • Subfamily S9A Dipeptidyl-peptidase; Oligopeptidase B (EC 3.4.21.83); Oligopeptidase B; Prolyl oligopeptidase (EC 3.4.21.26)
  • Subfamily S9B Dipeptidyl aminopeptidase A; Dipeptidyl aminopeptidase B; Dipeptidyl-peptidase IV (EC 3.4.14.5); Dipeptidyl-peptidase V; Fibroblast activation protein alpha subunit; Seprase
  • Subfamily S9C Acylaminoacyl-peptidase (EC 3.4.19.1)
  • the compounds of the present invention may also possess inhibitory activity for other S9 family members and thus may be used to address disease states associated with these other family members.
  • DPP-IV is a cylindrical shaped molecule with an approximate height of 70 A and a diameter of 60 A.
  • the catalytic triad of DPP-IV (Ser642, Asp720 and His752) is located in the peptidase domain or catalytic domain of DPP-IV.
  • the catalytic domain is covalently linked to the ⁇ -propeller domain.
  • the catalytic domain of DPP-IV includes residues 1-67 and 511-778.
  • the catalytic domain of DPP-IV adopts a characteristic ⁇ / ⁇ hydrolase fold.
  • the core of this domain contains an 8-stranded ⁇ -sheet with all strands being parallel except one.
  • the ⁇ -sheet is significantly twisted and is flanked by three ⁇ - helices on one side and five ⁇ -helices on the other.
  • the topology of the ⁇ -strands is 1, 2, - Ix, 2x and (Ix) (J. S. Richardson: The anatomy and taxonomy of protein structure; (1981) Adv. Protein Chem. 269, 15076-15084.).
  • a number of residues were identified that contribute to the shape and charge characteristics of the active site. Knowledge of these residues has been an important contribution to the design of DPP-IV inhibitors of the present invention.
  • DPP-IV inhibitors of the present invention include compounds comprising:
  • W is selected from the group consisting of CR 3 and N;
  • X is selected from the group consisting of CR 4 and N;
  • R 1 is selected from the group consisting of (Ci-io)alkyl, (C 3-12 )cycloalkyl, hetero(C 3 - 12 )cycloalkyl, aryl(C 1 - 1 o)alkyl, heteroaryl(C 1 - 5 )alkyl, (C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (Q ⁇ alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (Q ⁇ alkyl, imino (C 1-3 )alkyl, amino, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkenyl, alkynyl, carbonyl group, cyano, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted
  • R 2 is selected from the group consisting of amino (Ci_ 6 )alkyl, hetero(C 3-12 )cycloalkyl, hetero(C 4-12 )bicycloaryl, heteroaryl, and cyano, each substituted or unsubstituted;
  • R 3 is selected from the group consisting of hydrogen, halo, perhalo(C 1 - 1 o)alkyl, amino, nitro, cyano, thio, sulfonamide, (C ⁇ o)alkyl, (C 3-12 )cycloalkyl, hetero(C 3 - 12 )cycloalkyl, aryl(C 1 - 10 )alkyl, heteroaryl(C !
  • R 4 is selected from the group consisting of hydrogen, halo, perhalo(C 1 - 1 o)alkyl, amino, nitro, cyano, thio, sulfonamide, (C 1 - I o)alkyl, (C 3-12 )cycloalkyl, hetero(C 3 - 12 )cycloalkyl, aryl(C 1 - 1 o)alkyl, heteroaryl(Cr 5 )alkyl, hetero(C 4-12 )bicycloaryl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, sulfonylamino, imino(C 1-3 )alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group
  • R 5 and R 7 are independently selected from the group consisting of hydrogen, halo(C 1 - 1 o)alkyl, amino, nitro, thio, sulfonamide, (Ci-io)alkyl, (C 3-12 )cycloalkyl, hetero(C 3 - 12 )cycloalkyl, aryl(C 1 - 1 o)alkyl, heteroaryl(Cr 5 )alkyl, (C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, (C 3 - 12 )cycloalkyl(C 1 - 1 o)alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, imino(C 1-3 )alkyl, aryl, heteroaryl, hydroxy, al
  • R 6 and R 6 ' are each independently selected from the group consisting of hydrogen, amino, alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted, or R 5 and R 6 are taken together to from a ring, with the proviso that R 6 ' is absent when Y forms part of a double bond.
  • DPP-IV inhibitors of the present invention include compounds comprising:
  • R 1 is selected from the group consisting of (C 1 - 10 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3 - 12 )cycloalkyl, aryl(C 1 - 10 )alkyl, heteroaryl(C 1 - 5 )alkyl, (C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )alkyl, imino (C 1-3 )alkyl, amino, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkenyl, alkynyl, carbonyl group, cyano, imino group, sulfonyl group and sulfinyl group, each substituted or
  • R 2 is selected from the group consisting of amino (C 1-6 )alkyl, hetero(C 3-12 )cycloalkyl, hetero(C 4-12 )bicycloaryl, heteroaryl, and cyano, each substituted or unsubstituted;
  • R 3 is selected from the group consisting of hydrogen, halo, perhalo(C 1 - 1 o)alkyl, amino, nitro, cyano, thio, sulfonamide, (C 1 - 10 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3 - 12 )cycloalkyl, aryl(C 1 - 10 )alkyl, heteroaryl(Ci- 5 )alkyl, (Cg. ⁇ bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, imino(C 1-3 )alkyl, (C 1 - 10 )alkylamino, amino (C 1 - I o)alkyl, aryl, heteroary
  • R 5 and R 7 are independently selected from the group consisting of hydrogen, halo(C 1 - 1 o)alkyl, amino, nitro, thio, sulfonamide, (C 1 - 10 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3 - 12 )cycloalkyl, aryl(C 1 - 10 )alkyl, heteroaryl(C 1 - 5 )alkyl, (C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, (C 3 - 12 )cycloalkyl(C 1 - 10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(Ci_ 3 )alkyl, sulfinyl(C 1-3 )alkyl, imino(C 1-3 )alkyl, aryl, heteroaryl, hydroxy
  • DPP-IV inhibitors of the present invention include compounds comprising:
  • R 1 is selected from the group consisting of (C 1 - 10 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3 - 12 )cycloalkyl, aryl(C 1 - 1 o)alkyl, heteroaryl(Cr 5 )alkyl, (C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )alkyl, imino (C 1-3 )alkyl, amino, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkenyl, alkynyl, carbonyl group, cyano, imino group, sulfonyl group and sulfinyl group, each substituted or un
  • R 2 is selected from the group consisting of amino (C 1-6 )alkyl, hetero(C 3-12 )cycloalkyl, hetero(C 4 . 12 )bicycloaryl, heteroaryl, and cyano, each substituted or unsubstituted;
  • R 3 is selected from the group consisting of hydrogen, halo, perhalo(C 1 - 1 o)alkyl, amino, nitro, cyano, thio, sulfonamide, (C 1 - 10 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3 - 12 )cycloalkyl, aryl(C 1 - 1 o)alkyl, heteroaryl(Cr 5 )alkyl, (C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1 .
  • R 6 and R 6 ' are each independently selected from the group consisting of hydrogen, amino, alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted;
  • R 7 is selected from the group consisting of hydrogen, halo(Ci- 10 )alkyl, amino, nitro, thio, sulfonamide, (C 1 - 10 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3 - 12 )cycloalkyl, aryl(C 1 - 10 )alkyl, heteroaryl(Ci- 5 )alkyl, (Cg- ⁇ bicycloaryl, hetero(C 4-12 )bicycloai7l, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, SuIfOnVl(C 1- 3 )alkyl, sulfinyl(C 1-3 )alkyl, imino(C 1-3 )alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and
  • R 8 and R 9 are each independently selected from the group consisting of hydrogen, halogen, perhalo(C 1 - 10 )alkyl, cyano, nitro, alkyl, cycloalkyl, alkene, alkyne, aryl, and heteroaryl, each substituted or unsubstituted, or where R 8 and R 9 are taken together to form a substituted or unsubstituted ring; and
  • R 10 and R 11 are independently selected from the group consisting of hydrogen, perhalo(C 1 - 10 )alkyl, amino, thio, (Q-icOalkyl, (C 3-12 )cycloalkyl, hetero(C 3 - 12 )cycloalkyl, aryl(Ci-io)alkyl, heteroaryl(C 1 - 5 )alkyl, (Cc ⁇ -12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, imino(C 1-3 )alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, and imino group, each substituted or unsubstituted, or R 10 and R 11 are
  • R 2 and R 3 are optionally taken together to form a ring.
  • the ring formed by taking R 2 and R 3 together is a substituted or unsubstituted 5 or 6 membered ring.
  • the ring formed by taking R 2 and R 3 together is a substituted or unsubstituted cycloalkyl, bicycloalkyl, heterocycloalkyl, aryl, heteroaryl, (C 9-12 )bicycloaryl, or hetero(C 8-12 )bicycloaryl.
  • R 3 is optionally -NR 12 R 13 , wherein R 12 and R 13 are each independently selected from the group consisting of hydrogen, perhalo(C 1 - 10 )alkyl, amino, thio, (C 1 - 10 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3 - 12 )cycloalkyl, aryl(Cr lo )alkyl, heteroaryl(C 1 - 5 )alkyl, (C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, imino(C 1-3 )alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy,
  • the ring formed by R 12 and R 13 is a substituted or unsubstituted 3, 4, 5 or 6 membered ring.
  • the ring formed by R 12 and R 13 is a substituted or unsubstituted heterocycloalkyl, heterobicycloalkyl, aryl, heteroaryl, or hetero(C 8-12 )bicycloaryl.
  • R 3 and R 4 are optionally taken together to form a ring.
  • the ring formed by R 3 and R 4 is a substituted or unsubstituted 5 or 6 membered ring.
  • the ring formed by R 3 and R 4 is a substituted or unsubstituted cycloalkyl, bicycloalkyl, heterocycloalkyl, aryl, heteroaryl, (C 9-12 )bicycloaryl, or hetero(C 8-12 )bicycloaryl.
  • R 1 is optionally a substituted or unsubstituted (C 3-7 )cycloalkyl.
  • R 1 can be a substituted or unsubstituted (C 3-7 )heterocycloalkyl.
  • R 1 is optionally a substituted or unsubstituted aryl.
  • R 1 can be a substituted or unsubstituted phenyl.
  • R 1 is optionally a substituted or unsubstituted heteroaryl.
  • R 1 is :
  • a is O, 1, 2, 3, 4, or 5; and R 14 is selected from the group consisting of hydrogen, halo, perhalo(C 1 - 10 )alkyl, amino, nitro, cyano, thio, sulfonamide, (C 1 - I o)alkyl, (C 3-12 )cycloalkyl, hetero(C 3 - 12 )cycloalkyl, aryl(C ⁇ o)alkyl, heteroaryl(Cr 5 )alkyl, (C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, imino(C 1-3 )alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroary
  • R 1 is optionally a cyclic substituent having a ring with a non-hydrogen substituent at a 2 or 3 position of the ring.
  • the non-hydrogen substituent at the 2 or 3 position of the ring is (C 1 - 10 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3 - 12 )cycloalkyl, aryl(C 1 - 10 )alkyl, heteroaryl(C 1 - 5 )alkyl, (C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )alkyl, imino (C ⁇ alkyl, amino, aryl, heteroaryl, hydroxy
  • V is selected from the group consisting of S, O, and NR 16 ;
  • R 15 is selected from the group consisting of hydrogen, halo, perhalo(Ci- 10 )alkyl, amino, nitro, cyano, thio, sulfonamide, (C 1 - 10 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3 - 12 )cycloalkyl, aryl(C 1 - 10 )alkyl, heteroaryl(C 1 - 5 )alkyl, (C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, imino(C 1-3 )alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group
  • R 16 is selected from the group consisting of hydrogen, perhalo(C 1 - 1 o)alkyl, amino, (Ci- 10 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3 - 12 )cycloalkyl, aryl(C 1 - 10 )alkyl, heteroaryl (Ci- 5 )alkyl, (C 9-12 )bicycloaryl, hetero(C 8-12 )bicycloaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, imino group, carbonyl group, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, and sulfinyl group, each substituted or unsubstituted.
  • R 1 is optionally a substituted or unsubstituted halophenyl or dihalophenyl.
  • R 1 can be a substituted or unsubstituted haloaryl, haloheteroaryl, dihaloaryl or dihaloheteroaryl.
  • R 1 is optionally (2-cyano)phenyl; (3-cyano)phenyl; (2-hydroxy)phenyl; (3-hydroxy)phenyl; (2- alkenyl)phenyl; (3-alkenyl)phenyl; (2-alkynyl)phenyl; (3-alkynyl)phenyl; (2- methoxy)phenyl; (3-methoxy)phenyl; (2-nitro)phenyl; (3-nitro)phenyl; (2-carboxy)phenyl; (3-carboxy)phenyl; -(CH 2 )-(2-carboxamido)phenyl; (3-carboxamido)phenyl; (2- sulfonamido)phenyl; (3-sulfonamido)phenyl; (2-tetrazolyl)phenyl; (3-tetrazolyl)phenyl; (2-aminomethyl)phenyl;
  • A is S, O or NR 17 ;
  • B is CR 18 or N
  • R 17 is independently selected from the group consisting of hydrogen, perhalo(C 1 - 1 o)alkyl, amino, (Ci- 10 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3 - 12 )cycloalkyl, aryl(Cr !
  • R 18 is independently selected from the group consisting of hydrogen, halo, perhalo(C 1 - 1 o)alkyl, amino, thio, cyano, CF 3 , nitro, (C 1 - I o)alkyl, (C 3-12 )cycloalkyl, hetero(C 3 ⁇ 12 )cycloalkyl, aryl(C 1 - 1 o)alkyl, heteroaryl (C 1 - 5 )alkyl, (C 9-12 )bicycloaryl, hetero(C 8-12 )bicycloaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, imino group, carbonyl group, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, and sulf
  • R 1 can be selected from the group consisting of:
  • t is O, 1, 2, 3, 4 or 5; and each Ri 9 is independently selected from the group consisting of halo, perhalo(Ci- 10 )alkyl, CF 3 , (Q. ⁇ alkyl, alkenyl, alkynyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, cyano, nitro, hydroxy, alkoxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or two R ⁇ are taken together to form an unsubstituted or substituted ring.
  • R 1 is optional
  • each R 20 is independently selected from the group consisting of halo, perhalo(C 1 - 1 o)alkyl, CF 3 , (C 1-10 )alkyl, alkenyl, alkynyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, cyano, nitro, hydroxy, alkoxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or two R 20 are taken together to form an unsubstituted or substituted ring.
  • R 1 can be an aryl substituted with one or more substituents selected from the group consisting of halo; hydroxy (C 1-6 )alkyl; amino (C 1-6 )alkyl; and (C 1-6 )alkoxy.
  • DPP-IV inhibitors include, but are not limited to:
  • the present invention provides the compounds in the form of a pharmaceutically acceptable salt.
  • the present invention provides the compounds present in a mixture of stereoisomers. In yet another embodiment, the present invention provides the compounds as a single stereoisomer. [0130] In yet another embodiment, the present invention provides pharmaceutical compositions comprising the compound as an active ingredient. In yet another variation, the present invention provides pharmaceutical compositions wherein the composition is a solid formulation adapted for oral administration. In yet another particular variation, the present invention provides pharmaceutical composition wherein the composition is a tablet. In another particular variation, the present invention provides the pharmaceutical composition wherein the composition is a liquid formulation adapted for oral administration. In yet another particular variation, the present invention provides pharmaceutical composition wherein the composition is a liquid formulation adapted for parenteral administration.
  • the present invention provides the pharmaceutical composition comprising the compound of the invention wherein the composition is adapted for administration by a route selected from the group consisting of orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, and intrathecally.
  • the present invention provides a kit comprising a compound of the present invention and instructions which comprise one or more forms of information selected from the group consisting of indicating a disease state for which the compound is to be administered, storage information for the compound, dosing information and instructions regarding how to administer the compound.
  • the present invention provides the kit that comprises the compound in a multiple dose form.
  • the present invention provides an article of manufacture comprising a compound of the present invention, and packaging materials.
  • the packaging material comprises a container for housing the compound.
  • the invention provides the article of manufacture wherein the container comprises a label indicating one or more members of the group consisting of a disease state for which the compound is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition.
  • the present invention provides the article of manufacture wherein the article of manufacture comprises the compound in a multiple dose form.
  • the present invention provides a method of inhibiting
  • DPP-IV comprising contacting DPP-IV with a compound according to the present invention.
  • the present invention provides a method of inhibiting
  • DPP-IV comprising causing a compound according to the present invention to be present in a subject in order to inhibit DPP-IV in vivo.
  • the present invention provides a method of inhibiting
  • DPP-IV comprising: administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits DPP-IV in vivo, the second compound being a compound of the present invention.
  • the present invention provides therapeutic method comprising: administering a compound according to the present invention to a subject.
  • the present invention provides a method of treating a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state, the method comprising causing a compound of the present invention to be present in a subject in a therapeutically effective amount for the disease state.
  • the present invention provides a method of treating cancer in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention.
  • the cancer being treated is colorectal, prostate, breast, thyroid, skin, lung, or head and neck cancer.
  • the present invention provides a method of treating a disease where the disease is type I or type II diabetes.
  • the present invention provides a method of treating autoimmune disorders such as, but not limited to, rheumatoid arthritis, psoriasis, and multiple sclerosis in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention.
  • the present invention provides a method of treating a condition characterized by inadequate lymphocyte or hemapoietic cell activation or concentration in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention.
  • the present invention provides a method of treating a condition characterized by inadequate lymphocyte or hemapoietic cell activation or concentration in a patient in need thereof, wherein the condition is a side effect of chemotherapy or radiation therapy.
  • the present invention provides a method of treating a condition characterized by inadequate lymphocyte or hemapoietic cell activation or concentration in a patient in need thereof, wherein the condition is a result of kidney failure.
  • the present invention provides a method of treating a condition characterized by inadequate lymphocyte or hemapoietic cell activation or concentration in a patient in need thereof, wherein the condition is a result of a bone marrow disorder.
  • the present invention provides a method of treating HIV infection in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention.
  • the present invention provides a method of treating a condition characterized by immunodeficiency symptoms in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention.
  • the compounds of the present invention may be present and optionally administered in the form of salts, hydrates and prodrugs that are converted in vivo into the compounds of the present invention.
  • the compounds of the present invention possess a free base form
  • the compounds can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, e.g., hydrohalides such as hydrochloride, hydrobromide, hydroiodide; other mineral acids and their corresponding salts such as sulfate, nitrate, phosphate, etc.; and alkyl and monoarylsulfonates such as ethanesulfonate, toluenesulfonate and benzenesulfonate; and other organic acids and their corresponding salts such as acetate, tartrate, maleate, succinate, citrate, benzoate, salicylate and ascorbate.
  • a pharmaceutically acceptable inorganic or organic acid e.g., hydrohalides such as hydrochloride, hydrobromide, hydroiodide
  • other mineral acids and their corresponding salts such as sulfate, n
  • Further acid addition salts of the present invention include, but are not limited to: adipate, alginate, arginate, aspartate, bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptaoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, iso-butyrate, lactate, lactobionate, malate, malonate, man
  • a pharmaceutically acceptable base addition salt can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base.
  • bases are alkali metal hydroxides including potassium, sodium and lithium hydroxides; alkaline earth metal hydroxides such as barium and calcium hydroxides; alkali metal alkoxides, e.g.
  • potassium ethanolate and sodium propanolate potassium ethanolate and sodium propanolate
  • various organic bases such as ammonium hydroxide, piperidine, diethanolamine and N- methylglutamine.
  • aluminum salts of the compounds of the present invention include, but are not limited to: copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium and zinc salts.
  • Organic base salts include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, e.g., arginine, betaine, caffeine, chloroprocaine, choline, N,N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, iso-propylamine, lidocaine, lysine, meglumine, N-methyl-D- glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine,
  • N-oxides of compounds according to the present invention can be prepared by methods known to those of ordinary skill in the art.
  • iV-oxides can be prepared by treating an unoxidized form of the compound with an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, met ⁇ -chloroperoxybenzoic acid, or the like) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as dichloromethane) at approximately 0 0 C.
  • an oxidizing agent e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, met ⁇ -chloroperoxybenzoic acid, or the like
  • a suitable inert organic solvent e.g., a halogenated hydrocarbon such as dichloromethane
  • the iV-oxides of the compounds can be prepared from the N-oxide of an appropriate starting material.
  • Prodrug derivatives of compounds according to the present invention can be prepared by modifying substituents of compounds of the present invention that are then converted in vivo to a different substituent. It is noted that in many instances, the prodrugs themselves also fall within the scope of the range of compounds according to the present invention.
  • prodrugs can be prepared by reacting a compound with a carbamylating agent (e.g., 1,1-acyloxyalkylcarbonochloridate, p ⁇ r ⁇ -nitrophenyl carbonate, or the like) or an acylating agent. Further examples of methods of making prodrugs are described in Saulnier et ⁇ /.(1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985.
  • Hydrates of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.
  • a "pharmaceutically acceptable salt”, as used herein, is intended to encompass any compound according to the present invention that is utilized in the form of a salt thereof, especially where the salt confers on the compound improved pharmacokinetic properties as compared to the free form of compound or a different salt form of the compound.
  • the pharmaceutically acceptable salt form may also initially confer desirable pharmacokinetic properties on the compound that it did not previously possess, and may even positively affect the pharmacodynamics of the compound with respect to its therapeutic activity in the body.
  • An example of a pharmacokinetic property that may be favorably affected is the manner in which the compound is transported across cell membranes, which in turn may directly and positively affect the absorption, distribution, biotransformation and excretion of the compound.
  • the solubility of the compound is usually dependent upon the character of the particular salt form thereof, which it utilized.
  • an aqueous solution of the compound will provide the most rapid absorption of the compound into the body of a subject being treated, while lipid solutions and suspensions, as well as solid dosage forms, will result in less rapid adsorption of the compound.
  • DPP-IV is believed to contribute to the pathology and/or symptomology of several different diseases such that reduction of the activity of DPP-FV in a subject through inhibition may be used to therapeutically address these disease states. Examples of various diseases that may be treated using the DPP-IV inhibitors of the present invention are described herein. It is noted that additional diseases beyond those disclosed herein may be later identified as the biological roles that DPP-IV plays in various pathways becomes more fully understood.
  • DPP-IV inhibitors of the present invention may be used to treat are those involving the prevention and treatment of diabetes and obesity, in particular type 2 diabetes mellitus, diabetic dislipidemia, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose (IFG), metabolic acidosis, ketosis, appetite regulation and obesity.
  • DPP-IV inhibitors of the present invention may also be used as immunosuppressants (or cytokine release suppressant drugs) for the treatment of among other things: organ transplant rejection; autoimmune diseases such as inflammatory bowel disease, multiple sclerosis and rheumatoid arthritis; and the treatment of AIDS.
  • DPP-IV inhibitors of the present invention may also be used for treating various cancers including breast cancer, lung cancer and prostate cancer.
  • DPP-IV inhibitors of the present invention may also be used to treat dermatological diseases such as psoriasis, rheumatoid arthritis (RA) and lichen planus.
  • DPP-IV inhibitors of the present invention may also be used to treat infertility and amenorrhea.
  • DPP-IV inhibitors of the present invention may also be used to modulate cleavage of various cytokines (stimulating hematopoietic cells), growth factors and neuropeptides. For example, such conditions occur frequently in patients who are immunosuppressed, for example, as a consequence of chemotherapy and/or radiation therapy for cancer.
  • DPP-IV inhibitors of the present invention may also be used prevent or reduce cleavage of N-terminal Tyr-Ala from growth hormone-releasing factor. Accordingly, these inhibitors may be used in the treatment of short stature due to growth hormone deficiency (Dwarfism) and for promoting GH-dependent tissue growth or re-growth. [0167] DPP-IV inhibitors of the present invention may also be used to address disease states associated with cleavage of neuropeptides and thus may be useful for the regulation or normalization of neurological disorders.
  • DPP-IV inhibitors of the present invention may be used in conjunction with other agents to inhibit undesirable and uncontrolled cell proliferation.
  • examples of other anti-cell proliferation agents include, but are not limited to, retinoid acid and derivatives thereof, 2-methoxyestradiol, ANGIOSTATINTM protein, ENDOSTATBSfTM protein, suramin, squalamine, tissue inhibitor of metalloproteinase-I, tissue inhibitor of metalloproteinase-2, plasminogen activator inhibitor- 1, plasminogen activator inhibitor-2, cartilage-derived inhibitor, paclitaxel, platelet factor 4, protamine sulfate (clupeine), sulfated chitin derivatives (prepared from queen crab shells), sulfated polysaccharide peptidoglycan complex (sp-pg), staurosporine, modulators of matrix metabolism, including for example, proline analogs ((
  • anti-angiogenesis agents include antibodies, preferably monoclonal antibodies against these angiogenic growth factors: bFGF, aFGF, FGF-5, VEGF isoforms, VEGF-C, HGF/SF and Ang-l/Ang-2.
  • bFGF vascular endothelial growth factor
  • aFGF vascular endothelial growth factor
  • FGF-5 vascular endothelial growth factor
  • VEGF isoforms VEGF-C
  • HGF/SF Ang-l/Ang-2.
  • Ferrara N. and Alitalo, K. "Clinical application of angiogenic growth factors and their inhibitors" (1999) Nature Medicine 5:1359-1364.
  • compositions and administration methods may be used in conjunction with the DPP-IV inhibitors of the present invention.
  • Such compositions may include, in addition to the DPP-IV inhibitors of the present invention, conventional pharmaceutical excipients, and other conventional, pharmaceutically inactive agents.
  • the compositions may include active agents in addition to the DPP-IV inhibitors of the present invention.
  • These additional active agents may include additional compounds according to the invention, and/or one or more other pharmaceutically active agents.
  • compositions may be in gaseous, liquid, semi-liquid or solid form, formulated in a manner suitable for the route of administration to be used.
  • routes of administration for oral administration, capsules and tablets are typically used.
  • parenteral administration reconstitution of a lyophilized powder, prepared as described herein, is typically used.
  • compositions comprising DPP-IV inhibitors of the present invention may be administered or coadministered orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, or intrathecally.
  • the compounds and/or compositions according to the invention may also be administered or coadministered in slow release dosage forms.
  • the DPP-IV inhibitors and compositions comprising them may be administered or coadministered in any conventional dosage form.
  • Co-administration in the context of this invention is intended to mean the administration of more than one therapeutic agent, one of which includes a DPP-IV inhibitor, in the course of a coordinated treatment to achieve an improved clinical outcome.
  • Such co-administration may also be coextensive, that is, occurring during overlapping periods of time.
  • Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application may optionally include one or more of the following components: a sterile diluent, such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerine, propylene glycol or other synthetic solvent; antimicrobial agents, such as benzyl alcohol and methyl parabens; antioxidants, such as ascorbic acid and sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid (EDTA); buffers, such as acetates, citrates and phosphates; agents for the adjustment of tonicity such as sodium chloride or dextrose, and agents for adjusting the acidity or alkalinity of the composition, such as alkaline or acidifying agents or buffers like carbonates, bicarbonates, phosphates, hydrochloric acid, and organic acids like acetic and citric acid.
  • Parenteral preparations may optionally be enclosed in ampules
  • DPP-IV inhibitors according to the present invention exhibit insufficient solubility
  • methods for solubilizing the compounds may be used. Such methods are known to those of skill in this art, and include, but are not limited to, using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants, such as TWEEN, or dissolution in aqueous sodium bicarbonate. Derivatives of the compounds, such as prodrugs of the compounds may also be used in formulating effective pharmaceutical compositions.
  • DMSO dimethylsulfoxide
  • surfactants such as TWEEN
  • dissolution in aqueous sodium bicarbonate aqueous sodium bicarbonate
  • Derivatives of the compounds, such as prodrugs of the compounds may also be used in formulating effective pharmaceutical compositions.
  • a solution, suspension, emulsion or the like may be formed.
  • compositions according to the present invention are optionally provided for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, dry powders for inhalers, granules, sterile parenteral solutions or suspensions, and oral solutions or suspensions, and oil-water emulsions containing suitable quantities of the compounds, particularly the pharmaceutically acceptable salts, preferably the sodium salts, thereof.
  • the pharmaceutically therapeutically active compounds and derivatives thereof are typically formulated and administered in unit-dosage forms or multiple-dosage forms.
  • Unit-dose forms refers to physically discrete units suitable for human and animal subjects and packaged individually as is known in the art. Each unit- dose contains a predetermined quantity of the therapeutically active compound sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carrier, vehicle or diluent. Examples of unit-dose forms include ampoules and syringes individually packaged tablet or capsule. Unit-dose forms may be administered in fractions or multiples thereof.
  • a multiple-dose form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dose form. Examples of multiple-dose forms include vials, bottles of tablets or capsules or bottles of pint or gallons. Hence, multiple dose form is a multiple of unit-doses that are not segregated in packaging.
  • the composition may comprise: a diluent such as lactose, sucrose, dicalcium phosphate, or carboxymethylcellulose; a lubricant, such as magnesium stearate, calcium stearate and talc; and a binder such as starch, natural gums, such as gum acaciagelatin, glucose, molasses, polvinylpyrrolidine, celluloses and derivatives thereof, povidone, crospovidones and other such binders known to those of skill in the art.
  • a diluent such as lactose, sucrose, dicalcium phosphate, or carboxymethylcellulose
  • a lubricant such as magnesium stearate, calcium stearate and talc
  • a binder such as starch, natural gums, such as gum acaciagelatin, glucose, molasses, polvinylpyrrolidine, celluloses and derivatives thereof, povidone, crospovidones and other such binders
  • Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, or otherwise mixing an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to form a solution or suspension.
  • a carrier such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like
  • the pharmaceutical composition to be administered may also contain minor amounts of auxiliary substances such as wetting agents, emulsifying agents, or solubilizing agents, pH buffering agents and the like, for example, acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and other such agents.
  • composition or formulation to be administered will, in any event, contain a sufficient quantity of a DPP-IV inhibitor of the present invention to reduce DPP-IV activity in vivo, thereby treating the disease state of the subject.
  • Dosage forms or compositions may optionally comprise one or more DPP-IV inhibitors according to the present invention in the range of 0.005% to 100% (weight/weight) with the balance comprising additional substances such as those described herein.
  • a pharmaceutically acceptable composition may optionally comprise any one or more commonly employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, talcum, cellulose derivatives, sodium crosscarmellose, glucose, sucrose, magnesium carbonate, sodium saccharin, talcum.
  • compositions include solutions, suspensions, tablets, capsules, powders, dry powders for inhalers and sustained release formulations, such as, but not limited to, implants and microencapsulated delivery systems, and biodegradable, biocompatible polymers, such as collagen, ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and others. Methods for preparing these formulations are known to those skilled in the art.
  • the compositions may optionally contain 0.01%-100% (weight/weight) of one or more DPP-IV inhibitors, optionally 0.1- 95%, and optionally 1-95%.
  • Salts, preferably sodium salts, of the DPP-IV inhibitors may be prepared with carriers that protect the compound against rapid elimination from the body, such as time release formulations or coatings.
  • the formulations may further include other active compounds to obtain desired combinations of properties.
  • DPP-IV inhibitors according to the present invention are provided as solid dosage forms, preferably capsules or tablets.
  • the tablets, pills, capsules, troches and the like may optionally contain one or more of the following ingredients, or compounds of a similar nature: a binder; a diluent; a disintegrating agent; a lubricant; a glidant; a sweetening agent; and a flavoring agent.
  • binders include, but are not limited to, microcrystalline cellulose, gum tragacanth, glucose solution, acacia mucilage, gelatin solution, sucrose and starch paste.
  • lubricants examples include, but are not limited to, talc, starch, magnesium or calcium stearate, lycopodium and stearic acid.
  • diluents examples include, but are not limited to, lactose, sucrose, starch, kaolin, salt, mannitol and dicalcium phosphate.
  • glidants examples include, but are not limited to, colloidal silicon dioxide.
  • disintegrating agents examples include, but are not limited to, crosscarmellose sodium, sodium starch glycolate, alginic acid, corn starch, potato starch, bentonite, methylcellulose, agar and carboxymethylcellulose.
  • coloring agents examples include, but are not limited to, any of the approved certified water soluble FD and C dyes, mixtures thereof; and water insoluble FD and C dyes suspended on alumina hydrate.
  • sweetening agents examples include, but are not limited to, sucrose, lactose, mannitol and artificial sweetening agents such as sodium cyclamate and saccharin, and any number of spray-dried flavors.
  • flavoring agents examples include, but are not limited to, natural flavors extracted from plants such as fruits and synthetic blends of compounds that produce a pleasant sensation, such as, but not limited to peppermint and methyl salicylate.
  • wetting agents examples include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether.
  • anti-emetic coatings examples include, but are not limited to, fatty acids, fats, waxes, shellac, ammoniated shellac and cellulose acetate phthalates.
  • film coatings examples include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000 and cellulose acetate phthalate.
  • the salt of the compound may optionally be provided in a composition that protects it from the acidic environment of the stomach.
  • the composition can be formulated in an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine.
  • the composition may also be formulated in combination with an antacid or other such ingredient.
  • dosage unit form When the dosage unit form is a capsule, it may optionally additionally comprise a liquid carrier such as a fatty oil.
  • dosage unit forms may optionally additionally comprise various other materials that modify the physical form of the dosage unit, for example, coatings of sugar and other enteric agents.
  • Compounds according to the present invention may also be administered as a component of an elixir, suspension, syrup, wafer, sprinkle, chewing gum or the like.
  • a syrup may optionally comprise, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
  • the DPP-IV inhibitors of the present invention may also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antacids, H2 blockers, and diuretics.
  • active materials such as antacids, H2 blockers, and diuretics.
  • Examples of pharmaceutically acceptable carriers that may be included in tablets comprising DPP-IV inhibitors of the present invention include, but are not limited to binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, and wetting agents.
  • Enteric-coated tablets because of the enteric-coating, resist the action of stomach acid and dissolve or disintegrate in the neutral or alkaline intestines.
  • Sugar- coated tablets may be compressed tablets to which different layers of pharmaceutically acceptable substances are applied.
  • Film-coated tablets may be compressed tablets that have been coated with polymers or other suitable coating. Multiple compressed tablets may be compressed tablets made by more than one compression cycle utilizing the pharmaceutically acceptable substances previously mentioned. Coloring agents may also be used in tablets.
  • aqueous solutions examples include, but are not limited to, elixirs and syrups.
  • elixirs refer to clear, sweetened, hydroalcoholic preparations.
  • pharmaceutically acceptable carriers examples include, but are not limited to solvents.
  • solvents Particular examples include glycerin, sorbitol, ethyl alcohol and syrup.
  • syrups refer to concentrated aqueous solutions of a sugar, for example, sucrose. Syrups may optionally further comprise a preservative.
  • Emulsions refer to two-phase systems in which one liquid is dispersed in the form of small globules throughout another liquid. Emulsions may optionally be oil-in- water or water-in-oil emulsions. Examples of pharmaceutically acceptable carriers that may be used in emulsions include, but are not limited to non-aqueous liquids, emulsifying agents and preservatives.
  • Examples of pharmaceutically acceptable substances that may be used in non- effervescent granules, to be reconstituted into a liquid oral dosage form, include diluents, sweeteners and wetting agents.
  • Examples of pharmaceutically acceptable substances that may be used in effervescent granules, to be reconstituted into a liquid oral dosage form, include organic adds and a source of carbon dioxide.
  • Coloring and flavoring agents may optionally be used in all of the above dosage forms.
  • preservatives include glycerin, methyl and propylparaben, benzoic add, sodium benzoate and alcohol.
  • emulsifying agents include gelatin, acacia, tragacanth, bentonite, and surfactants such as polyoxyethylene sorbitan monooleate.
  • suspending agents include sodium carboxymethylcellulose, pectin, tragacanth, Veegum and acacia.
  • Diluents include lactose and sucrose.
  • Sweetening agents include sucrose, syrups, glycerin and artificial sweetening agents such as sodium cyclamate and saccharin.
  • wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether.
  • organic acids that may be used include citric and tartaric acid.
  • Sources of carbon dioxide that may be used in effervescent compositions include sodium bicarbonate and sodium carbonate.
  • Coloring agents include any of the approved certified water soluble FD and C dyes, and mixtures thereof.
  • flavoring agents include natural flavors extracted from plants such fruits, and synthetic blends of compounds that produce a pleasant taste sensation.
  • the solution or suspension in for example propylene carbonate, vegetable oils or triglycerides, is preferably encapsulated in a gelatin capsule.
  • liquid dosage form the solution, e.g., for example, in a polyethylene glycol, may be diluted with a sufficient quantity of a pharmaceutically acceptable liquid carrier, e.g. water, to be easily measured for administration.
  • a pharmaceutically acceptable liquid carrier e.g. water
  • liquid or semi-solid oral formulations may be prepared by dissolving or dispersing the active compound or salt in vegetable oils, glycols, triglycerides, propylene glycol esters (e.g. propylene carbonate) and other such carriers, and encapsulating these solutions or suspensions in hard or soft gelatin capsule shells.
  • Other useful formulations include those set forth in U.S. Pat. Nos. Re 28,819 and 4,358,603.
  • compositions designed to administer the DPP-IV inhibitors of the present invention by parenteral administration, generally characterized by injection, either subcutaneously, intramuscularly or intravenously.
  • injectables may be prepared in any conventional form, for example as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
  • excipients examples include, but are not limited to water, saline, dextrose, glycerol or ethanol.
  • the injectable compositions may also optionally comprise minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other such agents, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins.
  • Implantation of a slow-release or sustained-release system such that a constant level of dosage is maintained (see, e.g., U.S. Pat. No. 3,710,795) is also contemplated herein.
  • the percentage of active compound contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject.
  • Parenteral administration of the formulations includes intravenous, subcutaneous and intramuscular administrations.
  • Preparations for parenteral administration include sterile solutions ready for injection, sterile dry soluble products, such as the lyophilized powders described herein, ready to be combined with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle just prior to use and sterile emulsions.
  • the solutions may be either aqueous or nonaqueous.
  • suitable carriers include, but are not limited to physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.
  • PBS physiological saline or phosphate buffered saline
  • thickening and solubilizing agents such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.
  • Examples of pharmaceutically acceptable carriers that may optionally be used in parenteral preparations include, but are not limited to aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other pharmaceutically acceptable substances.
  • aqueous vehicles examples include Sodium Chloride Injection, Ringers Injection, Isotonic Dextrose Injection, Sterile Water Injection, Dextrose and Lactated Ringers Injection.
  • nonaqueous parenteral vehicles examples include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil and peanut oil.
  • Antimicrobial agents in bacteriostatic or fungistatic concentrations may be added to parenteral preparations, particularly when the preparations are packaged in multiple-dose containers and thus designed to be stored and multiple aliquots to be removed. Examples of antimicrobial agents that may used include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and benzethonium chloride.
  • Examples of isotonic agents that may be used include sodium chloride and dextrose.
  • Examples of buffers that may be used include phosphate and citrate.
  • antioxidants that may be used include sodium bisulfate.
  • Examples of local anesthetics that may be used include procaine hydrochloride.
  • Examples of suspending and dispersing agents that may be used include sodium carboxymethylcellulose, hydroxypropyl methylcellulose and polyvinylpyrrolidone.
  • Examples of emulsifying agents that may be used include Polysorbate 80 (TWEEN 80).
  • a sequestering or chelating agent of metal ions include EDTA.
  • Pharmaceutical carriers may also optionally include ethyl alcohol, polyethylene glycol and propylene glycol for water miscible vehicles and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment.
  • concentration of a DPP-IV inhibitor in the parenteral formulation may be adjusted so that an injection administers a pharmaceutically effective amount sufficient to produce the desired pharmacological effect.
  • concentration of a DPP-IV inhibitor and/or dosage to be used will ultimately depend on the age, weight and condition of the patient or animal as is known in the art.
  • Unit-dose parenteral preparations may be packaged in an ampoule, a vial or a syringe with a needle. All preparations for parenteral administration should be sterile, as is know and practiced in the art.
  • Injectables may be designed for local and systemic administration. Typically a therapeutically effective dosage is formulated to contain a concentration of at least about 0.1% w/w up to about 90% w/w or more, preferably more than 1 % w/w of the DPP-IV inhibitor to the treated tissue(s).
  • the DPP-IV inhibitor may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment will be a function of the location of where the composition is parenterally administered, the carrier and other variables that may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data.
  • concentrations and dosage values may also vary with the age of the individual treated. It is to be further understood that for any particular subject, specific dosage regimens may need to be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations. Hence, the concentration ranges set forth herein are intended to be exemplary and are not intended to limit the scope or practice of the claimed formulations.
  • the DPP-IV inhibitor may optionally be suspended in micronized or other suitable form or may be derivatized to produce a more soluble active product or to produce a prodrug.
  • the form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the selected carrier or vehicle. The effective concentration is sufficient for ameliorating the symptoms of the disease state and may be empirically determined.
  • the DPP-IV inhibitors of the present invention may also be prepared as lyophilized powders, which can be reconstituted for administration as solutions, emulsions and other mixtures.
  • the lyophilized powders may also be formulated as solids or gels.
  • Sterile, lyophilized powder may be prepared by dissolving the compound in a sodium phosphate buffer solution containing dextrose or other suitable excipient. Subsequent sterile filtration of the solution followed by lyophilization under standard conditions known to those of skill in the art provides the desired formulation.
  • the lyophilized powder may optionally be prepared by dissolving dextrose, sorbitol, fructose, corn syrup, xylitol, glycerin, glucose, sucrose or other suitable agent, about 1-20%, preferably about 5 to 15%, in a suitable buffer, such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the ait at, typically, about neutral pH.
  • a suitable buffer such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the ait at, typically, about neutral pH.
  • a DPP-IV inhibitor is added to the resulting mixture, preferably above room temperature, more preferably at about 30-35 0 C, and stirred until it dissolves.
  • the resulting mixture is diluted by adding more buffer to a desired concentration.
  • the resulting mixture is sterile filtered or treated to remove particulates and to insure sterility, and apportioned into vials for lyophilization.
  • the DPP-IV inhibitors of the present invention may also be administered as topical mixtures.
  • Topical mixtures may be used for local and systemic administration.
  • the resulting mixture may be a solution, suspension, emulsions or the like and are formulated as creams, gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, irrigations, sprays, suppositories, bandages, dermal patches or any other formulations suitable for topical administration.
  • the DPP-IV inhibitors may be formulated as aerosols for topical application, such as by inhalation (see, U.S. Pat. Nos.
  • compositions for administration to the respiratory tract can be in the form of an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose.
  • the particles of the formulation will typically have diameters of less than 50 microns, preferably less than 10 microns.
  • the DPP-IV inhibitors may also be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye or for intracisternal or intraspinal application. Topical administration is contemplated for transdermal delivery and also for administration to the eyes or mucosa, or for inhalation therapies. Nasal solutions of the DPP-IV inhibitor alone or in combination with other pharmaceutically acceptable excipients can also be administered.
  • rectal administration Depending upon the disease state being treated, other routes of administration, such as topical application, transdermal patches, and rectal administration, may also be used.
  • pharmaceutical dosage forms for rectal administration are rectal suppositories, capsules and tablets for systemic effect.
  • Rectal suppositories are used herein mean solid bodies for insertion into the rectum that melt or soften at body temperature releasing one or more pharmacologically or therapeutically active ingredients.
  • Pharmaceutically acceptable substances utilized in rectal suppositories are bases or vehicles and agents to raise the melting point.
  • bases examples include cocoa butter (theobroma oil), glycerin-gelatin, carbowax, (polyoxyethylene glycol) and appropriate mixtures of mono-, di- and triglycerides of fatty acids. Combinations of the various bases may be used.
  • Agents to raise the melting point of suppositories include spermaceti and wax. Rectal suppositories may be prepared either by the compressed method or by molding. The typical weight of a rectal suppository is about 2 to 3 gm. Tablets and capsules for rectal administration may be manufactured using the same pharmaceutically acceptable substance and by the same methods as for formulations for oral administration.
  • Citric Acid Monohydrate 1.05 mg
  • the invention is also directed to kits and other articles of manufacture for treating diseases associated with DPP-IV. It is noted that diseases are intended to cover all conditions for which the DPP-IV possesses activity that contributes to the pathology and/or symptomology of the condition.
  • a kit comprising a composition comprising at least one DPP-IV inhibitor of the present invention in combination with instructions.
  • the instructions may indicate the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition.
  • the kit may also comprise packaging materials.
  • the packaging material may comprise a container for housing the composition.
  • the kit may also optionally comprise additional components, such as syringes for administration of the composition.
  • the kit may comprise the composition in single or multiple dose forms.
  • an article of manufacture is provided that comprises a composition comprising at least one DPP-IV inhibitor of the present invention in combination with packaging materials.
  • the packaging material may comprise a container for housing the composition.
  • the container may optionally comprise a label indicating the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition.
  • the kit may also optionally comprise additional components, such as syringes for administration of the composition.
  • the kit may comprise the composition in single or multiple dose forms.
  • the packaging material used in kits and articles of manufacture according to the present invention may form a plurality of divided containers such as a divided bottle or a divided foil packet.
  • the container can be in any conventional shape or form as known in the art which is made of a pharmaceutically acceptable material, for example a paper or cardboard box, a glass or plastic bottle or jar, a re-sealable bag (for example, to hold a "refill" of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule.
  • a pharmaceutically acceptable material for example a paper or cardboard box, a glass or plastic bottle or jar, a re-sealable bag (for example, to hold a "refill" of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule.
  • the container that is employed will depend on the exact dosage form involved, for example a conventional cardboard box would not generally be used to hold a liquid suspension. It is feasible that more than one container can be used together in a single package to market a single dosage form. For example, tablets may be contained in a bottle that is in
  • kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral, topical, transdermal and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.
  • dosage forms e.g., oral, topical, transdermal and parenteral
  • Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process recesses are formed in the plastic foil. The recesses have the size and shape of individual tablets or capsules to be packed or may have the size and shape to accommodate multiple tablets and/or capsules to be packed. Next, the tablets or capsules are placed in the recesses accordingly and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed.
  • kits are a dispenser designed to dispense the daily doses one at a time in the order of their intended use.
  • the dispenser is equipped with a memory-aid, so as to further facilitate compliance with the regimen.
  • a memory-aid is a mechanical counter that indicates the number of daily doses that has been dispensed.
  • a memory-aid is a battery- powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal which, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.
  • a racemic mixture of a compound may be reacted with an optically active resolving agent to form a pair of diastereoisomeric compounds.
  • the diastereomers may then be separated in order to recover the optically pure enantiomers.
  • Dissociable complexes may also be used to resolve enantiomers (e.g., crystalline diastereoisomeric salts).
  • Diastereomers typically have sufficiently distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) that they can be readily separated by taking advantage of these dissimilarities.
  • diastereomers can typically be separated by chromatography or by separation/resolution techniques based upon differences in solubility.
  • separation/resolution techniques A more detailed description of techniques that can be used to resolve stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981).
  • Compounds according to the present invention can also be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid.
  • a pharmaceutically acceptable base addition salt of a compound can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base.
  • Inorganic and organic acids and bases suitable for the preparation of the pharmaceutically acceptable salts of compounds are set forth in the definitions section of this Application.
  • the salt forms of the compounds can be prepared using salts of the starting materials or intermediates.
  • the free acid or free base forms of the compounds can be prepared from the corresponding base addition salt or acid addition salt form.
  • a compound in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like).
  • a compound in a base addition salt form can be converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc).
  • N-oxides of compounds according to the present invention can be prepared by methods known to those of ordinary skill in the art.
  • N-oxides can be prepared by treating an unoxidized form of the compound with an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as dichloromethane) at approximately 0 0 C.
  • an oxidizing agent e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like
  • a suitable inert organic solvent e.g., a halogenated hydrocarbon such as dichloromethane
  • the iV-oxides of the compounds can be prepared from the N-oxide of an appropriate starting material.
  • Compounds in an unoxidized form can be prepared from iV-oxides of compounds by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in an suitable inert organic solvent (e.g., acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80 0 C.
  • a reducing agent e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like
  • an inert organic solvent e.g., acetonitrile, ethanol, aqueous dioxane, or the like
  • Prodrug derivatives of the compounds can be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et al. (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985).
  • appropriate prodrugs can be prepared by reacting a non-derivatized compound with a suitable carbamylating agent (e.g., lj-acyloxyalkylcarbonochloridate ⁇ ara-nitrophenyl carbonate, or the like).
  • Protected derivatives of the compounds can be made by methods known to those of ordinary skill in the ait. A detailed description of the techniques applicable to the creation of protecting groups and their removal can be found in T.W. Greene, Protecting Groups in Organic Synthesis, 3 rd edition, John Wiley & Sons, Inc. 1999.
  • Compounds according to the present invention may be conveniently prepared, or formed during the process of the invention, as solvates (e.g. hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.
  • Compounds according to the present invention can also be prepared as then- individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomer. While resolution of enantiomers can be carried out using covalent diastereomeric derivatives of compounds, dissociable complexes are preferred (e.g., crystalline diastereoisomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities.
  • the diastereomers can be separated by chromatography or, preferably, by separation/resolution techniques based upon differences in solubility.
  • the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization.
  • a more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981).
  • M molar
  • mM millimolar
  • i.v. intravenous
  • Hz Hertz
  • Tr retention time
  • RP reverse phase
  • TEA triethylamine
  • TFA trifluoroacetic acid
  • TFAA trifluoroacetic anhydride
  • THF tetrahydrofuran
  • DMSO dimethylsulf oxide
  • EtOAc ethyl acetate
  • DME 1 ,2-dimethoxyethane
  • DCM dichloromethane
  • DCE dichloroethane
  • DMF N,N-dimethylformamide
  • DMPU N,N' -dimethylpropyleneurea
  • CDI 1,1 -carbonyldiimidazole
  • IBCF isobutyl chloroformate
  • HOAc acetic acid
  • HOSu N-hydroxysuccinimino
  • HOBT 1-hydroxybenzotriazole
  • TIPS triisopropylsilyl
  • TBS t-butyldimethylsilyl
  • HPLC high pressure liquid chomatography
  • BOP bis(2-oxo-3-oxazolidinyl)phosphinic chloride
  • TBAF tetra-n-butylammonium fluoride
  • mCPBA metal-chloroperbenzoic acid
  • DPP-IV inhibitors according to the present invention may be synthesized according to a variety of reaction schemes. Some illustrative schemes are provided herein in the examples. Other reaction schemes could be readily devised by those skilled in the art.
  • a synthetic route for producing other compounds of the present invention is shown in Scheme 5.
  • Treatment of Compound Q with sodium nitrite and a halide source provides Compound T, which is then treated with an amine or an alcohol to give Compound U.
  • Reduction gives Compound V of the present invention.
  • Compound T is subjected to a Suzuki or other transition metal mediated coupling to provide Compound W. Reduction then gives Compound Z of the present invention.
  • Example 1 7-Amino-6-aminomethyl-5-(2,4-dichloro-phenyl)- 1 ,3-dimethyl- IH- pyrido [2,3-d]pyrimidine-2,4-dione
  • Example 7 was isolated by LC-MS as the TFA salt.
  • [M-NH 2 ] calc'd for C 16 H 13 BrFN 3 O 3 , 393; found, 393.
  • Example 8 7-Amino-6-aminomethyl-5-(2,5-dichloro-phenyl)- 1 ,3-dimethyl- IH- pyrido[2,3- ⁇ i] pyrimidine-2, 4-dione
  • Example 11 7-Amino-6-aminomethyl — 1,3-dimethyl- 5- (3-methyl-thiophen-2-yl)-lH- pyrido[2,3-d] pyrimidine-2, 4-dione
  • the title compound was prepared using the procedures described in the preparation of Compounds AE and AF, and Example 8. The only difference was that after the synthesis of 2-(3-Methyl-thiophen-2-ylmethylene)-malononitrile, the reaction was carried onto the next step without further work-up or purification, and propanol was used instead of ethanol. Furthermore, after the hydrogenation using BH 3 • THF, the reaction mixture was concentrated. An ample amount of MeOH was added until there was no more bubbling. The mixture was dried in vacuo, and purified by prep. HPLC. After washing the product with EtoAc, an amount of 82.4mg (17.1% yield) of the title compound was collected.
  • Example 12 7-Amino-6-aminomethyl-5- (2-chloro-phenyl)-l,3-dimethyl-lH-pyrido [2,3- d] pyrimidine-2, 4-dione
  • Example 13 7-Amino-6-aminomethyl-5- (4-fluoro-phenyl)-l,3-dimethyl-lH-pyrido [2,3- d] pyrimidine-2, 4-dione
  • Example 17 7-Amino-6-aminomethyl-5- (2-chloro-6-fluoro-phenyl)-l,3-dimefhyl-lH- pyrido [2,3-d] pyrimidine-2, 4-dione
  • Example 25 7-Amino-6-aminomethyl-5-(2-chloro-4-fluoro-phenyl)-l,3-dimethyl-lH- pyrido [2,3-d] pyrimidine-2, 4-dione
  • Example 28 7-Amino-6-aminomethyl-5-(4,5-dimethyl-thiophen-2-yl)-l,3-dimethyl-lH- pyrido [2,3-d] pyrimidine-2, 4-dione
  • Example 34 6-(aminomethyl)-7-chloro-5-(2,4-dichlorophenyl)- 1 ,3-dimethylpyrido[2,3- d]pyrimidine-2,4( lH,3H)-dione
  • Example 35 7-amino-6-(aminomethyl)-5-(2-chloro-5-fluorophenyl)-3-methylpyrido[2,3- d]pyrimidine-2,4( lH,3H)-dione
  • Example 36 7-amino-6-(aminomethyl)-5-(2-(aminomethyl)phenyl)-l,3- dimethylpyrido[2,3-d]pyrimidine-2,4(lH,3H)-dione
  • Example 38 7-amino-5-(2-(aminomethyl)phenyl)- 1 ,3-dimethyl-2,4-dioxo- 1 ,2,3,4- tetrahydropyrido[2,3-d]pyrimidine-6-carbonitrile
  • Example 39 6-(arninomethyl)-7-(cyclopropylmethylamino)-5-(2,4-dichlorophenyl)- 1 ,3- dimethylpyrido[2,3-d]pyrimidine-2,4(lH,3H)-dione
  • Example 34 (70 mg, 0.19 mmol) in a mixture of THF (5mL) and DIPEA (0.2mL) was stirred with 10% Pd/C (20 mg) under H 2 atmosphere for 4 h, and then filtered and concentrated. The residue was purified by LC-MS to give the title compound.
  • Example 44 7-Amino-6-(aminomethyl)-5-(2-bromo-5-fluorophenyl)-l- methyrpyrido[2,3-d] pyrimidine-2, 4(iH,5H)-dione
  • protease inhibitory activities of DPP-IV inhibitors can be readily determined by methods known to those of ordinary skill in the art since suitable in vitro assays for measuring protease activity and the inhibition thereof by test compounds are known. Examples of assays that may be used for measuring protease inhibitory activity and selectivity are set forth below.
  • test compounds in varying concentrations ( ⁇ lOmM final concentration) were prepared in Dimethyl Sulfoxide (DMSO) and then diluted into assay buffer comprising: 2OmM Tris, pH 7.4; 2OmM KCl; and O.lmg/mL BSA.
  • DMSO Dimethyl Sulfoxide
  • Human DPP-IV (0.1 nM final concentration) was added to the dilutions and pre-incubated for 10 minutes at ambient temperature before the reaction was initiated with A-P-7-amido-4- trifluoromethylcoumarin (AP-AFC; 10 ⁇ M final concentration).
  • the total volume of the reaction mixture was 10-100 ⁇ L depending on assay formats used (384 or 96 well plates).
  • FAP ⁇ Assay Solutions of test compounds in varying concentrations ( ⁇ lOmM final concentration) were prepared in Dimethyl Sulfoxide (DMSO) and then diluted into assay buffer comprising: 2OmM Tris, pH 7.4; 2OmM KCl; and O.lmg/mL BSA. Human FAP ⁇ (2 nM final concentration) was added to the dilutions and pre-incubated for 10 minutes at ambient temperature before the reaction was initiated with A-P-7-amido-4- trifluoromethylcoumarin (AP-AFC; 40 ⁇ M final concentration). The total volume of the reaction mixture was 10-100 ⁇ L depending on assay formats used (384 or 96 well plates).
  • DMSO Dimethyl Sulfoxide
  • test compounds in varying concentrations ( ⁇ lOmM final concentration) were prepared in Dimethyl Sulfoxide (DMSO) and then diluted into assay buffer comprising: 10OmM Hepes, pH 7.4; 0.01% Brij35; and 10% glycerol. Tryptase (rhLung beta; 0.1 nM final concentration) was added to the dilutions and pre-incubated with compound for 10 minutes at ambient temperature. The enzymatic reaction was initiated with 25 ⁇ M Z-lys-SBzl and 400 ⁇ M DTNB. The total volume of the reaction mixture was lOO ⁇ L in Costar A/2 96 well plates. The reaction was followed colorimetrically ( ⁇ 405 nm) for 10 minutes.
  • DMSO Dimethyl Sulfoxide
  • Inhibition constants were calculated from the enzyme progress curves using standard mathematical models.
  • Compounds of the invention were tested according to the above-described assays for protease inhibition and observed to exhibit selective DPP-IV inhibitory activity. For example, compounds of the invention were found to inhibit DPP-IV activity at concentrations that are at least 50 fold less than those concentrations required to produce an equiactive inhibition of protease activity for FAP ⁇ .
  • the apparent inhibition constants (Ki) for compounds of the invention, against DPP-IV were in the range from about 10 "9 M to about 10 "5 M.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compounds, pharmaceutical compositions, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound of formula (I) wherein R2 is amino (C1-6)alkyl, hetero(C3-12)cycloalkyl, hetero(C4-12)bicycloaryl, heteroaryl, or cyano; and W, X, Y, Z, R1, R5 and R7 are as defined herein.

Description

DIPEPTIDYL PEPTIDASE INHIBITORS
FIELD OF THE INVENTION
[0001] The invention relates to compounds that may be used to inhibit dipeptidyl peptidases as well as compositions of matter and kits comprising these compounds. The present invention also relates to methods for inhibiting dipeptidyl peptidases as well as treatment methods using compounds according to the present invention.
DESCRIPTION OF RELATED ART
[0002] Dipeptidyl Peptidase IV (IUBMB Enzyme Nomenclature EC.3.4.14.5) is a type π membrane protein that has been referred to in the literature by a wide a variety of names including DPP4, DP4, DAP-IV, FAPβ, adenosine deaminase complexing protein 2, adenosine deaminase binding protein (AD Abp), dipeptidyl aminopeptidase IV; Xaa-Pro- dipeptidyl-aminopeptidase; Gly-Pro naphthylamidase; postproline dipeptidyl aminopeptidase PV; lymphocyte antigen CD26; glycoprotein GPIlO; dipeptidyl peptidase PV; glycylproline aminopeptidase; glycylproline aminopeptidase; X-prolyl dipeptidyl aminopeptidase; pep X; leukocyte antigen CD26; glycylprolyl dipeptidylaminopeptidase; dipeptidyl-peptide hydrolase; glycylprolyl aminopeptidase; dipeptidyl-aminopeptidase IV; DPP rV/CD26; amino acyl-prolyl dipeptidyl aminopeptidase; T cell triggering molecule Tp 103; X-PDAP. Dipeptidyl Peptidase PV is referred to herein as "DPP-W." [0003] DPP-PV is a non-classical serine aminodipeptidase that removes Xaa-Pro dipeptides from the amino terminus (N-terminus) of polypeptides and proteins. DPP-PV dependent slow release of dipeptides of the type X-GIy or X-Ser has also been reported for some naturally occurring peptides.
[0004] DPP-PV is constitutively expressed on epithelial and endothelial cells of a variety of different tissues (intestine, liver, lung, kidney and placenta), and is also found in body fluids. DPP-FV is also expressed on circulating T-lymphocytes and has been shown to be synonymous with the cell-surface antigen, CD-26. DPP-PV has been implicated in a number of disease states, some of which are discussed below. [0005] DPP-PV is responsible for the metabolic cleavage of certain endogenous peptides (GLP-I (7-36), glucagon) in vivo and has demonstrated proteolytic activity against a variety of other peptides (GHRH, NPY, GLP-2, VIP) in vitro.
1 Express Mail No. EW 19890360US [0006] GLP-I (7-36) is a 29 amino-acid peptide derived by post-translational processing of proglucagon in the small intestine. GLP-I (7-36) has multiple actions in vivo including the stimulation of insulin secretion, inhibition of glucagon secretion, the promotion of satiety, and the slowing of gastric emptying. Based on its physiological profile, the actions of GLP-I (7-36) are believed to be beneficial in the prevention and treatment of type II diabetes and potentially obesity. For example, exogenous administration of GLP-I (7-36) (continuous infusion) in diabetic patients has been found to be efficacious in this patient population. Unfortunately, GLP-I (7-36) is degraded rapidly in vivo and has been shown to have a short half-life in vivo (ty2=1.5 minutes).
[0007] Based on a study of genetically bred DPP-IV knock out mice and on in vivo I in vitro studies with selective DPP-IV inhibitors, DPP-IV has been shown to be the primary degrading enzyme of GLP-I (7-36) in vivo. GLP-I (7-36) is degraded by DPP-IV efficiently to GLP-I (9-36), which has been speculated to act as a physiological antagonist to GLP-I (7-36). Inhibiting DPP-IV in vivo is therefore believed to be useful for potentiating endogenous levels of GLP-I (7-36) and attenuating the formation of its antagonist GLP-I (9-36). Thus, DPP-IV inhibitors are believed to be useful agents for the prevention, delay of progression, and/or treatment of conditions mediated by DPP-IV, in particular diabetes and more particularly, type 2 diabetes mellitus, diabetic dislipidemia, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose (IFG), metabolic acidosis, ketosis, appetite regulation and obesity. [0008] DPP-IV expression is increased in T-cells upon mitogenic or antigenic stimulation (Mattem, T., et al., Scand. J. Immunol, 1991, 33, 737). It has been reported that inhibitors of DPP-IV and antibodies to DPP-IV suppress the proliferation of mitogen- stimulated and antigen-stimulated T-cells in a dose-dependant manner (Schon, E., et al., Biol. Chem., 1991, 372, 305). Various other functions of T-lymphocytes such as cytokine production, IL-2 mediated cell proliferation and B-cell helper activity have been shown to be dependent on DPP-IV activity (Schon, E., et al., Scand. J. Immunol, 1989, 29, 127). DPP-IV inhibitors, based on boroProline, (Flentke, G. R., et al., Proc. Nat. Acad. ScL USA, 1991, 88, 1556) although unstable, were effective at inhibiting antigen-induced lymphocyte proliferation and IL-2 production in murine CD4+ T-helper cells. Such boronic acid inhibitors have been shown to have an effect in vivo in mice causing suppression of antibody production induced by immune challenge (Kubota, T. et al., Clin. Exp. Imtnun., 1992, 89, 192). The role of DPP-IV in regulating T lymphocyte activation may also be attributed, in part, to its cell-surface association with the transmembrane phosphatase, CD45. DPP-IV inhibitors or non-active site ligands may possibly disrupt the CD45-DPP-IV association. CD45 is known to be an integral component of the T-cell signaling apparatus. It has been reported that DPP-IV is essential for the penetration and infectivity of HIV-I and HIV-2 viruses in CD4+ T-cells (Wakselman, M., Nguyen, C, Mazaleyrat, J.-P., Callebaut, C, Krust, B., Hovanessian, A. G., Inhibition of HIV-I infection of CD 26+ but not CD 26-cells by a potent cyclopeptidic inhibitor of the DPP-IV activity of CD 26. Abstract P.44 of the 24.sup.th European Peptide Symposium 1996). Additionally, DPP-IV has been shown to associate with the enzyme adenosine deaminase (ADA) on the surface of T-cells (Kameoka, J., et al., Science, 193, 26 466). ADA deficiency causes severe combined immunodeficiency disease (SCID) in humans. This ADA-CD26 interaction may provide clues to the pathophysiology of SCID. It follows that inhibitors of DPP-IV may be useful immunosuppressants (or cytokine release suppressant drugs) for the treatment of among other things: organ transplant rejection; autoimmune diseases such as inflammatory bowel disease, multiple sclerosis and rheumatoid arthritis; and the treatment of AIDS.
[0009] It has been shown that lung endothelial cell DPP-IV is an adhesion molecule for lung-metastatic rat breast and prostate carcinoma cells (Johnson, R. C, et al., J. Cell. Biol, 1993, 121, 1423). DPP-IV is known to bind to fibronectin and some metastatic tumor cells are known to carry large amounts of fibronectin on their surface. Potent DPP-IV inhibitors may be useful as drugs to prevent metastases of, for example, breast and prostrate tumors to the lungs.
[0010] High levels of DPP-FV expression have also been found in human skin fibroblast cells from patients with psoriasis, rheumatoid arthritis (RA) and lichen planus (Raynaud, F., et al., J. Cell. Physiol, 1992, 151, 378). Therefore, DPP-IV inhibitors may be useful as agents to treat dermatological diseases such as psoriasis and lichen planus. [0011] High DPP-IV activity has been found in tissue homogenates from patients with benign prostate hypertrophy and in prostatosomes. These are prostate derived organelles important for the enhancement of sperm forward motility (Vanhoof, G., et al., Eur. J. Clin. Chem. Clin. Biochem., 1992, 30, 333). DPP-IV inhibitors may also act to suppress sperm motility and therefore act as a male contraceptive agent. Conversely, DPP-IV inhibitors have been implicated as novel for treatment of infertility, and particularly human female infertility due to Polycystic ovary syndrome (PCOS, Stein-Leventhal syndrome) which is a condition characterized by thickening of the ovarian capsule and formation of multiple follicular cysts. It results in infertility and amenorrhea.
[0012] DPP-IV is thought to play a role in the cleavage of various cytokines (stimulating hematopoietic cells), growth factors and neuropeptides. [0013] Stimulated hematopoietic cells are useful for the treatment of disorders that are characterized by a reduced number of hematopoietic cells or their precursors in vivo. Such conditions occur frequently in patients who are immunosuppressed, for example, as a consequence of chemotherapy and/or radiation therapy for cancer. It was discovered that inhibitors of dipeptidyl peptidase type IV are useful for stimulating the growth and differentiation of hematopoietic cells in the absence of exogenously added cytokines or other growth factors or stromal cells. This discovery contradicts the dogma in the field of hematopoietic cell stimulation, which provides that the addition of cytokines or cells that produce cytokines (stromal cells) is an essential element for maintaining and stimulating the growth and differentiation of hematopoietic cells in culture. (See, e.g., PCT Ml. Application No. PCT /US93/017173 published as WO 94/03055). [0014] DPP-IV in human plasma has been shown to cleave N-terminal Tyr-Ala from growth hormone-releasing factor and cause inactivation of this hormone. Therefore, inhibitors of DPP-IV may be useful in the treatment of short stature due to growth hormone deficiency (Dwarfism) and for promoting GH-dependent tissue growth or re- growth.
[0015] DPP-IV can also cleave neuropeptides and has been shown to modulate the activity of neuroactive peptides substance P, neuropeptide Y and CLIP (Mentlein, R., Dahms, P., Grandt, D., Kruger, R., Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV, Regul. Pept., 49, 133, 1993; Wetzel, W., Wagner, T., Vogel, D., Demuth, H.-U., Balschun, D., Effects of the CLIP fragment ACTH 20-24 on the duration of REM sleep episodes, Neuropeptides, 31, 41, 1997). Thus DPP-IV inhibitors may also be useful agents for the regulation or normalization of neurological disorders.
[0016] Several compounds have been shown to inhibit DPP-IV. Nonetheless, a need still exists for new DPP-IV inhibitors that have advantageous potency, stability, selectivity, toxicity and/or pharmacodynamics properties. In this regard, a novel class of DPP-IV inhibitors are provided herein.
SUMMARY OF THE INVENTION
[0017] The present invention relates to compounds that have activity for inhibiting DPP-IV. It is noted that these compounds may also have activity for inhibiting other S9 proteases and thus may be used against these other S9 proteases as well as DPP-IV. The present invention also provides compositions, articles of manufacture and kits comprising these compounds.
[0018] In one embodiment, a pharmaceutical composition is provided that comprises a DPP-IV inhibitor according to the present invention as an active ingredient. Pharmaceutical compositions according to the invention may optionally comprise 0.001%- 100% of one or more DPP-IV inhibitors of this invention. These pharmaceutical compositions may be administered or coadministered by a wide variety of routes, including for example, orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, or intrathecally. The compositions may also be administered or coadministered in slow release dosage forms. [0019] The invention is also directed to kits and other articles of manufacture for treating disease states associated with DPP-IV.
[0020] In one embodiment, a kit is provided that comprises a composition comprising at least one DPP-IV inhibitor of the present invention in combination with instructions. The instructions may indicate the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition. The kit may also comprise packaging materials. The packaging material may comprise a container for housing the composition. The kit may also optionally comprise additional components, such as syringes for administration of the composition. The kit may comprise the composition in single or multiple dose forms.
[0021] In another embodiment, an article of manufacture is provided that comprises a composition comprising at least one DPP-IV inhibitor of the present invention in combination with packaging materials. The packaging material may comprise a container for housing the composition. The container may optionally comprise a label indicating the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition. The kit may also optionally comprise additional components, such as syringes for administration of the composition. The kit may comprise the composition in single or multiple dose forms.
[0022] Also provided are methods for preparing compounds, compositions and kits according to the present invention. For example, several synthetic schemes are provided herein for synthesizing compounds according to the present invention.
[0023] Also provided are methods for using compounds, compositions, kits and articles of manufacture according to the present invention.
[0024] In one embodiment, the compounds, compositions, kits and articles of manufacture are used to inhibit DPP-IV.
[0025] In another embodiment, the compounds, compositions, kits and articles of manufacture are used to treat a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state.
[0026] In another embodiment, a compound is administered to a subject wherein DPP-
IV activity within the subject is altered, preferably reduced.
[0027] In another embodiment, a prodrug of a compound is administered to a subject that is converted to the compound in vivo where it inhibits DPP-IV.
[0028] In another embodiment, a method of inhibiting DPP-IV is provided that comprises contacting DPP-IV with a compound according to the present invention.
[0029] In another embodiment, a method of inhibiting DPP-IV is provided that comprises causing a compound according to the present invention to be present in a subject in order to inhibit DPP-IV in vivo.
[0030] In another embodiment, a method of inhibiting DPP-IV is provided that comprises administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits DPP-IV in vivo. It is noted that the compounds of the present invention may be the first or second compounds.
[0031] In another embodiment, a therapeutic method is provided that comprises administering a compound according to the present invention.
[0032] In another embodiment, a method of inhibiting cell proliferation is provided that comprises contacting a cell with an effective amount of a compound according to the present invention.
[0033] In another embodiment, a method of inhibiting cell proliferation in a patient is provided that comprises administering to the patient a therapeutically effective amount of a compound according to the present invention.
[0034] In another embodiment, a method of treating a condition in a patient which is known to be mediated by DPP-IV, or which is known to be treated by DPP-IV inhibitors, comprising administering to the patient a therapeutically effective amount of a compound according to the present invention.
[0035] In another embodiment, a method is provided for using a compound according to the present invention in order to manufacture a medicament for use in the treatment of disease state which is known to be mediated by DPP-IV, or which is known to be treated by DPP-IV inhibitors.
[0036] In another embodiment, a method is provided for treating a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state, the method comprising: causing a compound according to the present invention to be present in a subject in a therapeutically effective amount for the disease state.
[0037] In another embodiment, a method is provided for treating a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state, the method comprising: administering a first compound to a subject that is converted in vivo to a second compound such that the second compound is present in the subject in a therapeutically effective amount for the disease state. It is noted that the compounds of the present invention may be the first or second compounds.
[0038] In another embodiment, a method is provided for treating a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state, the method comprising: administering a compound according to the present invention to a subject such that the compound is present in the subject in a therapeutically effective amount for the disease state.
[0039] In another embodiment, a method is provided for treating a cell proliferative disease state comprising treating cells with a compound according to the present invention in combination with an anti-proliferative agent, wherein the cells are treated with the compound according to the present invention before, at the same time, and/or after the cells are treated with the anti-proliferative agent, referred to herein as combination therapy. It is noted that treatment of one agent before another is referred to herein as sequential therapy, even if the agents are also administered together. It is noted that combination therapy is intended to cover when agents are administered before or after each other (sequential therapy) as well as when the agents are administered at the same time. [0040] Examples of diseases that may be treated by administration of compounds and compositions according to the present invention include, but are not limited to conditions mediated by DPP-IV, in particular diabetes, more particular type 2 diabetes mellitus, diabetic dislipidemia, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose (IFG), metabolic acidosis, ketosis, appetite regulation, obesity, immunosuppressants or cytokine release regulation, autoimmune diseases such as inflammatory bowel disease, multiple sclerosis and rheumatoid arthritis, AIDS, cancers (prevention of metastases, for example, breast and prostrate tumors to the lungs), dermatological diseases such as psoriasis and lichen planus, treatment of female infertility, osteoporosis, male contraception and neurological disorders.
[0041] It is noted in regard to all of the above embodiments that the present invention is intended to encompass all pharmaceutically acceptable ionized forms (e.g., salts) and solvates (e.g., hydrates) of the compounds, regardless of whether such ionized forms and solvates are specified since it is well known in the art to administer pharmaceutical agents in an ionized or solvated form. It is also noted that unless a particular stereochemistry is specified, recitation of a compound is intended to encompass all possible stereoisomers (e.g., enantiomers or diastereomers depending on the number of chiral centers), independent of whether the compound is present as an individual isomer or a mixture of isomers. Further, unless otherwise specified, recitation of a compound is intended to encompass all possible resonance forms and tautomers. With regard to the claims, the language "compound comprising the formula" is intended to encompass the compound and all pharmaceutically acceptable ionized forms and solvates, all possible stereoisomers, and all possible resonance forms and tautomers unless otherwise specifically specified in the particular claim.
[0042] It is further noted that prodrugs may also be administered which are altered in vivo and become a compound according to the present invention. The various methods of using the compounds of the present invention are intended, regardless of whether prodrug delivery is specified, to encompass the administration of a prodrug that is converted in vivo to a compound according to the present invention. It is also noted that certain compounds of the present invention may be altered in vivo prior to inhibiting DPP-IV and thus may themselves be prodrugs for another compound. Such prodrugs of another compound may or may not themselves independently have DPP-IV inhibitory activity.
DEFINITIONS
[0043] Unless otherwise stated, the following terms used in the specification and claims shall have the following meanings for the purposes of this Application. [0044] "Alicyclic" means a moiety comprising a non-aromatic ring structure. Alicyclic moieties may be saturated or partially unsaturated with one, two or more double or triple bonds. Alicyclic moieties may also optionally comprise heteroatoms such as nitrogen, oxygen and sulfur. The nitrogen atoms can be optionally quaternerized or oxidized and the sulfur atoms can be optionally oxidized. Examples of alicyclic moieties include, but are not limited to moieties with C3 - C8 rings such as cyclopropyl, cyclohexane, cyclopentane, cyclopentene, cyclopentadiene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptene, cycloheptadiene, cyclooctane, cyclooctene, and cyclooctadiene. [0045] "Aliphatic" means a moiety characterized by a straight or branched chain arrangement of constituent carbon atoms and may be saturated or partially unsaturated with one, two or more double or triple bonds.
[0046] "Alkenyl" represented by itself means a straight or branched, unsaturated, aliphatic radical having a chain of carbon atoms having at least one double bond between adjacent carbon atoms. Cx alkenyl and Cχ.γ alkenyl are typically used where X and Y indicate the number of carbon atoms in the chain. For example, C2-6 alkenyl includes alkenyls that have a chain of between 2 and 6 carbons.
[0047] "Alkoxy" means an oxygen moiety having a further alkyl substituent. The alkoxy groups of the present invention can be optionally substituted. [0048] "Alkyl" represented by itself means a straight or branched, saturated or unsaturated, aliphatic radical having a chain of carbon atoms, optionally with oxygen (See "oxaalkyl") or nitrogen atoms (See "aminoalkyl") between the carbon atoms. Cx alkyl and Cx-Y alkyl are typically used where X and Y indicate the number of carbon atoms in the chain. For example, C1-6 alkyl includes alkyls that have a chain of between 1 and 6 carbons (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-bvftyl, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylallyl, ethynyl, 1-propynyl, 2-propynyl, and the like). Alkyl represented along with another radical (e.g., as in arylalkyl, heteroarylalkyl) means a straight or branched, saturated or unsaturated aliphatic divalent radical having the number of atoms indicated or when no atoms are indicated means a bond (e.g., (C6-10)aryl(C1-3)alkyl includes, benzyl, phenethyl, 1-phenylethyl, 3-phenylpropyl, 2-thienylmethyl, 2-pyridinylmethyl and the like). [0049] "Alkylene", unless indicated otherwise, means a straight or branched, saturated or unsaturated, aliphatic, divalent radical. Cx alkylene and Cχ.γ alkylene are typically used where X and Y indicate the number of carbon atoms in the chain. For example, C1-6 alkylene includes methylene (-CH2-), ethylene (-CH2CH2-), trimethylene (-CH2CH2CH2-), tetramethylene (-CH2CH2CH2CH2-) 2-butenylene (-CH2CH=CHCH2-), 2-methyltetramethylene (-CH2CH(CH3)CH2CH2-), pentamethylene (-CH2CH2CH2CH2CH2-) and the like).
[0050] "Alkylidene" means a straight or branched saturated or unsaturated, aliphatic radical connected to the parent molecule by a double bond. Cx alkylidene and Cχ.γ alkylidene are typically used where X and Y indicate the number of carbon atoms in the chain. For example, C1-6 alkylidene includes methylene (=CH2), ethylidene (=CHCH3), isopropylidene (=C(CH3)2), propylidene (=CHCH2CH3), aUylidene (=CH-CH=CH2), and the like).
[0051] " Alkynyl" represented by itself means a straight or branched, unsaturated, aliphatic radical having a chain of carbon atoms having at least one triple bond between adjacent carbon atoms. Cx alkynyl and Cχ.γ alkynyl are typically used where X and Y indicate the number of carbon atoms in the chain. For example, C2-6 alkynyl includes alkynyls that have a chain of between 2 and 6 carbons.
[0052] "Amino" means a nitrogen moiety having two further substituents where a hydrogen or carbon atom is attached to the nitrogen. For example, representative amino groups include -NH2, -NHCH3, -N(CH3)2, -NHC1-3-alkyl, -N(Ci-3-alkyl)2 and the like.
Unless indicated otherwise, the compounds of the invention containing amino moieties may include protected derivatives thereof. Suitable protecting groups for amino moieties include acetyl, tert-butoxycarbonyl, benzyloxycarbonyl, and the like.
[0053] "Aminoalkyl" means an alkyl, as defined above, except where one or more substituted or unsubstituted nitrogen atoms (-N-) are positioned between carbon atoms of the alkyl. For example, an (C2.6) aminoalkyl refers to a chain comprising between 2 and 6 carbons and one or more nitrogen atoms positioned between the carbon atoms.
[0054] "Animal" includes humans, non-human mammals (e.g., dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like) and non-mammals (e.g., birds, and the like).
[0055] "Aromatic" means a moiety wherein the constituent atoms make up an unsaturated ring system, all atoms in the ring system are sp2 hybridized and the total number of pi electrons is equal to 4n+2. An aromatic ring may be such that the ring atoms are only carbon atoms or may include carbon and non-carbon atoms (see Heteroaryl).
[0056] "Aryl" means a monocyclic or polycyclic ring assembly wherein each ring is aromatic or when fused with one or more rings forms an aromatic ring assembly. If one or more ring atoms is not carbon (e.g., N, S), the aryl is a heteroaryl. Cx aryl and Cχ.γ aryl are typically used where X and Y indicate the number of atoms in the ring.
[0057] "Bicycloalkyl" means a saturated or partially unsaturated fused bicyclic or bridged polycyclic ring assembly.
[0058] "Bicycloaryl" means a bicyclic ring assembly wherein the rings are linked by a single bond or fused and at least one of the rings comprising the assembly is aromatic. Cx bicycloaryl and Cχ.γ bicycloaryl are typically used where X and Y indicate the number of carbon atoms in the bicyclic ring assembly and directly attached to the ring. [0059] "Bridging ring" as used herein refers to a ring that is bonded to another ring to form a compound having a bicyclic structure where two ring atoms that are common to both rings are not directly bound to each other. Non-exclusive examples of common compounds having a bridging ring include boraeol, norbornane, 7- oxabicyclo[2.2. l]heptane, and the like. One or both rings of the bicyclic system may also comprise heteroatoms.
[0060] "Carbamoyl" means the radical -OC(O)NRaRb where Ra and Rb are each independently two further substituents where a hydrogen or carbon atom is attached to the nitrogen.
[0061] "Carbocycle" means a ring consisting of carbon atoms.
[0062] "Carbocyclic ketone derivative" means a carbocyclic derivative wherein the ring contains a -CO- moiety.
[0063] "Carbonyl" means the radical -CO-. It is noted that the carbonyl radical may be further substituted with a variety of substituents to form different carbonyl groups including acids, acid halides, aldehydes, amides, esters, and ketones.
[0064] "Carboxy" means the radical -CO2-. It is noted that compounds of the invention containing carboxy moieties may include protected derivatives thereof, i.e., where the oxygen is substituted with a protecting group. Suitable protecting groups for carboxy moieties include benzyl, tert-butyl, and the like.
[0065] "Cyano" means the radical -CN.
[0066] "Cycloalkyl" means a non-aromatic, saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly. Cx cycloalkyl and Cχ.γ cycloalkyl are typically used where X and Y indicate the number of carbon atoms in the ring assembly. For example, C3-10 cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,5-cyclohexadienyl, bicyclo[2.2.2]octyl, adamantan-1-yl, decahydronaphthyl, oxocyclohexyl, dioxocyclohexyl, thiocyclohexyl,
2-oxobicyclo[2.2.1]hept-l-yl, and the like.
[0067] "Cycloalkylene" means a divalent saturated or partially unsaturated, monocyclic or polycyclic ring assembly. Cx cycloalkylene and Cχ.γ cycloalkylene are typically used where X and Y indicate the number of carbon atoms in the ring assembly. [0068] "Disease" specifically includes any unhealthy condition of an animal or part thereof and includes an unhealthy condition that may be caused by, or incident to, medical or veterinary therapy applied to that animal, i.e., the "side effects" of such therapy.
[0069] "Fused ring" as used herein refers to a ring that is bonded to another ring to form a compound having a bicyclic structure where the ring atoms that are common to both rings are directly bound to each other. Non-exclusive examples of common fused rings include decalin, naphthalene, anthracene, phenanthrene, indole, furan, benzofuran, quinoline, and the like. Compounds having fused ring systems may be saturated, partially saturated, carbocyclics, heterocyclics, aromatics, heteroaromatics, and the like.
[0070] "Halo" means fluoro, chloro, bromo or iodo.
[0071] "Halo-substituted alkyl", as an isolated group or part of a larger group, means
"alkyl" substituted by one or more "halo" atoms, as such terms are defined in this
Application. Halo-substituted alkyl includes haloalkyl, dihaloalkyl, trihaloalkyl, perhaloalkyl and the like (e.g. halo-substituted (C1-3)alkyl includes chloromethyl, dichloromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, perfluoroethyl,
2,2,2-trifluoro-l,l-dichloroethyl, and the like).
[0072] "Heteroatom" refers to an atom that is not a carbon atom. Particular examples of heteroatoms include, but are not limited to nitrogen, oxygen, and sulfur.
[0073] "Heteroatom moiety" includes a moiety where the atom by which the moiety is attached is not a carbon. Examples of heteroatom moieties include -N=, -NR0-, -N+(O")=,
-O-, -S- or -S(O)2-, wherein Rc is further substituent.
[0074] "Heterobicycloalkyl" means bicycloalkyl, as defined in this Application, provided that one or more of the atoms within the ring is a heteroatom. For example hetero(C9-12)bicycloalkyl as used in this application includes, but is not limited to, 3-aza- bicyclo[4.1.0]hept-3-yl, 2-aza-bicyclo[3.1.0]hex-2-yl , 3-aza-bicyclo[3.1.0]hex-3-yl, and the like.
[0075] "Heterocycloalkylene" means cycloalkylene, as defined in this Application, provided that one or more of the ring member carbon atoms is replaced by a heteroatom.
[0076] "Heteroaryl" means a cyclic aromatic group having five or six ring atoms, wherein at least one ring atom is a heteroatom and the remaining ring atoms are carbon.
The nitrogen atoms can be optionally quaternerized and the sulfur atoms can be optionally oxidized. Heteroaryl groups of this invention include, but are not limited to, those derived from furan, imidazole, isothiazole, isoxazole, oxadiazole, oxazole, 1,2,3-oxadiazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrroline, thiazole, 1,3,4-thiadiazole, triazole and tetrazole. "Heteroaryl" also includes, but is not limited to, bicyclic or tricyclic rings, wherein the heteroaryl ring is fused to one or two rings independently selected from the group consisting of an aryl ring, a cycloalkyl ring, a cycloalkenyl ring, and another monocyclic heteroaryl or heterocycloalkyl ring. These bicyclic or tricyclic heteroaryls include, but are not limited to, those derived from benzo[b]furan, benzo[b]thiophene, benzimidazole, imidazo[4,5-c]pyridine, quinazoline, thieno[2,3-c]pyridine, thieno[3,2- b]pyridine, thieno[2,3-b]pyridine, indolizine, imidazo[l,2a]pyridine, quinoline, isoquinoline, phthalazine, quinoxaline, naphthyridine, quinolizine, indole, isoindole, indazole, indoline, benzoxazole, benzopyrazole, benzothiazole, imidazo[l,5-a]pyridine, pyrazolo [ 1 ,5-a]pyridine, imidazo [ 1 ,2-a]pyrimidine, imidazo [ 1 ,2-c]pyrimidine, imidazo[l,5-a]pyrimidine, imidazo [l,5-c]pyrimidine, pyrrolo[2,3-b]pyridine, pyrrolo[2,3- c]pyridine, pyrrolo[3,2-c]pyridine, pyrrolo[3,2-b]pyridine, pyrrolo[2,3-d]pyrimidine, pyrrolo[3,2-d]pyrimidine, pyrrolo[2,3-b]pyrazine, pyrazolo [l,5-a]pyridine, pyrrolo[l,2- b]pyridazine, pyrrolo[l,2-c]pyrimidine, pyrrolo[l,2-a]pyrimidine, pyrrolo[l,2-a]pyrazine, triazo[l,5-a]pyridine, pteridine, purine, carbazole, acridine, phenazine, phenothiazene, phenoxazine, l,2-dihydropyrrolo[3,2,l-Λ/]indole, indolizine, pyrido[l,2-a]indole and 2(lH)-pyridinone. The bicyclic or tricyclic heteroaryl rings can be attached to the parent molecule through either the heteroaryl group itself or the aryl, cycloalkyl, cycloalkenyl or heterocycloalkyl group to which it is fused. The heteroaryl groups of this invention can be substituted or unsubstituted.
[0077] "Heterobicycloaryl" means bicycloaryl, as defined in this Application, provided that one or more of the atoms within the ring is a heteroatom. For example, hetero(C4-10)bicycloaryl as used in this Application includes, but is not limited to, 2-amino- 4-0X0-3 ,4-dihydropteridin-6-yl, tetrahydroisoquinolinyl, and the like. [0078] "Heterocycloalkyl" means cycloalkyl, as defined in this Application, provided that one or more of the atoms forming the ring is a heteroatom selected, independently from N, O, or S. Non-exclusive examples of heterocycloalkyl include piperidyl, A- morpholyl, 4-piperazinyl, pyrrolidinyl, perhydropyrrolizinyl, 1,4-diazaperhydroepinyl, 1,3- dioxanyl, 1,4-dioxanyl and the like.
[0079] "Hydroxy" means the radical -OH.
[0080] "Iminoketone derivative" means a derivative comprising the moiety -C(NR)-, wherein R comprises a hydrogen or carbon atom attached to the nitrogen.
[0081] "Isomers" mean any compound having an identical molecular formulae but differing in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed
"stereoisomers." Stereoisomers that are not mirror images of one another are termed
"diastereomers" and stereoisomers that are nonsuperimposable mirror images are termed
"enantiomers" or sometimes "optical isomers." A carbon atom bonded to four nonidentical substituents is termed a "chiral center." A compound with one chiral center has two enantiomeric forms of opposite chirality. A mixture of the two enantiomeric forms is termed a "racemic mixture." A compound that has more than one chiral center has 2nΛ enantiomeric pairs, where n is the number of chiral centers. Compounds with more than one chiral center may exist as ether an individual diastereomer or as a mixture of diastereomers, termed a "diastereomeric mixture." When one chiral center is present a stereoisomer may be characterized by the absolute configuration of that chiral center.
Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. Enantiomers are characterized by the absolute configuration of their chiral centers and described by the R- and S-sequencing rules of Cahn, Ingold and Prelog.
Conventions for stereochemical nomenclature, methods for the determination of stereochemistry and the separation of stereoisomers are well known in the art (e.g., see
"Advanced Organic Chemistry", 4th edition, March, Jerry, John Wiley & Sons, New York,
1992).
[0082] "Nitro" means the radical -NO2.
[0083] "Oxaalkyl" means an alkyl, as defined above, except where one or more oxygen atoms (-O-) are positioned between carbon atoms of the alkyl. For example, an (C2-
6)oxaalkyl refers to a chain comprising between 2 and 6 carbons and one or more oxygen atoms positioned between the carbon atoms. [0084] "Oxoalkyl" means an alkyl, further substituted with a carbonyl group. The carbonyl group may be an aldehyde, ketone, ester, amide, acid or acid chloride. [0085] "Pharmaceutically acceptable" means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use.
[0086] "Pharmaceutically acceptable salts" means salts of inhibitors of the present invention which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, o-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]oct-2-ene-l-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis(3-hydroxy-2-ene-l-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid and the like. [0087] Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic bases. Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydroxide. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, JV-mefhylglucamine and the like.
[0088] "Prodrug" means a compound that is convertible in vivo metabolically into an inhibitor according to the present invention. The prodrug itself may or may not also have DPP-IV inhibitory activity. For example, an inhibitor comprising a hydroxy group may be administered as an ester that is converted by hydrolysis in vivo to the hydroxy compound. Suitable esters that may be converted in vivo into hydroxy compounds include acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates, quinates, esters of amino acids, and the like. Similarly, an inhibitor comprising an amine group may be administered as an amide that is converted by hydrolysis in vivo to the amine compound.
[0089] "Protected derivatives" means derivatives of inhibitors in which a reactive site or sites are blocked with protecting groups. Protected derivatives are useful in the preparation of inhibitors or in themselves may be active as inhibitors. A comprehensive list of suitable protecting groups can be found in T.W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999.
[0090] "Substituted or unsubstituted" means that a given moiety may consist of only hydrogen substituents through available valencies (unsubstituted) or may further comprise one or more non-hydrogen substituents through available valencies (substituted) that are not otherwise specified by the name of the given moiety. For example, isopropyl is an example of an ethylene moiety that is substituted by -CH3. In general, a non-hydrogen substituent may be any substituent that may be bound to an atom of the given moiety that is specified to be substituted. Examples of substituents include, but are not limited to, aldehyde, alicyclic, aliphatic, alkyl, alkylene, alkylidene, amide, amino, aminoalkyl, aromatic, aryl, bicycloalkyl, bicycloaryl, carbamoyl, carbocyclyl, carboxyl, carbonyl group, cycloalkyl, cycloalkylene, ester, halo, heterobicycloalkyl, heterocycloalkylene, heteroaryl, heterobicycloaryl, heterocycloalkyl, oxo, hydroxy, iminoketone, ketone, nitro, oxaalkyl, and oxoalkyl moieties, each of which may optionally also be substituted or unsubstituted. [0091] "Sulfinyl" means the radical -SO-. It is noted that the sulfinyl radical may be further substituted with a variety of substituents to form different sulfinyl groups including sulfinic acids, sulfinamides, sulfinyl esters, and sulfoxides.
[0092] "Sulfonyl" means the radical -SO2-. It is noted that the sulfonyl radical may be further substituted with a variety of substituents to form different sulfonyl groups including sulfonic acids, sulfonamides, sulfonate esters, and sulfones. [0093] "Therapeutically effective amount" means that amount which, when administered to an animal for treating a disease, is sufficient to effect such treatment for the disease.
[0094] "Thiocarbonyl" means the radical -CS-. It is noted that the thiocarbonyl radical may be further substituted with a variety of substituents to form different thiocarbonyl groups including thioacids, thioamides, thioesters, and thioketones.
[0095] "Treatment" or "treating" means any administration of a compound of the present invention and includes:
(1) preventing the disease from occurring in an animal which may be predisposed to the disease but does not yet experience or display the pathology or symptomatology of the disease,
(2) inhibiting the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., arresting further development of the pathology and/or symptomatology), or
(3) ameliorating the disease in an animal that is experiencing or displaying the pathology or symptomatology of the disease (i.e., reversing the pathology and/or symptomatology) .
[0096] It is noted in regard to all of the definitions provided herein that the definitions should be interpreted as being open ended in the sense that further substituents beyond those specified may be included. Hence, a C1 alkyl indicates that there is one carbon atom but does not indicate what are the substituents on the carbon atom. Hence, a C1 alkyl comprises methyl (i.e., -CH3) as well as -RaRbRc where Ra, Rb, and Rc may each independently be hydrogen or any other substituent where the atom attached to the carbon is a heteroatom or cyano. Hence, CF3, CH2OH and CH2CN, for example, are all C1 alkyls.
DETAILED DESCRIPTION OF THE INVENTION
[0097] The present invention relates to compounds, compositions, kits and articles of manufacture that may be used to inhibit dipeptidyl peptidases IV (referred to herein as
DPP-IV).
[0098] DPP-IV (EC.3.4.14.5 also known as DPP4, DP4, DAP-IV, adenosine deaminase complexing protein 2, adenosine deaminase binding protein (AD Abp) or CD26) is a 766 residue, 24OkDa protein that is a highly specific membrane bound non-classical serine aminodipeptidase. DPP-IV has a serine type mechanism of protease activity, cleaving off dipeptides from the amino-terminus of peptides with proline or alanine at the penultimate position. In addition the slow release of dipeptides of the type X-GIy or X-Ser is reported for some naturally occurring peptides. DPP-IV is constitutively expressed on epithelial and endothelial cells of a variety of different tissues (intestine, liver, lung, kidney and placenta), and is also found in body fluids. DPP-IV is also expressed on circulating T- lymphocytes and has been shown to be synonymous with the cell-surface antigen, CD-26. The wild-type form of full length DPP-IV is described in GenBank Accession Number NM_001935 ("Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation", Darmoul, D., Lacasa, M., Baricault, L., Marguet, D., Sapin, C, Trotot, P., Barbat, A. and Trugnan, G., J. Biol. Chem., 267 (7), 4824-4833, 1992).
[0100] DPP-IV is a member of the S9 family of serine proteases, more particularly the S9B family. Other members of the S9 family include, but are not limited to:
Subfamily S9A: Dipeptidyl-peptidase; Oligopeptidase B (EC 3.4.21.83); Oligopeptidase B; Prolyl oligopeptidase (EC 3.4.21.26)
Subfamily S9B: Dipeptidyl aminopeptidase A; Dipeptidyl aminopeptidase B; Dipeptidyl-peptidase IV (EC 3.4.14.5); Dipeptidyl-peptidase V; Fibroblast activation protein alpha subunit; Seprase
Subfamily S9C: Acylaminoacyl-peptidase (EC 3.4.19.1)
[0101] It is noted that the compounds of the present invention may also possess inhibitory activity for other S9 family members and thus may be used to address disease states associated with these other family members.
1. CRYSTAL STRUCTURE OF DPP-IV
[0102] Syrrx, Inc. (San Diego, California) recently solved the crystal structure of DPP- IV. Knowledge of the crystal structure was used to guide the design of the DPP-IV inhibitors provided herein. [0103] DPP-IV is a cylindrical shaped molecule with an approximate height of 70 A and a diameter of 60 A. The catalytic triad of DPP-IV (Ser642, Asp720 and His752) is located in the peptidase domain or catalytic domain of DPP-IV. The catalytic domain is covalently linked to the β-propeller domain. The catalytic domain of DPP-IV includes residues 1-67 and 511-778. The catalytic domain of DPP-IV adopts a characteristic α/β hydrolase fold. The core of this domain contains an 8-stranded β-sheet with all strands being parallel except one. The α-sheet is significantly twisted and is flanked by three α- helices on one side and five α-helices on the other. The topology of the β-strands is 1, 2, - Ix, 2x and (Ix) (J. S. Richardson: The anatomy and taxonomy of protein structure; (1981) Adv. Protein Chem. 269, 15076-15084.). A number of residues were identified that contribute to the shape and charge characteristics of the active site. Knowledge of these residues has been an important contribution to the design of DPP-IV inhibitors of the present invention.
2. DPP-IV INHIBITORS
[0104] In one embodiment, DPP-IV inhibitors of the present invention include compounds comprising:
Figure imgf000021_0001
wherein:
W is selected from the group consisting of CR3 and N;
X is selected from the group consisting of CR4 and N;
Y is selected from the group consisting of CO, CS, SO, SO2, CR6R6' and C=NR6;
Z is selected from the group consisting of CO, CS, SO, SO2, and C=NR6;
R1 is selected from the group consisting of (Ci-io)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-1o)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl (C1-3)alkyl, thiocarbonyl (Q^alkyl, sulfonyl (C1-3)alkyl, sulfinyl (Q^alkyl, imino (C1-3)alkyl, amino, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkenyl, alkynyl, carbonyl group, cyano, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted;
R2 is selected from the group consisting of amino (Ci_6)alkyl, hetero(C3-12)cycloalkyl, hetero(C4-12)bicycloaryl, heteroaryl, and cyano, each substituted or unsubstituted;
R3 is selected from the group consisting of hydrogen, halo, perhalo(C1-1o)alkyl, amino, nitro, cyano, thio, sulfonamide, (Cπo)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-10)alkyl, heteroaryl(C!-5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, (Cπ^alkylamino, amino (C1-10)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or R2 and R3 are taken together to form a ring;
R4 is selected from the group consisting of hydrogen, halo, perhalo(C1-1o)alkyl, amino, nitro, cyano, thio, sulfonamide, (C1-Io)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-1o)alkyl, heteroaryl(Cr5)alkyl,
Figure imgf000022_0001
hetero(C4-12)bicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, sulfonylamino, imino(C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or R3 and R4 are taken together to form a ring;
R5 and R7 are independently selected from the group consisting of hydrogen, halo(C1-1o)alkyl, amino, nitro, thio, sulfonamide, (Ci-io)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-1o)alkyl, heteroaryl(Cr5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, (C3-12)cycloalkyl(C1-1o)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or R5 is absent when the N to which it is bound forms part of a double bond; and
R6 and R6' are each independently selected from the group consisting of hydrogen, amino, alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted, or R5 and R6 are taken together to from a ring, with the proviso that R6' is absent when Y forms part of a double bond. [0105] In another embodiment, DPP-IV inhibitors of the present invention include compounds comprising:
Figure imgf000023_0001
wherein:
R1 is selected from the group consisting of (C1-10)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C1-3)alkyl, amino, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkenyl, alkynyl, carbonyl group, cyano, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted;
R2 is selected from the group consisting of amino (C1-6)alkyl, hetero(C3-12)cycloalkyl, hetero(C4-12)bicycloaryl, heteroaryl, and cyano, each substituted or unsubstituted;
R3 is selected from the group consisting of hydrogen, halo, perhalo(C1-1o)alkyl, amino, nitro, cyano, thio, sulfonamide, (C1-10)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-10)alkyl, heteroaryl(Ci-5)alkyl, (Cg.^bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, (C1-10)alkylamino, amino (C1-Io)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or R2 and R3 are taken together to form a ring; and
R5 and R7 are independently selected from the group consisting of hydrogen, halo(C1-1o)alkyl, amino, nitro, thio, sulfonamide, (C1-10)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, (C3-12)cycloalkyl(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(Ci_3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted.
[0106] In another embodiment, DPP-IV inhibitors of the present invention include compounds comprising:
Figure imgf000024_0001
wherein:
R1 is selected from the group consisting of (C1-10)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-1o)alkyl, heteroaryl(Cr5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C1-3)alkyl, amino, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkenyl, alkynyl, carbonyl group, cyano, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted;
R2 is selected from the group consisting of amino (C1-6)alkyl, hetero(C3-12)cycloalkyl, hetero(C4.12)bicycloaryl, heteroaryl, and cyano, each substituted or unsubstituted;
R3 is selected from the group consisting of hydrogen, halo, perhalo(C1-1o)alkyl, amino, nitro, cyano, thio, sulfonamide, (C1-10)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-1o)alkyl, heteroaryl(Cr5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1.3)alkyl, imino(C1-3)alkyl, (C1-10)alkylamino, amino (Cr^alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or R2 and R3 are taken together to form a ring; R6 and R6' are each independently selected from the group consisting of hydrogen, amino, alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and
R7 is selected from the group consisting of hydrogen, halo(Ci-10)alkyl, amino, nitro, thio, sulfonamide, (C1-10)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-10)alkyl, heteroaryl(Ci-5)alkyl, (Cg-^bicycloaryl, hetero(C4-12)bicycloai7l,
Figure imgf000025_0001
carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, SuIfOnVl(C1- 3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted. [0107] In each of the above embodiments, R2 is optionally -CR8RgNR10R11, wherein:
R8 and R9 are each independently selected from the group consisting of hydrogen, halogen, perhalo(C1-10)alkyl, cyano, nitro, alkyl, cycloalkyl, alkene, alkyne, aryl, and heteroaryl, each substituted or unsubstituted, or where R8 and R9 are taken together to form a substituted or unsubstituted ring; and
R10 and R11 are independently selected from the group consisting of hydrogen, perhalo(C1-10)alkyl, amino, thio, (Q-icOalkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(Ci-io)alkyl, heteroaryl(C1-5)alkyl, (Ccι-12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, and imino group, each substituted or unsubstituted, or R10 and R11 are taken together to form a ring. [0108] Alternatively, R2 and R3 are optionally taken together to form a ring. In one variation, the ring formed by taking R2 and R3 together is a substituted or unsubstituted 5 or 6 membered ring. In another variation, the ring formed by taking R2 and R3 together is a substituted or unsubstituted cycloalkyl, bicycloalkyl, heterocycloalkyl, aryl, heteroaryl, (C9-12)bicycloaryl, or hetero(C8-12)bicycloaryl.
[0109] In each of the above embodiments and variations, R3 is optionally -NR12R13, wherein R12 and R13 are each independently selected from the group consisting of hydrogen, perhalo(C1-10)alkyl, amino, thio, (C1-10)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(Crlo)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, and imino group, each substituted or unsubstituted, or R12 and R13 are taken together to form a ring.
[0110] In one particular variation when R12 and R13 are taken together to form a ring, the ring formed by R12 and R13 is a substituted or unsubstituted 3, 4, 5 or 6 membered ring. In another variation, the ring formed by R12 and R13 is a substituted or unsubstituted heterocycloalkyl, heterobicycloalkyl, aryl, heteroaryl, or hetero(C8-12)bicycloaryl. [0111] In the above embodiments and variations, R3 and R4 are optionally taken together to form a ring. In one particular variation, the ring formed by R3 and R4 is a substituted or unsubstituted 5 or 6 membered ring. In another variation, the ring formed by R3 and R4 is a substituted or unsubstituted cycloalkyl, bicycloalkyl, heterocycloalkyl, aryl, heteroaryl, (C9-12)bicycloaryl, or hetero(C8-12)bicycloaryl.
[0112] In each of the above embodiments and variations, R1 is optionally a substituted or unsubstituted (C3-7)cycloalkyl.
[0113] Further, in each of the above embodiments and variations, R1 can be a substituted or unsubstituted (C3-7)heterocycloalkyl.
[0114] Alternatively, in each of the above embodiments and variations, R1 is optionally a substituted or unsubstituted aryl.
[0115] In another variation of each of the above embodiments and variations, R1 can be a substituted or unsubstituted phenyl.
[0116] In still another variation of each of the above embodiments and variations, R1 is optionally a substituted or unsubstituted heteroaryl. [0117] In yet another variation of each of the above embodiments and variations, R1 is :
Figure imgf000026_0001
wherein: a is O, 1, 2, 3, 4, or 5; and R14 is selected from the group consisting of hydrogen, halo, perhalo(C1-10)alkyl, amino, nitro, cyano, thio, sulfonamide, (C1-Io)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(Cπo)alkyl, heteroaryl(Cr5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted.
[0118] Further, in each of the above embodiments and variations, R1 is optionally a cyclic substituent having a ring with a non-hydrogen substituent at a 2 or 3 position of the ring. In particular variations, the non-hydrogen substituent at the 2 or 3 position of the ring is (C1-10)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C^alkyl, amino, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, cyano, nitro, halo, imino group, sulfonyl group or sulfinyl group, each substituted or unsubstituted. [0119] Additionally, in each of the above embodiments and variations, R1 can be selected from the group consisting of:
Figure imgf000027_0001
wherein:
V is selected from the group consisting of S, O, and NR16;
R15 is selected from the group consisting of hydrogen, halo, perhalo(Ci-10)alkyl, amino, nitro, cyano, thio, sulfonamide, (C1-10)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted; and
R16 is selected from the group consisting of hydrogen, perhalo(C1-1o)alkyl, amino, (Ci-10)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-10)alkyl, heteroaryl (Ci-5)alkyl, (C9-12)bicycloaryl, hetero(C8-12)bicycloaryl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, imino group, carbonyl group, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, and sulfinyl group, each substituted or unsubstituted.
[0120] In another variation of each of the above embodiments and variations, R1 is optionally a substituted or unsubstituted halophenyl or dihalophenyl. [0121] In still another variation of each of the above embodiments and variations, R1 can be a substituted or unsubstituted haloaryl, haloheteroaryl, dihaloaryl or dihaloheteroaryl.
[0122] In yet another variation of each of the above embodiments and variations, R1 is optionally (2-cyano)phenyl; (3-cyano)phenyl; (2-hydroxy)phenyl; (3-hydroxy)phenyl; (2- alkenyl)phenyl; (3-alkenyl)phenyl; (2-alkynyl)phenyl; (3-alkynyl)phenyl; (2- methoxy)phenyl; (3-methoxy)phenyl; (2-nitro)phenyl; (3-nitro)phenyl; (2-carboxy)phenyl; (3-carboxy)phenyl; -(CH2)-(2-carboxamido)phenyl; (3-carboxamido)phenyl; (2- sulfonamido)phenyl; (3-sulfonamido)phenyl; (2-tetrazolyl)phenyl; (3-tetrazolyl)phenyl; (2-aminomethyl)phenyl; (3-aminomethyl)phenyl; (2-hydroxymethyl)phenyl; (3-hydroxymethyl)phenyl; (2-phenyl)phenyl; (3-phenyl)phenyl; (2-halo)phenyl; (3- halo)phenyl; (2-CONH2)phenyl; (3-CONH2)ρhenyl; (2-CONH(Cr7)alkyl)phenyl; (3-CONH(Ci-7)alkyl)phenyl; (2-CO2(C1-7)alkyl)phenyl; (3-CO2(C1-7)alkyl)phenyl; (2- NH2)phenyl; (3-NH2)phenyl; (2-(C3-7)alkyl)phenyl; (3-(C3-7)alkyl)phenyl; (2-(C3-7)cycloalkyl)phenyl; (3-(C3-7)cycloalkyl)phenyl; (2-aryl)phenyl; (3-aryl)phenyl; (2-heteroaryl)phenyl; (3-heteroaryl)phenyl; 2-bromo-5-fluoro phenyl; 2-chloro-5-fluoro phenyl; 2-cyano-5-fluoro phenyl; 2,5-dichloro phenyl; 2,5-difluoro phenyl; 2,5-dibromo phenyl; 2-bromo-3,5-difluoro phenyl; 2-chloro-3,5-difluoro phenyl; 2,3,5-trifluoro phenyl; 2,3,5,6-tetrafluorophenyl; 2-bromo-3,5,6-trifluoro phenyl; 2-chloro-3,5,6-trifluoro phenyl; 2-cyano-3,5-difluoro phenyl; 2-cyano-3,5,6-trifluoro phenyl; (2-heterocycloalkyl)phenyl; or (3-heterocycloalkyl)phenyl, each substituted or unsubstituted. [0123] Also, in each of the above embodiments and variations, R1 is optionally selected from the group consisting of:
Figure imgf000029_0001
wherein:
A is S, O or NR17;
B is CR18 or N;
R17 is independently selected from the group consisting of hydrogen, perhalo(C1-1o)alkyl, amino, (Ci-10)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(Cr !o)alkyl, heteroaryl (C1-5)alkyl, (C9-12)bicycloaryl, hetero(C8-12)bicycloaryl, carbonyl (C1- 3)alkyl, thiocarbonyl (C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, imino group, carbonyl group, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, and sulfinyl group, each substituted or unsubstituted; and
R18 is independently selected from the group consisting of hydrogen, halo, perhalo(C1-1o)alkyl, amino, thio, cyano, CF3, nitro, (C1-Io)alkyl, (C3-12)cycloalkyl, hetero(C3~12)cycloalkyl, aryl(C1-1o)alkyl, heteroaryl (C1-5)alkyl, (C9-12)bicycloaryl, hetero(C8-12)bicycloaryl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, imino group, carbonyl group, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, and sulfinyl group, each substituted or unsubstituted, or R17 and R18, or two R18 are taken together to form an unsubstituted or substituted ring.
[0124] Further, in each of the above embodiments and variations, wherein R1 can be selected from the group consisting of:
Figure imgf000029_0002
wherein: t is O, 1, 2, 3, 4 or 5; and each Ri9 is independently selected from the group consisting of halo, perhalo(Ci-10)alkyl, CF3, (Q.^alkyl, alkenyl, alkynyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, cyano, nitro, hydroxy, alkoxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or two R^ are taken together to form an unsubstituted or substituted ring. [0125] Also, in each of the above embodiments and variations, R1 is optionally selected from the group consisting of:
Figure imgf000030_0001
wherein: s is O, 1, 2, or 3; and each R20 is independently selected from the group consisting of halo, perhalo(C1-1o)alkyl, CF3, (C1-10)alkyl, alkenyl, alkynyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, cyano, nitro, hydroxy, alkoxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or two R20 are taken together to form an unsubstituted or substituted ring. [0126] Even further, in each of the above embodiments and variations, R1 can be an aryl substituted with one or more substituents selected from the group consisting of halo; hydroxy (C1-6)alkyl; amino (C1-6)alkyl; and (C1-6)alkoxy.
[0127] Particular examples of DPP-IV inhibitors according to the present invention include, but are not limited to:
7-Amino-6-aminomethyl-5-(2,4-dichloro-phenyl)-l,3-dimethyl-lH-pyrido[2,3- d]pyrimidine-2,4-dione;
7-Amino-6-aminomethyl-5-(2-bromo-4-fluoro-phenyl)- 1 ,3-dimethyl- IH- pyrido[2,3-d]pyrimidine-2,4-dione; -Aniino-6-aminomethyl-5-(2-bromo-phenyl)-l,3-dimethyl-lH-pyrido[2,3- d]pyrimidine-2,4-dione; -Aminomethyl-5-(2,4-dichloro-phenyl)-7-ethylamino- 1 ,3-dimethyl- IH- pyrido[2,3-d]pyrimidine-2,4-dione; -Aminomethyl-5-(2,4-dichloro-phenyl)- 1 ,3-dimethyl-7-methylamino- IH- pyrido[2,3-d]pyrimidine-2,4-dione; -Aminomethyl-5-(2,4-dichloro-phenyl)-7-dimethylamino-l,3-dimethyl-lH- pyrido[2,3-d]pyrimidine-2,4-dione; -Hydroxy-5-(2-bromo-5-fluoro-phenyl)- 1 ,3-dimethyl-2,4-dioxo- 1 ,2,3 ,4- tetrahydropyrido[2,3-d]pyrirnidine-6-carbonitrile; -Aminomethyl-5-(2-bromo-5-fluoro-phenyl)-7-hydroxy- 1 ,3-dimethyl- IH- pyrido[2,3-d]pyrimidine-2,4-dione; -Amino-5-(2,5-dichloro-phenyl)- 1 ,3-dimethyl-2,4-dioxo- 1 ,2,3 ,4- tetrahydropyrido[2,3-J]pyrimidine-6-carbonitrile; -Amino-6-aminomethyl-5-(2,5-dichloro-phenyl)- 1 ,3-dimethyl- lH-pyrido [2,3-d\ pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (2-bromo-5-fluoro-phenyl)- 1 ,3-dimethyl- lH-pyrido
[2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl — 1 ,3-dimethyl- 5- (3-methyl-thiophen-2-yl)- IH- pyrido[2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (2-chloro-phenyl)- 1 ,3-dimethyl- lH-pyrido [2,3- J] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (4-fluoro-phenyl)- 1 ,3-dimethyl- lH-pyrido [2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (5-chloro-thiophen-2-yl)- 1 ,3-dimethyl- lH-pyrido [2,3- d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (4-bromo-phenyl)-l,3-dimethyl-lH-pyrido [2,3-dj pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (2,3-dichloro-phenyl)- 1 ,3-dimethyl- lH-pyrido [2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (2-chloro-6-fluoro-phenyl)- 1 ,3-dimethyl- lH-pyrido
[2,3-d\ pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (3-methoxy-phenyl)- 1 ,3-dimethyl- lH-pyrido [2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (2-methoxy-phenyl)- 1 ,3-dimethyl- lH-pyrido [2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (2-chloro-3, 6-difluoro-phenyl)-l,3-dimethyl-lH- pyrido [2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5-phenyl- 1 ,3-dimethyl- lH-pyrido [2,3-d] pyrimidine-2,
4-dione; -Amino-6-aminomethyl-5- (3-bromo-thiophen-2-yl)- 1 ,3-dimethyl- lH-pyrido [2,3- d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (2-chloro-5-fluoro-phenyl)- 1 ,3-dimethyl- lH-pyrido
[2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (2-bromo-5-fluoro-phenyl)- 1 ,3-dimethyl- lH-pyrido
[2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5-(2-chloro-4-fluoro-phenyl)-l,3-dimethyl-lH-pyrido
[2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5-cyclopentyl-l,3-dimethyl-lΗ-pyrido [2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-l,3-dimethyl-5-pyridin-3-yl-lH-pyrido [2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5-(4,5-dimethyl-thiophen-2-yl)-l,3-dimethyl-lH-pyrido
[2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (5-fluoro-2-nitro-phenyl)- 1 ,3-dimethyl- lH-pyrido
[2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-l,3-dimethyl-5-(3-methyl-3H-imidazol-4-yl)-lH-pyrido
[2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5-benzo [b] thiophen-2-yl-l,3-dimethyl-lH-pyrido [2,3- d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-l, 3- dimethyl-5- (3-methyl-benzo [b] thiophen-2-yl)-lH- pyrido [2,3-d] pyrimidine-2, 4-dione; -(aminomethyl)-5-(2,4-dichlorophenyl)-7-hydroxy-l,3-dimethylpyrido[2,3- d]pyrimidine-2,4(lH,3H)-dione; -(aminomethyl)-7-chloro-5-(2,4-dichlorophenyl)-l,3-dimethylpyrido[2,3- d]pyrimidine-2,4( lH,3H)-dione;
-amino-6-(aminomethyl)-5-(2-chloro-5-fluorophenyl)-3-methylpyrido[2,3- d]pyrimidine-2,4( lH,3H)-dione; -amino-6-(aminomethyl)-5-(2-(aminomethyl)phenyl)-l,3-dimethylpyrido[2,3- d]pyrimidine-2,4(lH,3H)-dione; -(7-arnino-6-(aminomethyl)-l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydropyrido[2,3- d]pyrimidin-5-yl)benzonitrile; -amino-5-(2-(aminomethyl)phenyl)-l,3-dimethyl-2,4-dioxo-l,2,3,4- tetrahydropyrido[2,3-d]pyrimidine-6-carbonitrile; -(aminomethyl)-7-(cyclopropylmethylamino)-5-(2,4-dichlorophenyl)-l,3- dimethylpyrido[2,3-d]pyrimidine-2,4(lH,3H)-dione; -(7-amino-6-(aminomethyl)- 1 -isobutyl-3-methyl-2,4-dioxo- 1 ,2,3 ,4- tetrahydropyrido[2,3-d]pyrimidin-5-yl)benzonitrile; -(aminomethyl)-5-(2,4-dichlorophenyl)-l,3-dimethylpyrido[2,3-d]pyrimidine- 2,4(lH,3H)-dione; -Amino-6- (aminomethyl)-5-(2-chloro-5- (trifluoromethyl) phenyl)- 1,3- dimethylpyrido [2,3-d] pyrimidine-2, 4(2H, 3H)-dione; -Amino-6- (aminomethyl)-5-(2-chloro-5-fluorophenyl)-l-methylpyrido [2,3-d] pyrimidine-2, 4(iH 3H)-dione; -Amino-6-(aminomethyl)-5-(2-bromo-5-fluorophenyl)-l-methylpyrido[2,3-d] pyrimidine-2, 4(iH3H)-dione; -(7-amino-6-(aminomethyl)-l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydropyrido[2,3- d]pyrimidin-5-yl)-4-fluorobenzonitrile; 2-(6-(aminomethyl)-7-chloro-l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydropyrido[2,3- J]pyrimidin-5-yl)-4-fluorobenzonitrile;
2-(6-(aminomethyl)-l,3,7-trimethyl-2,4-dioxo-l,2,3,4-tetrahydropyrido[2,3- rf]pyrimidin-5-yl)-4-fluorobenzonitrile;
2-(6-(aminomethyl)-l,3-dimethyl-2,4-dioxo-7-(trifluorometliyl)-l,2,3,4- tetrahydropyrido[2,3-<f|pyrimidin-5-yl)-4-fluorobenzonitrile;
2-(6-(aminomethyl)-l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydropyrido[2,3- J]pyrimidin-5-yl)-4-fluorobenzonitrile;
2-(6-(aminomethyl)-l,3-dimethyl-2,4-dioxo-7-(2,2,2-trifluoroethylamino)-l,2,3,4- tetrahydropyrido[2,3-<i]pyrimidin-5-yl)-4-fluorobenzonitrile;
2-(6-(aminomethyl)-l,3-dimethyl-7-(methyl(2,2,2-trifluoroethyl)amino)-2,4-dioxo- l,2,3,4-tetrahydropyrido[2,3-J]pyrimidin-5-yl)-4-fluorobenzonitrile;
2-(6-(aminomethyl)-7-(bis(trifluoromethyl)amino)-l,3-dimethyl-2,4-dioxo-l,2,3,4- tetrahydropyrido[2,3-d]pyrimidin-5-yl)-4-fluorobenzonitrile;
2-(6-(aminomethyl)- 1 ,3-dimethyl-2,4-dioxo-7,8-imidazo-[ 1 ,2-a]- 1 ,2,3,4,7,8- hexahydropyrido[2,3-d]pyrimidin-5-yl)-5-chlorobenzonitrile;
2-(6-(aminomethyl)-3-(cyclopropylmethyl)- 1 ,7-dimethyl-2,4-dioxo- 1 ,2,3,4- tetrahydropyrido[2,3-(i]pyrimidin-5-yl)-5-chlorobenzonitrile;
6-(aminomethyl)-5-(4-chloro-2-metb.oxyphenyl)-l,3,7-trimethylpyrido[2,3- ύT|pyrimidine-2,4( lH,3H)-dione;
2-(6-(aminomethyl)-7-methoxy- 1 ,3-dimethyl-2,4-dioxo- 1 ,2,3 ,4- tetrahydropyrido[2,3-d]pyrimidin-5-yl)-5-chlorobenzonitrile;
2-(6-(aminomethyl)- 1 ,3-dimethyl-2,4-dioxo-7-(pyrrolidin- 1 -yl)- 1 ,2,3 ,4- tetrahydropyrido[2,3-rf]pyrimidin-5-yl)-5-chlorobenzonitrile;
6-(aminomethyl)-5-(5-fluoro-2-methoxyphenyl)- 1 ,3-dimethyl-7- morpholinopyrido[2,3-J]pyrimidine-2,4(lH,3H)-dione;
N-(6-(aminomethyl)-5-(4-chloro-2-methoxyphenyl)-l,3-dimethyl-2,4-dioxo- l,2,3,4-tetrahydropyrido[2,3-J]pyrimidin-7-yl)methanesulfonamide; 2-(6-(aminomemyl)-3-benzyl-7-methoxy-l-methyl-2,4-dioxo-l,2,3,4- tetrahydropyrido[2,3-d]pyrimidin-5-yl)-5-chlorobenzonitrile;
6-(aminomethyl)-3-benzyl-5-(4-chloro-2-methoxyphenyl)-l-methyl-7- (trifluoromethyl)pyrido[2,3-(f|pyrimidine-2,4(lH,3H)-dione;
6-(aminomethyl)-5-(3,5-difluoro-2-methoxyphenyl)-l,3-dimethyl-7- (trifluoromethyl)pyrido[2,3-d]pyriπήdine-2,4(lH,3H)-dione;
6-(aminomethyl)-3-benzyl-5-(2-chloro-3,5-difluorophenyl)-l-inethyl-7- (trifluoromethyl)pyrido[2,3-d]pyrimidine-2,4(lH,3H)-dione;
6-(aminomethyl)-5-(2-bromo-3,5-difluorophenyl)-l,3-dimethyl-7- (trifluoromethyl)pyrido[2,3-J]pyrimidine-2,4(lH,3H)-dione;
6-(aminomethyl)-5-(3 ,5-difluoro-2-methoxyphenyl)- 1 ,2-imidazo- [ 1 ,2-a]-3-methyl- 7-(trifluoromethyl)-2,3-dihydropyrido[2,3-d]pyrimidin-4(lH)-one;
6-(aminomethyl)-5-(3,5-difluoro-2-methoxyphenyl)-3-methyl-2-(methylamino)-7- (trifluoromethyl)pyrido[2,3-(f|pyrimidin-4(3H)-one;
2-amino-6-(aminomethyl)-5-(2-chloro-3,5-difluorophenyl)-3-metliyl-7- (trifluoromethyl)pyrido[2,3-(i]pyrimidin-4(3H)-one;
2,7-diamino-6-(l-aminoethyl)-5-(2-chloro-5-fluorophenyl)-3-methylpyrido[2,3- <i]pyrimidm-4(3H)-one;
2-(6-(aminomethyl)-7-ethoxy- 1 ,3-dimethyl-2,4-dioxo- 1 ,2,3 ,4-tetrahydropyrido [2,3- J]pyrimidin-5-yl)-5-chlorobenzonitxile; and
6-(aminomethyl)-5-(3,5-difluoro-2-methoxyphenyl)-2-(dimethylamino)-3-methyl- 7-(trifluoromethyl)pyrido[2,3-J]pyrimidin-4(3H)-one.
[0128] In another embodiment, the present invention provides the compounds in the form of a pharmaceutically acceptable salt.
[0129] In yet another embodiment, the present invention provides the compounds present in a mixture of stereoisomers. In yet another embodiment, the present invention provides the compounds as a single stereoisomer. [0130] In yet another embodiment, the present invention provides pharmaceutical compositions comprising the compound as an active ingredient. In yet another variation, the present invention provides pharmaceutical compositions wherein the composition is a solid formulation adapted for oral administration. In yet another particular variation, the present invention provides pharmaceutical composition wherein the composition is a tablet. In another particular variation, the present invention provides the pharmaceutical composition wherein the composition is a liquid formulation adapted for oral administration. In yet another particular variation, the present invention provides pharmaceutical composition wherein the composition is a liquid formulation adapted for parenteral administration.
[0131] In yet another particular variation, the present invention provides the pharmaceutical composition comprising the compound of the invention wherein the composition is adapted for administration by a route selected from the group consisting of orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, and intrathecally. [0132] In another embodiment, the present invention provides a kit comprising a compound of the present invention and instructions which comprise one or more forms of information selected from the group consisting of indicating a disease state for which the compound is to be administered, storage information for the compound, dosing information and instructions regarding how to administer the compound. In another embodiment, the present invention provides the kit that comprises the compound in a multiple dose form.
[0133] In another embodiment, the present invention provides an article of manufacture comprising a compound of the present invention, and packaging materials. In another variation, the packaging material comprises a container for housing the compound. In yet another variation, the invention provides the article of manufacture wherein the container comprises a label indicating one or more members of the group consisting of a disease state for which the compound is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition. [0134] In another variation, the present invention provides the article of manufacture wherein the article of manufacture comprises the compound in a multiple dose form.
[0135] In another embodiment, the present invention provides a method of inhibiting
DPP-IV comprising contacting DPP-IV with a compound according to the present invention.
[0136] In another embodiment, the present invention provides a method of inhibiting
DPP-IV comprising causing a compound according to the present invention to be present in a subject in order to inhibit DPP-IV in vivo.
[0137] In another embodiment, the present invention provides a method of inhibiting
DPP-IV comprising: administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits DPP-IV in vivo, the second compound being a compound of the present invention.
[0138] In another embodiment, the present invention provides therapeutic method comprising: administering a compound according to the present invention to a subject.
[0139] In another embodiment, the present invention provides a method of treating a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state, the method comprising causing a compound of the present invention to be present in a subject in a therapeutically effective amount for the disease state.
[0140] In another embodiment, the present invention provides a method of treating cancer in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention. In particular variations, the cancer being treated is colorectal, prostate, breast, thyroid, skin, lung, or head and neck cancer.
[0141] In another embodiment, the present invention provides a method of treating a disease where the disease is type I or type II diabetes.
[0142] In another embodiment, the present invention provides a method of treating autoimmune disorders such as, but not limited to, rheumatoid arthritis, psoriasis, and multiple sclerosis in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention. [0143] In another embodiment, the present invention provides a method of treating a condition characterized by inadequate lymphocyte or hemapoietic cell activation or concentration in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention. [0144] In yet another embodiment, the present invention provides a method of treating a condition characterized by inadequate lymphocyte or hemapoietic cell activation or concentration in a patient in need thereof, wherein the condition is a side effect of chemotherapy or radiation therapy.
[0145] In yet another embodiment, the present invention provides a method of treating a condition characterized by inadequate lymphocyte or hemapoietic cell activation or concentration in a patient in need thereof, wherein the condition is a result of kidney failure.
[0146] In yet another embodiment, the present invention provides a method of treating a condition characterized by inadequate lymphocyte or hemapoietic cell activation or concentration in a patient in need thereof, wherein the condition is a result of a bone marrow disorder.
[0147] In another embodiment, the present invention provides a method of treating HIV infection in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention. [0148] In another embodiment, the present invention provides a method of treating a condition characterized by immunodeficiency symptoms in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention.
[0149] It is noted in regard to all of the embodiments, and any further embodiments, variations, or individual compounds described or claimed herein that all such embodiments, variations, and/or individual compounds are intended to encompass all pharmaceutical acceptable salt forms whether in the form of a single stereoisomer or mixture of stereoisomers unless it is specifically specified otherwise. Similarly, when one or more potentially chiral centers are present in any of the embodiments, variations, and/or individual compounds specified or claimed herein, both possible chiral centers are intended to be encompassed unless it is specifically specified otherwise. A. Salts, Hydrates, and Prodrugs of DPP-IV Inhibitors
[0150] It should be recognized that the compounds of the present invention may be present and optionally administered in the form of salts, hydrates and prodrugs that are converted in vivo into the compounds of the present invention. For example, it is within the scope of the present invention to convert the compounds of the present invention into and use them in the form of their pharmaceutically acceptable salts derived from various organic and inorganic acids and bases in accordance with procedures well known in the art.
[0151] When the compounds of the present invention possess a free base form, the compounds can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, e.g., hydrohalides such as hydrochloride, hydrobromide, hydroiodide; other mineral acids and their corresponding salts such as sulfate, nitrate, phosphate, etc.; and alkyl and monoarylsulfonates such as ethanesulfonate, toluenesulfonate and benzenesulfonate; and other organic acids and their corresponding salts such as acetate, tartrate, maleate, succinate, citrate, benzoate, salicylate and ascorbate. Further acid addition salts of the present invention include, but are not limited to: adipate, alginate, arginate, aspartate, bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptaoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, iso-butyrate, lactate, lactobionate, malate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphosphate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, pamoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate and phthalate. It should be recognized that the free base forms will typically differ from their respective salt forms somewhat in physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base forms for the purposes of the present invention. [0152] When the compounds of the present invention possess a free acid form, a pharmaceutically acceptable base addition salt can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base. Examples of such bases are alkali metal hydroxides including potassium, sodium and lithium hydroxides; alkaline earth metal hydroxides such as barium and calcium hydroxides; alkali metal alkoxides, e.g. potassium ethanolate and sodium propanolate; and various organic bases such as ammonium hydroxide, piperidine, diethanolamine and N- methylglutamine. Also included are the aluminum salts of the compounds of the present invention. Further base salts of the present invention include, but are not limited to: copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium and zinc salts. Organic base salts include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, e.g., arginine, betaine, caffeine, chloroprocaine, choline, N,N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, iso-propylamine, lidocaine, lysine, meglumine, N-methyl-D- glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and tris- (hydroxymethyl)-methylamine (tromethamine). It should be recognized that the free acid forms will typically differ from their respective salt forms somewhat in physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid forms for the purposes of the present invention. [0153] Compounds of the present invention that comprise basic nitrogen-containing groups may be quaternized with such agents as (C1-4)alkyl halides, e.g., methyl, ethyl, iso- propyl and tert-butyl chlorides, bromides and iodides; di (C^alkyl sulfates, e.g., dimethyl, diethyl and diamyl sulfates; (C10-18)alkyl halides, e.g., decyl, dodecyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; and aryl (C1-4)alkyl halides, e.g., benzyl chloride and phenethyl bromide. Such salts permit the preparation of both water-soluble and oil- soluble compounds of the present invention. [0154] N-oxides of compounds according to the present invention can be prepared by methods known to those of ordinary skill in the art. For example, iV-oxides can be prepared by treating an unoxidized form of the compound with an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, metα-chloroperoxybenzoic acid, or the like) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as dichloromethane) at approximately 0 0C. Alternatively, the iV-oxides of the compounds can be prepared from the N-oxide of an appropriate starting material.
[0155] Prodrug derivatives of compounds according to the present invention can be prepared by modifying substituents of compounds of the present invention that are then converted in vivo to a different substituent. It is noted that in many instances, the prodrugs themselves also fall within the scope of the range of compounds according to the present invention. For example, prodrugs can be prepared by reacting a compound with a carbamylating agent (e.g., 1,1-acyloxyalkylcarbonochloridate, pαrα-nitrophenyl carbonate, or the like) or an acylating agent. Further examples of methods of making prodrugs are described in Saulnier et α/.(1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985.
[0156] Protected derivatives of compounds of the present invention can also be made. Examples of techniques applicable to the creation of protecting groups and their removal can be found in T.W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999.
[0157] Compounds of the present invention may also be conveniently prepared, or formed during the process of the invention, as solvates (e.g. hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.
[0158] A "pharmaceutically acceptable salt", as used herein, is intended to encompass any compound according to the present invention that is utilized in the form of a salt thereof, especially where the salt confers on the compound improved pharmacokinetic properties as compared to the free form of compound or a different salt form of the compound. The pharmaceutically acceptable salt form may also initially confer desirable pharmacokinetic properties on the compound that it did not previously possess, and may even positively affect the pharmacodynamics of the compound with respect to its therapeutic activity in the body. An example of a pharmacokinetic property that may be favorably affected is the manner in which the compound is transported across cell membranes, which in turn may directly and positively affect the absorption, distribution, biotransformation and excretion of the compound. While the route of administration of the pharmaceutical composition is important, and various anatomical, physiological and pathological factors can critically affect bioavailability, the solubility of the compound is usually dependent upon the character of the particular salt form thereof, which it utilized. One of skill in the art will appreciate that an aqueous solution of the compound will provide the most rapid absorption of the compound into the body of a subject being treated, while lipid solutions and suspensions, as well as solid dosage forms, will result in less rapid adsorption of the compound.
3. INDICATIONS FOR USE OF DPP-IV INHIBITORS
[0159] DPP-IV is believed to contribute to the pathology and/or symptomology of several different diseases such that reduction of the activity of DPP-FV in a subject through inhibition may be used to therapeutically address these disease states. Examples of various diseases that may be treated using the DPP-IV inhibitors of the present invention are described herein. It is noted that additional diseases beyond those disclosed herein may be later identified as the biological roles that DPP-IV plays in various pathways becomes more fully understood.
[0160] One set of indications that DPP-IV inhibitors of the present invention may be used to treat are those involving the prevention and treatment of diabetes and obesity, in particular type 2 diabetes mellitus, diabetic dislipidemia, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose (IFG), metabolic acidosis, ketosis, appetite regulation and obesity.
[0161] DPP-IV inhibitors of the present invention may also be used as immunosuppressants (or cytokine release suppressant drugs) for the treatment of among other things: organ transplant rejection; autoimmune diseases such as inflammatory bowel disease, multiple sclerosis and rheumatoid arthritis; and the treatment of AIDS. [0162] DPP-IV inhibitors of the present invention may also be used for treating various cancers including breast cancer, lung cancer and prostate cancer. [0163] DPP-IV inhibitors of the present invention may also be used to treat dermatological diseases such as psoriasis, rheumatoid arthritis (RA) and lichen planus. [0164] DPP-IV inhibitors of the present invention may also be used to treat infertility and amenorrhea.
[0165] DPP-IV inhibitors of the present invention may also be used to modulate cleavage of various cytokines (stimulating hematopoietic cells), growth factors and neuropeptides. For example, such conditions occur frequently in patients who are immunosuppressed, for example, as a consequence of chemotherapy and/or radiation therapy for cancer.
[0166] DPP-IV inhibitors of the present invention may also be used prevent or reduce cleavage of N-terminal Tyr-Ala from growth hormone-releasing factor. Accordingly, these inhibitors may be used in the treatment of short stature due to growth hormone deficiency (Dwarfism) and for promoting GH-dependent tissue growth or re-growth. [0167] DPP-IV inhibitors of the present invention may also be used to address disease states associated with cleavage of neuropeptides and thus may be useful for the regulation or normalization of neurological disorders.
[0168] For oncology indications, DPP-IV inhibitors of the present invention may be used in conjunction with other agents to inhibit undesirable and uncontrolled cell proliferation. Examples of other anti-cell proliferation agents that may be used in conjunction with the DPP-IV inhibitors of the present invention include, but are not limited to, retinoid acid and derivatives thereof, 2-methoxyestradiol, ANGIOSTATIN™ protein, ENDOSTATBSf™ protein, suramin, squalamine, tissue inhibitor of metalloproteinase-I, tissue inhibitor of metalloproteinase-2, plasminogen activator inhibitor- 1, plasminogen activator inhibitor-2, cartilage-derived inhibitor, paclitaxel, platelet factor 4, protamine sulfate (clupeine), sulfated chitin derivatives (prepared from queen crab shells), sulfated polysaccharide peptidoglycan complex (sp-pg), staurosporine, modulators of matrix metabolism, including for example, proline analogs ((l-azetidine-2- carboxylic acid (LACA)), cishydroxyproline, d,l-3,4-dehydroproline, thiaproline, beta.- aminopropionitrile fumarate, 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone, methotrexate, mitoxantrone, heparin, interferons, 2 macroglobulin-serum, chimp-3, chymostatin, beta.- cyclodextrin tetradecasulfate, eponemycin; fumagillin, gold sodium thiomalate, d- penicillamine (CDPT), beta.-1-anticollagenase-serum, alpha.2-antiplasmin, bisantrene, lobenzarit disodium, n-2-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA", thalidomide; angostatic steroid, carboxyaminoimidazole; metalloproteinase inhibitors such as BB94. Other anti-angiogenesis agents that may be used include antibodies, preferably monoclonal antibodies against these angiogenic growth factors: bFGF, aFGF, FGF-5, VEGF isoforms, VEGF-C, HGF/SF and Ang-l/Ang-2. Ferrara N. and Alitalo, K. "Clinical application of angiogenic growth factors and their inhibitors" (1999) Nature Medicine 5:1359-1364.
4. COMPOSITIONS COMPRISING DPP-IV INHIBITORS
[0169] A wide variety of compositions and administration methods may be used in conjunction with the DPP-IV inhibitors of the present invention. Such compositions may include, in addition to the DPP-IV inhibitors of the present invention, conventional pharmaceutical excipients, and other conventional, pharmaceutically inactive agents. Additionally, the compositions may include active agents in addition to the DPP-IV inhibitors of the present invention. These additional active agents may include additional compounds according to the invention, and/or one or more other pharmaceutically active agents.
[0170] The compositions may be in gaseous, liquid, semi-liquid or solid form, formulated in a manner suitable for the route of administration to be used. For oral administration, capsules and tablets are typically used. For parenteral administration, reconstitution of a lyophilized powder, prepared as described herein, is typically used. [0171] Compositions comprising DPP-IV inhibitors of the present invention may be administered or coadministered orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, or intrathecally. The compounds and/or compositions according to the invention may also be administered or coadministered in slow release dosage forms. [0172] The DPP-IV inhibitors and compositions comprising them may be administered or coadministered in any conventional dosage form. Co-administration in the context of this invention is intended to mean the administration of more than one therapeutic agent, one of which includes a DPP-IV inhibitor, in the course of a coordinated treatment to achieve an improved clinical outcome. Such co-administration may also be coextensive, that is, occurring during overlapping periods of time.
[0173] Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application may optionally include one or more of the following components: a sterile diluent, such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerine, propylene glycol or other synthetic solvent; antimicrobial agents, such as benzyl alcohol and methyl parabens; antioxidants, such as ascorbic acid and sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid (EDTA); buffers, such as acetates, citrates and phosphates; agents for the adjustment of tonicity such as sodium chloride or dextrose, and agents for adjusting the acidity or alkalinity of the composition, such as alkaline or acidifying agents or buffers like carbonates, bicarbonates, phosphates, hydrochloric acid, and organic acids like acetic and citric acid. Parenteral preparations may optionally be enclosed in ampules, disposable syringes or single or multiple dose vials made of glass, plastic or other suitable material.
[0174] When DPP-IV inhibitors according to the present invention exhibit insufficient solubility, methods for solubilizing the compounds may be used. Such methods are known to those of skill in this art, and include, but are not limited to, using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants, such as TWEEN, or dissolution in aqueous sodium bicarbonate. Derivatives of the compounds, such as prodrugs of the compounds may also be used in formulating effective pharmaceutical compositions. [0175] Upon mixing or adding DPP-IV inhibitors according to the present invention to a composition, a solution, suspension, emulsion or the like may be formed. The form of the resulting composition will depend upon a number of factors, including the intended mode of administration, and the solubility of the compound in the selected carrier or vehicle. The effective concentration needed to ameliorate the disease being treated may be empirically determined. [0176] Compositions according to the present invention are optionally provided for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, dry powders for inhalers, granules, sterile parenteral solutions or suspensions, and oral solutions or suspensions, and oil-water emulsions containing suitable quantities of the compounds, particularly the pharmaceutically acceptable salts, preferably the sodium salts, thereof. The pharmaceutically therapeutically active compounds and derivatives thereof are typically formulated and administered in unit-dosage forms or multiple-dosage forms. Unit-dose forms, as used herein, refers to physically discrete units suitable for human and animal subjects and packaged individually as is known in the art. Each unit- dose contains a predetermined quantity of the therapeutically active compound sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carrier, vehicle or diluent. Examples of unit-dose forms include ampoules and syringes individually packaged tablet or capsule. Unit-dose forms may be administered in fractions or multiples thereof. A multiple-dose form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dose form. Examples of multiple-dose forms include vials, bottles of tablets or capsules or bottles of pint or gallons. Hence, multiple dose form is a multiple of unit-doses that are not segregated in packaging.
[0177] In addition to one or more DPP-IV inhibitors according to the present invention, the composition may comprise: a diluent such as lactose, sucrose, dicalcium phosphate, or carboxymethylcellulose; a lubricant, such as magnesium stearate, calcium stearate and talc; and a binder such as starch, natural gums, such as gum acaciagelatin, glucose, molasses, polvinylpyrrolidine, celluloses and derivatives thereof, povidone, crospovidones and other such binders known to those of skill in the art. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, or otherwise mixing an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of auxiliary substances such as wetting agents, emulsifying agents, or solubilizing agents, pH buffering agents and the like, for example, acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and other such agents. Actual methods of preparing such dosage forms are known in the art, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 15th Edition, 1975. The composition or formulation to be administered will, in any event, contain a sufficient quantity of a DPP-IV inhibitor of the present invention to reduce DPP-IV activity in vivo, thereby treating the disease state of the subject.
[0178] Dosage forms or compositions may optionally comprise one or more DPP-IV inhibitors according to the present invention in the range of 0.005% to 100% (weight/weight) with the balance comprising additional substances such as those described herein. For oral administration, a pharmaceutically acceptable composition may optionally comprise any one or more commonly employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, talcum, cellulose derivatives, sodium crosscarmellose, glucose, sucrose, magnesium carbonate, sodium saccharin, talcum. Such compositions include solutions, suspensions, tablets, capsules, powders, dry powders for inhalers and sustained release formulations, such as, but not limited to, implants and microencapsulated delivery systems, and biodegradable, biocompatible polymers, such as collagen, ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and others. Methods for preparing these formulations are known to those skilled in the art. The compositions may optionally contain 0.01%-100% (weight/weight) of one or more DPP-IV inhibitors, optionally 0.1- 95%, and optionally 1-95%.
[0179] Salts, preferably sodium salts, of the DPP-IV inhibitors may be prepared with carriers that protect the compound against rapid elimination from the body, such as time release formulations or coatings. The formulations may further include other active compounds to obtain desired combinations of properties.
A. Formulations for oral administration
[0180] Oral pharmaceutical dosage forms may be as a solid, gel or liquid. Examples of solid dosage forms include, but are not limited to tablets, capsules, granules, and bulk powders. More specific examples of oral tablets include compressed, chewable lozenges and tablets that may be enteric-coated, sugar-coated or film-coated. Examples of capsules include hard or soft gelatin capsules. Granules and powders may be provided in non- effervescent or effervescent forms. Each may be combined with other ingredients known to those skilled in the art.
[0181] In certain embodiments, DPP-IV inhibitors according to the present invention are provided as solid dosage forms, preferably capsules or tablets. The tablets, pills, capsules, troches and the like may optionally contain one or more of the following ingredients, or compounds of a similar nature: a binder; a diluent; a disintegrating agent; a lubricant; a glidant; a sweetening agent; and a flavoring agent. [0182] Examples of binders that may be used include, but are not limited to, microcrystalline cellulose, gum tragacanth, glucose solution, acacia mucilage, gelatin solution, sucrose and starch paste.
[0183] Examples of lubricants that may be used include, but are not limited to, talc, starch, magnesium or calcium stearate, lycopodium and stearic acid. [0184] Examples of diluents that may be used include, but are not limited to, lactose, sucrose, starch, kaolin, salt, mannitol and dicalcium phosphate.
[0185] Examples of glidants that may be used include, but are not limited to, colloidal silicon dioxide.
[0186] Examples of disintegrating agents that may be used include, but are not limited to, crosscarmellose sodium, sodium starch glycolate, alginic acid, corn starch, potato starch, bentonite, methylcellulose, agar and carboxymethylcellulose. [0187] Examples of coloring agents that may be used include, but are not limited to, any of the approved certified water soluble FD and C dyes, mixtures thereof; and water insoluble FD and C dyes suspended on alumina hydrate.
[0188] Examples of sweetening agents that may be used include, but are not limited to, sucrose, lactose, mannitol and artificial sweetening agents such as sodium cyclamate and saccharin, and any number of spray-dried flavors.
[0189] Examples of flavoring agents that may be used include, but are not limited to, natural flavors extracted from plants such as fruits and synthetic blends of compounds that produce a pleasant sensation, such as, but not limited to peppermint and methyl salicylate. [0190] Examples of wetting agents that may be used include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether.
[0191] Examples of anti-emetic coatings that may be used include, but are not limited to, fatty acids, fats, waxes, shellac, ammoniated shellac and cellulose acetate phthalates.
[0192] Examples of film coatings that may be used include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000 and cellulose acetate phthalate.
[0193] If oral administration is desired, the salt of the compound may optionally be provided in a composition that protects it from the acidic environment of the stomach. For example, the composition can be formulated in an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine. The composition may also be formulated in combination with an antacid or other such ingredient.
[0194] When the dosage unit form is a capsule, it may optionally additionally comprise a liquid carrier such as a fatty oil. In addition, dosage unit forms may optionally additionally comprise various other materials that modify the physical form of the dosage unit, for example, coatings of sugar and other enteric agents.
[0195] Compounds according to the present invention may also be administered as a component of an elixir, suspension, syrup, wafer, sprinkle, chewing gum or the like. A syrup may optionally comprise, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
[0196] The DPP-IV inhibitors of the present invention may also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antacids, H2 blockers, and diuretics. For example, if a compound is used for treating asthma or hypertension, it may be used with other bronchodilators and antihypertensive agents, respectively.
[0197] Examples of pharmaceutically acceptable carriers that may be included in tablets comprising DPP-IV inhibitors of the present invention include, but are not limited to binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, and wetting agents. Enteric-coated tablets, because of the enteric-coating, resist the action of stomach acid and dissolve or disintegrate in the neutral or alkaline intestines. Sugar- coated tablets may be compressed tablets to which different layers of pharmaceutically acceptable substances are applied. Film-coated tablets may be compressed tablets that have been coated with polymers or other suitable coating. Multiple compressed tablets may be compressed tablets made by more than one compression cycle utilizing the pharmaceutically acceptable substances previously mentioned. Coloring agents may also be used in tablets. Flavoring and sweetening agents may be used in tablets, and are especially useful in the formation of chewable tablets and lozenges. [0198] Examples of liquid oral dosage forms that may be used include, but are not limited to, aqueous solutions, emulsions, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules.
[0199] Examples of aqueous solutions that may be used include, but are not limited to, elixirs and syrups. As used herein, elixirs refer to clear, sweetened, hydroalcoholic preparations. Examples of pharmaceutically acceptable carriers that may be used in elixirs include, but are not limited to solvents. Particular examples of solvents that may be used include glycerin, sorbitol, ethyl alcohol and syrup. As used herein, syrups refer to concentrated aqueous solutions of a sugar, for example, sucrose. Syrups may optionally further comprise a preservative.
[0200] Emulsions refer to two-phase systems in which one liquid is dispersed in the form of small globules throughout another liquid. Emulsions may optionally be oil-in- water or water-in-oil emulsions. Examples of pharmaceutically acceptable carriers that may be used in emulsions include, but are not limited to non-aqueous liquids, emulsifying agents and preservatives.
[0201] Examples of pharmaceutically acceptable substances that may be used in non- effervescent granules, to be reconstituted into a liquid oral dosage form, include diluents, sweeteners and wetting agents.
[0202] Examples of pharmaceutically acceptable substances that may be used in effervescent granules, to be reconstituted into a liquid oral dosage form, include organic adds and a source of carbon dioxide. [0203] Coloring and flavoring agents may optionally be used in all of the above dosage forms.
[0204] Particular examples of preservatives that may be used include glycerin, methyl and propylparaben, benzoic add, sodium benzoate and alcohol.
[0205] Particular examples of non-aqueous liquids that may be used in emulsions include mineral oil and cottonseed oil.
[0206] Particular examples of emulsifying agents that may be used include gelatin, acacia, tragacanth, bentonite, and surfactants such as polyoxyethylene sorbitan monooleate.
[0207] Particular examples of suspending agents that may be used include sodium carboxymethylcellulose, pectin, tragacanth, Veegum and acacia. Diluents include lactose and sucrose. Sweetening agents include sucrose, syrups, glycerin and artificial sweetening agents such as sodium cyclamate and saccharin.
[0208] Particular examples of wetting agents that may be used include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether.
[0209] Particular examples of organic acids that may be used include citric and tartaric acid.
[0210] Sources of carbon dioxide that may be used in effervescent compositions include sodium bicarbonate and sodium carbonate. Coloring agents include any of the approved certified water soluble FD and C dyes, and mixtures thereof.
[0211] Particular examples of flavoring agents that may be used include natural flavors extracted from plants such fruits, and synthetic blends of compounds that produce a pleasant taste sensation.
[0212] For a solid dosage form, the solution or suspension, in for example propylene carbonate, vegetable oils or triglycerides, is preferably encapsulated in a gelatin capsule.
Such solutions, and the preparation and encapsulation thereof, are disclosed in U.S. Pat.
Nos. 4,328,245; 4,409,239; and 4,410,545. For a liquid dosage form, the solution, e.g., for example, in a polyethylene glycol, may be diluted with a sufficient quantity of a pharmaceutically acceptable liquid carrier, e.g. water, to be easily measured for administration. [0213] Alternatively, liquid or semi-solid oral formulations may be prepared by dissolving or dispersing the active compound or salt in vegetable oils, glycols, triglycerides, propylene glycol esters (e.g. propylene carbonate) and other such carriers, and encapsulating these solutions or suspensions in hard or soft gelatin capsule shells. Other useful formulations include those set forth in U.S. Pat. Nos. Re 28,819 and 4,358,603.
B. Injectables, solutions and emulsions
[0214] The present invention is also directed to compositions designed to administer the DPP-IV inhibitors of the present invention by parenteral administration, generally characterized by injection, either subcutaneously, intramuscularly or intravenously. Injectables may be prepared in any conventional form, for example as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
[0215] Examples of excipients that may be used in conjunction with injectables according to the present invention include, but are not limited to water, saline, dextrose, glycerol or ethanol. The injectable compositions may also optionally comprise minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other such agents, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins. Implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained (see, e.g., U.S. Pat. No. 3,710,795) is also contemplated herein. The percentage of active compound contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject.
[0216] Parenteral administration of the formulations includes intravenous, subcutaneous and intramuscular administrations. Preparations for parenteral administration include sterile solutions ready for injection, sterile dry soluble products, such as the lyophilized powders described herein, ready to be combined with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle just prior to use and sterile emulsions. The solutions may be either aqueous or nonaqueous. [0217] When administered intravenously, examples of suitable carriers include, but are not limited to physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.
[0218] Examples of pharmaceutically acceptable carriers that may optionally be used in parenteral preparations include, but are not limited to aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other pharmaceutically acceptable substances.
[0219] Examples of aqueous vehicles that may optionally be used include Sodium Chloride Injection, Ringers Injection, Isotonic Dextrose Injection, Sterile Water Injection, Dextrose and Lactated Ringers Injection.
[0220] Examples of nonaqueous parenteral vehicles that may optionally be used include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil and peanut oil. [0221] Antimicrobial agents in bacteriostatic or fungistatic concentrations may be added to parenteral preparations, particularly when the preparations are packaged in multiple-dose containers and thus designed to be stored and multiple aliquots to be removed. Examples of antimicrobial agents that may used include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and benzethonium chloride. [0222] Examples of isotonic agents that may be used include sodium chloride and dextrose. Examples of buffers that may be used include phosphate and citrate. Examples of antioxidants that may be used include sodium bisulfate. Examples of local anesthetics that may be used include procaine hydrochloride. Examples of suspending and dispersing agents that may be used include sodium carboxymethylcellulose, hydroxypropyl methylcellulose and polyvinylpyrrolidone. Examples of emulsifying agents that may be used include Polysorbate 80 (TWEEN 80). A sequestering or chelating agent of metal ions include EDTA.
[0223] Pharmaceutical carriers may also optionally include ethyl alcohol, polyethylene glycol and propylene glycol for water miscible vehicles and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment. [0224] The concentration of a DPP-IV inhibitor in the parenteral formulation may be adjusted so that an injection administers a pharmaceutically effective amount sufficient to produce the desired pharmacological effect. The exact concentration of a DPP-IV inhibitor and/or dosage to be used will ultimately depend on the age, weight and condition of the patient or animal as is known in the art.
[0225] Unit-dose parenteral preparations may be packaged in an ampoule, a vial or a syringe with a needle. All preparations for parenteral administration should be sterile, as is know and practiced in the art.
[0226] Injectables may be designed for local and systemic administration. Typically a therapeutically effective dosage is formulated to contain a concentration of at least about 0.1% w/w up to about 90% w/w or more, preferably more than 1 % w/w of the DPP-IV inhibitor to the treated tissue(s). The DPP-IV inhibitor may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment will be a function of the location of where the composition is parenterally administered, the carrier and other variables that may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the age of the individual treated. It is to be further understood that for any particular subject, specific dosage regimens may need to be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations. Hence, the concentration ranges set forth herein are intended to be exemplary and are not intended to limit the scope or practice of the claimed formulations.
[0227] The DPP-IV inhibitor may optionally be suspended in micronized or other suitable form or may be derivatized to produce a more soluble active product or to produce a prodrug. The form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the selected carrier or vehicle. The effective concentration is sufficient for ameliorating the symptoms of the disease state and may be empirically determined. C. Lyophilized powders
[0228] The DPP-IV inhibitors of the present invention may also be prepared as lyophilized powders, which can be reconstituted for administration as solutions, emulsions and other mixtures. The lyophilized powders may also be formulated as solids or gels. [0229] Sterile, lyophilized powder may be prepared by dissolving the compound in a sodium phosphate buffer solution containing dextrose or other suitable excipient. Subsequent sterile filtration of the solution followed by lyophilization under standard conditions known to those of skill in the art provides the desired formulation. Briefly, the lyophilized powder may optionally be prepared by dissolving dextrose, sorbitol, fructose, corn syrup, xylitol, glycerin, glucose, sucrose or other suitable agent, about 1-20%, preferably about 5 to 15%, in a suitable buffer, such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the ait at, typically, about neutral pH. Then, a DPP-IV inhibitor is added to the resulting mixture, preferably above room temperature, more preferably at about 30-35 0C, and stirred until it dissolves. The resulting mixture is diluted by adding more buffer to a desired concentration. The resulting mixture is sterile filtered or treated to remove particulates and to insure sterility, and apportioned into vials for lyophilization. Each vial may contain a single dosage or multiple dosages of the DPP-IV inhibitor.
D. Topical administration
[0230] The DPP-IV inhibitors of the present invention may also be administered as topical mixtures. Topical mixtures may be used for local and systemic administration. The resulting mixture may be a solution, suspension, emulsions or the like and are formulated as creams, gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, irrigations, sprays, suppositories, bandages, dermal patches or any other formulations suitable for topical administration. [0231] The DPP-IV inhibitors may be formulated as aerosols for topical application, such as by inhalation (see, U.S. Pat. Nos. 4,044,126, 4,414,209, and 4,364,923, which describe aerosols for delivery of a steroid useful for treatment inflammatory diseases, particularly asthma). These formulations for administration to the respiratory tract can be in the form of an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case, the particles of the formulation will typically have diameters of less than 50 microns, preferably less than 10 microns.
[0232] The DPP-IV inhibitors may also be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye or for intracisternal or intraspinal application. Topical administration is contemplated for transdermal delivery and also for administration to the eyes or mucosa, or for inhalation therapies. Nasal solutions of the DPP-IV inhibitor alone or in combination with other pharmaceutically acceptable excipients can also be administered.
E. Formulations for other routes of administration
[0233] Depending upon the disease state being treated, other routes of administration, such as topical application, transdermal patches, and rectal administration, may also be used. For example, pharmaceutical dosage forms for rectal administration are rectal suppositories, capsules and tablets for systemic effect. Rectal suppositories are used herein mean solid bodies for insertion into the rectum that melt or soften at body temperature releasing one or more pharmacologically or therapeutically active ingredients. Pharmaceutically acceptable substances utilized in rectal suppositories are bases or vehicles and agents to raise the melting point. Examples of bases include cocoa butter (theobroma oil), glycerin-gelatin, carbowax, (polyoxyethylene glycol) and appropriate mixtures of mono-, di- and triglycerides of fatty acids. Combinations of the various bases may be used. Agents to raise the melting point of suppositories include spermaceti and wax. Rectal suppositories may be prepared either by the compressed method or by molding. The typical weight of a rectal suppository is about 2 to 3 gm. Tablets and capsules for rectal administration may be manufactured using the same pharmaceutically acceptable substance and by the same methods as for formulations for oral administration.
F. Examples of Formulations
[0234] The following are particular examples of oral, intravenous and tablet formulations that may optionally be used with compounds of the present invention. It is noted that these formulations may be varied depending on the particular compound being used and the indication for which the formulation is going to be used. ORAL FORMULATION
Compound of the Present Invention 10-100 mg
Citric Acid Monohydrate 105 mg
Sodium Hydroxide 18 mg
Flavoring
Water q.s. to 100 mL
INTRAVENOUS FORMULATION
Compound of the Present Invention 0.1-10 mg
Dextrose Monohydrate q.s. to make isotonic
Citric Acid Monohydrate 1.05 mg
Sodium Hydroxide 0.18 mg
Water for Injection q.s. to 1.0 mL
TABLET FORMULATION
Compound of the Present Invention 1 %
Microcrystalline Cellulose 73%
Stearic Acid 25%
Colloidal Silica 1%.
5. KITS COMPRISING DPP-IV INHIBITORS
[0235] The invention is also directed to kits and other articles of manufacture for treating diseases associated with DPP-IV. It is noted that diseases are intended to cover all conditions for which the DPP-IV possesses activity that contributes to the pathology and/or symptomology of the condition.
[0236] In one embodiment, a kit is provided that comprises a composition comprising at least one DPP-IV inhibitor of the present invention in combination with instructions. The instructions may indicate the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition. The kit may also comprise packaging materials. The packaging material may comprise a container for housing the composition. The kit may also optionally comprise additional components, such as syringes for administration of the composition. The kit may comprise the composition in single or multiple dose forms. [0237] In another embodiment, an article of manufacture is provided that comprises a composition comprising at least one DPP-IV inhibitor of the present invention in combination with packaging materials. The packaging material may comprise a container for housing the composition. The container may optionally comprise a label indicating the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition. The kit may also optionally comprise additional components, such as syringes for administration of the composition. The kit may comprise the composition in single or multiple dose forms. [0238] It is noted that the packaging material used in kits and articles of manufacture according to the present invention may form a plurality of divided containers such as a divided bottle or a divided foil packet. The container can be in any conventional shape or form as known in the art which is made of a pharmaceutically acceptable material, for example a paper or cardboard box, a glass or plastic bottle or jar, a re-sealable bag (for example, to hold a "refill" of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule. The container that is employed will depend on the exact dosage form involved, for example a conventional cardboard box would not generally be used to hold a liquid suspension. It is feasible that more than one container can be used together in a single package to market a single dosage form. For example, tablets may be contained in a bottle that is in turn contained within a box. Typically the kit includes directions for the administration of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral, topical, transdermal and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.
[0239] One particular example of a kit according to the present invention is a so-called blister pack. Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process recesses are formed in the plastic foil. The recesses have the size and shape of individual tablets or capsules to be packed or may have the size and shape to accommodate multiple tablets and/or capsules to be packed. Next, the tablets or capsules are placed in the recesses accordingly and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are individually sealed or collectively sealed, as desired, in the recesses between the plastic foil and the sheet. Preferably the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening. [0240] Another specific embodiment of a kit is a dispenser designed to dispense the daily doses one at a time in the order of their intended use. Preferably, the dispenser is equipped with a memory-aid, so as to further facilitate compliance with the regimen. An example of such a memory-aid is a mechanical counter that indicates the number of daily doses that has been dispensed. Another example of such a memory-aid is a battery- powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal which, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.
EXAMPLES
1. Preparation Of DPP-IV Inhibitors
[0241] Various methods may be developed for synthesizing compounds according to the present invention. Representative methods for synthesizing these compounds are provided in the Examples. It is noted, however, that the compounds of the present invention may also be synthesized by other synthetic routes that others may devise. [0242] It will be readily recognized that certain compounds according to the present invention have atoms with linkages to other atoms that confer a particular stereochemistry to the compound (e.g., chiral centers). It is recognized that synthesis of compounds according to the present invention may result in the creation of mixtures of different stereoisomers (enantiomers, diastereomers). Unless a particular stereochemistry is specified, recitation of a compound is intended to encompass all of the different possible stereoisomers. [0243] Various methods for separating mixtures of different stereoisomers are known in the art. For example, a racemic mixture of a compound may be reacted with an optically active resolving agent to form a pair of diastereoisomeric compounds. The diastereomers may then be separated in order to recover the optically pure enantiomers. Dissociable complexes may also be used to resolve enantiomers (e.g., crystalline diastereoisomeric salts). Diastereomers typically have sufficiently distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) that they can be readily separated by taking advantage of these dissimilarities. For example, diastereomers can typically be separated by chromatography or by separation/resolution techniques based upon differences in solubility. A more detailed description of techniques that can be used to resolve stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981).
[0244] Compounds according to the present invention can also be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid. Alternatively, a pharmaceutically acceptable base addition salt of a compound can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base. Inorganic and organic acids and bases suitable for the preparation of the pharmaceutically acceptable salts of compounds are set forth in the definitions section of this Application. Alternatively, the salt forms of the compounds can be prepared using salts of the starting materials or intermediates.
[0245] The free acid or free base forms of the compounds can be prepared from the corresponding base addition salt or acid addition salt form. For example, a compound in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like). A compound in a base addition salt form can be converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc).
[0246] The N-oxides of compounds according to the present invention can be prepared by methods known to those of ordinary skill in the art. For example, N-oxides can be prepared by treating an unoxidized form of the compound with an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as dichloromethane) at approximately 0 0C. Alternatively, the iV-oxides of the compounds can be prepared from the N-oxide of an appropriate starting material.
[0247] Compounds in an unoxidized form can be prepared from iV-oxides of compounds by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in an suitable inert organic solvent (e.g., acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80 0C.
[0248] Prodrug derivatives of the compounds can be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et al. (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985). For example, appropriate prodrugs can be prepared by reacting a non-derivatized compound with a suitable carbamylating agent (e.g., lj-acyloxyalkylcarbonochloridate^ara-nitrophenyl carbonate, or the like).
[0249] Protected derivatives of the compounds can be made by methods known to those of ordinary skill in the ait. A detailed description of the techniques applicable to the creation of protecting groups and their removal can be found in T.W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999. [0250] Compounds according to the present invention may be conveniently prepared, or formed during the process of the invention, as solvates (e.g. hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.
[0251] Compounds according to the present invention can also be prepared as then- individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomer. While resolution of enantiomers can be carried out using covalent diastereomeric derivatives of compounds, dissociable complexes are preferred (e.g., crystalline diastereoisomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities. The diastereomers can be separated by chromatography or, preferably, by separation/resolution techniques based upon differences in solubility. The optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization. A more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981).
[0252] As used herein the symbols and conventions used in these processes, schemes and examples are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society or the Journal of Biological Chemistry. Standard single-letter or thee-letter abbreviations are generally used to designate amino acid residues, which are assumed to be in the L-configuration unless otherwise noted. Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification. Specifically, the following abbreviations may be used in the examples and throughout the specification: g (grams); mg (milligrams);
L (liters); mL (milliliters); μL (microliters); psi (pounds per square inch);
M (molar); mM (millimolar); i.v. (intravenous); Hz (Hertz);
MHz (megahertz); mol (moles); mmol (millimoles); RT (ambient temperature); min (minutes); h (hours); mp (melting point); TLC (thin layer chromatography);
Tr (retention time); RP (reverse phase);
MeOH (methanol); i-PrOH (isopropanol);
TEA (triethylamine); TFA (trifluoroacetic acid);
TFAA (trifluoroacetic anhydride); THF (tetrahydrofuran);
DMSO (dimethylsulf oxide); EtOAc (ethyl acetate); DME ( 1 ,2-dimethoxyethane) ; DCM (dichloromethane) ;
DCE (dichloroethane); DMF (N,N-dimethylformamide);
DMPU (N,N' -dimethylpropyleneurea) ; CDI (1,1 -carbonyldiimidazole) ;
IBCF (isobutyl chloroformate); HOAc (acetic acid);
HOSu (N-hydroxysuccinimino); HOBT (1-hydroxybenzotriazole);
Et2O (diethyl ether);
EDCI (ethylcarbodiimino hydrochloride);
BOC (tert-butyloxycarbonyl); FMOC (9-fluorenylmethoxycarbonyl);
DCC (dicyclohexylcarbodiimino); CBZ (benzyloxycarbonyl);
Ac (acetyl); atm (atmosphere);
TMSE (2-(trimethylsilyl)ethyl); TMS (trimethylsilyl);
TIPS (triisopropylsilyl); TBS (t-butyldimethylsilyl);
DMAP (4-dimethylaminopyridine); Me (methyl);
OMe (methoxy); Et (ethyl);
Et (ethyl); tBu (tert-butyl);
HPLC (high pressure liquid chomatography);
BOP (bis(2-oxo-3-oxazolidinyl)phosphinic chloride);
TBAF (tetra-n-butylammonium fluoride); and mCPBA (meta-chloroperbenzoic acid.
[0253] All references to ether or Et2O are to diethyl ether; brine refers to a saturated aqueous solution of NaCl. Unless otherwise indicated, all temperatures are expressed in
0C (degrees Centigrade). All reactions conducted under an inert atmosphere at RT unless otherwise noted.
[0254] 1H NMR spectra were recorded on a Bruker Avance 400. Chemical shifts are expressed in parts per million (ppm). Coupling constants are in units of hertz (Hz).
Splitting patterns describe apparent multiplicities and are designated as s (singlet), d
(doublet), t (triplet), q (quartet), m (multiplet), br (broad).
[0255] Low-resolution mass spectra (MS) and compound purity data were acquired on a Waters ZQ LC/MS single quadrupole system equipped with electrospray ionization (ESI) source, UV detector (220 and 254 nm), and evaporative light scattering detector (ELSD). Thin-layer chromatography was performed on 0.25 mm E. Merck silica gel plates (60F- 254), visualized with UV light, 5% ethanolic phosphomolybdic acid, Ninhydrin or p- anisaldehyde solution. Hash column chromatography was performed on silica gel (230- 400 mesh, Merck).
2. Synthetic Schemes For DPP-IV Inhibitors Of The Present Invention
[0256] DPP-IV inhibitors according to the present invention may be synthesized according to a variety of reaction schemes. Some illustrative schemes are provided herein in the examples. Other reaction schemes could be readily devised by those skilled in the art.
[0257] In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T.W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991.
[0258] By varying the V, W, X, Y, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, Rn, R12, Ri3, Ri4, Ri5, Ri6, Ri7, Ris, R19, and R20 groups, a wide variety of different DPP-IV inhibitors according to the present invention may be synthesized.
[0259] In each of the above reaction schemes, the various substituents may be selected from among the various substituents otherwise taught herein.
[0260] Descriptions of the syntheses of particular compounds according to the present invention based on the above reaction schemes are set forth herein.
3. Examples Of DPP-IV Inhibitors
[0261] The present invention is further exemplified, but not limited by, the following examples that describe the synthesis of particular compounds according to the invention.
Experimental Methods
[0262] A general synthetic route for producing compounds of the present invention is shown in Scheme 1. Condensation of Compound A with an aldehyde provides Compound B, which is then treated with Compound C to give Compound D. Finally, reduction gives the compound of the present invention.
Scheme 1:
VJL
Figure imgf000065_0001
[0263] A synthetic route for producing other compounds of the present invention is shown in Scheme 2. Condensation of Compound F with an aldehyde provides Compound G, which is then treated with Compound H to give Compound I. Reductive animation gives the compound of the present invention.
Scheme 2:
1^r,
Figure imgf000065_0002
[0264] A synthetic route for producing other compounds of the present invention is shown in Scheme 3. Treatment of Compound B with Compound K provides Compound L, which is then halogenated to give Compound M. Animation followed by reduction gives the compound of the present invention.
Scheme 3: NΛN N^R R,3
Figure imgf000066_0001
M N
[0265] A synthetic route for producing other compounds of the present invention is shown in Scheme 4. Treatment of Compound O with malononitrile provides Compound P, which is then treated with Compound H to give Compound Q. Alkylation followed by reduction gives the compound of the present invention.
Scheme 4:
Figure imgf000066_0002
Propanol, Reflux
Figure imgf000066_0003
Figure imgf000066_0004
[0266] A synthetic route for producing other compounds of the present invention is shown in Scheme 5. Treatment of Compound Q with sodium nitrite and a halide source provides Compound T, which is then treated with an amine or an alcohol to give Compound U. Reduction gives Compound V of the present invention. Alternatively, Compound T is subjected to a Suzuki or other transition metal mediated coupling to provide Compound W. Reduction then gives Compound Z of the present invention.
Scheme 5:
Figure imgf000067_0001
I Suzuki coupling U V
Figure imgf000067_0002
W
[0267] For example, the above reaction schemes, and variations thereof, can be used to prepare the following:
Figure imgf000067_0003
2-(7-amino-6-(aminomethyl)- 1 ,3-dimethyl- 2-(6-(aminomethyl)-7-chloro- 1 ,3-dimethyl- 2,4-dioxo- 1 ,2,3 ,4-tetrahydropyrido [2,3- 2,4-dioxo- 1 ,2,3 ,4-tetrahydropyrido [2,3- J]pyrimidin-5-yl)-4-fluorobenzonitrile J]pyrimidin-5-yl)-4-fluorobenzonitrile
Figure imgf000067_0004
2-(6-(aminomethyl)- 1 ,3 ,7-trimethyl-2,4- 2-(6-(aminomethyl)- 1 ,3-dimethyl-2,4- dioxo-l,2,3,4-tetrahydropyrido[2,3- dioxo-7-(trifluoromethyl)- 1 ,2,3 ,4- rf]pyrimidin-5-yl)-4-fluorobenzonitrile tetrahydropyrido[2,3-J]pyrimidin-5-yl)-4- fluorobenzonitrile
Figure imgf000067_0005
2-(6-(aminomethyl)- 1 ,3-dimethyl-2,4- 2-(6-(aminomethyl)- 1 ,3-dimethyl-2,4- dioxo-l,2,3,4-tetrahydropyrido[2,3- dioxo-7-(2,2,2-trifluoroethylamino)- 1 ,2,3 ,4-
J]pyrimidin-5-yl)-4-fluorobenzonitrile tetrahydropyrido[2,3-<i]pyrirnidin-5-yi)-4- fluorobenzonitrile
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Compound IA: 2-(2,4-Dichloro-benzylidene)-malononitrile
Figure imgf000070_0002
[0268] Referring to Scheme 4, to a solution of 2,4-dichlorobenzaldehyde (1.75g, 10 mmol) and malononitrile (660 mg, 10 mmol) in ethanol (10 ml) was added 200 μL of 10% aqueous KOH. The mixture was stirred at room temperature for 15 min, allowed to stand for 30 min, cooled with ice-bath and then filtered to give Compound IA as a white solid (1-8 g).
Example 1 : 7-Amino-6-aminomethyl-5-(2,4-dichloro-phenyl)- 1 ,3-dimethyl- IH- pyrido [2,3-d]pyrimidine-2,4-dione
Figure imgf000071_0001
[0269] A mixture of Compound IA (150 mg, 0.6 mmol) and 6-Amino-l,3-dimethyl uracil (200 mg, 1.2 mmol) in propanol (5 ml) was refluxed overnight, concentrated, redissolved in DCM, washed with 5 % aqueous HCl, water, dried over Na2SO4, and concentrated to give the crude product Compound IB.
[0270] To a solution of the crude Compound IB in THF (3 mL), a solution of IM BH3-THF (2.4 mL, 2.4 mmol) and two drops of 4 M HCl in dioxane were added. The mixture was heated under reflux for 4 h, concentrated, co-evaporated with MeOH, redissolved in MeOH and acidified with TFA. The residue was purified by LC-MS to give the title compound as the TFA salt. 1H NMR (400 MHz, CDCl3-CD3OD) δ 7.47 (d, /=2.0 Hz, 1 H) 7.32 (dd, /=8.1, 2.0 Hz, 1 H) 7.03 (d, /=8.1 Hz, 1 H) 3.74 and 3.58 (ABq, /=14.9 and 59.4Hz, 2 H) 3.56 (s, 3 H) 3.19 (s, 3 H). [M-NH2] calc'd for C16Hi3Cl2N4O2, 363; found, 363.
Example 2: 7-Amino-6-aminomethyl-5-(2-bromo-4-fluoro-phenyl)- 1 ,3-dimethyl- IH- pyrido [2,3-d]pyrimidine-2,4-dione
Figure imgf000071_0002
[0271] The title compound was synthesized from 2-bromo-4-fluoro-benzaldehyde following the same procedure described in the synthesis of Example 1. 1H NMR (400 MHz, CDCl3-CD3OD 10:1) 7.40 (dd, /=8.2, 2.4 Hz, 1 H) 7.12 (td, /=8.2, 2.5 Hz, 1 H) 7.04 - 7.09 (dd, 7=5.9, 8.6 Hz, IH), 3.71 (d, /=14.7 Hz 1 H) 3.55 - 3.62 (m, 4 H), 3.20 (s, 3 H). [M-NH2] calc'd for C16H13BrFN4O2, 391; found, 391.
Example 3: 7-Amino-6-aminomethyl-5-(2-bromo-phenyl)- 1 ,3-dimethyl- lH-pyrido[2,3- d]pyrimidine-2,4-dione
Figure imgf000072_0001
[0272] The title compound was synthesized from 2-bromo-benzaldehyde following the same procedure described in the synthesis of Example 1. 1H NMR (400 MHz, DMSO- D6) 67.68 (dd, /=7.96, 1.1 Hz, 1 H) 7.43 - 7.47 (dd, /=7.5, 1.5 Hz, 1 H) 7.34 (td, /=7.7, 1.5 Hz, 1 H) 7.27 (dd, /=7.6, 1.5 Hz, 1 H) 3.81(d, /=13.9 Hz, 1 H) 3.53 (m, 4 H), 3.07 (s, 3 H). [M-NH2] calc'd for C16H14BrN4O2, 373; found, 373.
Example 4: 6-Aminomethyl-5-(2,4-dichloro-phenyl)-7-ethylamino-l,3-dimethyl-lH- pyrido[2,3-d]pyrimidine-2,4-dione
Figure imgf000072_0002
[0273] To a solution of Compound IB (300 mg, 0.8 mmol) in a mixture of pyridine and DCM (5:1, 5 niL) was added AcCl (0.5 mL). The mixture was heated at 100 °C in a microwave for 10 min, concentrated, redissolved in DCM, washed with 5 % aqueous HCl and water. The crude product was dissolved in THF (2 mL), treated with BH3-THF (4mL) and two drops of 4 M HCl in dioxane under reflux overnight. General workup as described in the synthesis of Example 1 and LC-MS purification gave Example 4 as the TFA salt. 1H NMR (400 MHz, CDCl3-CD3OD 10:1) δ 7.46 (d, /=1.8 Hz, 1 H) 7.31 (dd, /=8.2, 1.9 Hz, 1 H) 7.05 (d, /=8.3 Hz, 1 H) 3.74 (d, /=14.7 Hz, 1 H) 3.61 (s, 3 H) 3.51 - 3.59 (m, 3 H) 3.19 (s, 3 H) 1.24 (t, /=7.074 Hz, 3 H). [M-NH2] calc'd for C18H17Cl2N4O2, 391; found, 391.
Example 5: 6-Aminomethyl-5-(2,4-dichloro-phenyl)- 1 ,3-dimethyl-7-methylamino- IH- pyrido[2,3-d]pyrimidine-2,4-dione
Figure imgf000073_0001
Example 6: 6-Aminomethyl-5-(2,4-dichloro-phenyl)-7-dimethylamino- 1 ,3-dimethyl- IH- pyrido [2,3-d]pyrimidine-2,4-dione
Figure imgf000073_0002
[0274] Compound IB (200 mg, 0.5 mmol) in dry DMF (3 mL) was treated with 60 % NaH (22 mg, 0.55 mmol), followed by MeI (105 mg, 0.75 mmol). The mixture was stirred at room temperature for 2 h, and then concentrated to dryness. The crude product was dissolved in DCM and washed with water. The crude mixture was dissolved in THF (2 mL) and then treated with BH3-THF (2 mL) under reflux overnight. General workup as described in the synthesis of Example 1 and LC-MS purification gave Examples 5 and 6. [0275] Example 5: 1H NMR (400 MHz, CDCl3-CD3OD 10: 1) δ 7.47 (d, /=2.0 Hz, 1 H) 7.32 (dd, /=8.3, 2.0 Hz, 1 H) 7.03 (d, /=8.3 Hz, 1 H) 3.72, 3.57 (ABq, /=14.9, 57.6 Hz, 2 H), 3.63 (s, 3 H), 3.20 (s, 3 H), 3.03 (s, 3H). [M-NH2] calc'd for C17H15Cl2N4O2, 377; found, 377. [0276] Example 6: 1H NMR (400 MHz, CDCl3-CD3OD 10: 1) δ 7.47 (d, /=2.0 Hz, 1 H) 7.31 (dd, 7=8.1, 2.0 Hz, 1 H) 7.07 (d, 7=8.3 Hz, 1 H) 3.91, 3.72 (ABq, 7=14.9, 78.1 Hz, 2 H), 3.63 (s, 3 H) 3.22 (s, 3 H) 3.02 (s, 6 H). [M-NH2] calc'd for C18Hi8Cl2N4O2, 392; found, 392.
Scheme 6:
Figure imgf000074_0001
Example 7
Example 7: 6-Aminomethyl-5-(2-bromo-5-fluoro-phenyl)-7-hydroxy- 1 ,3-dimethyl- IH- pyrido[2,3-d]pyrimidine-2,4-dione
Figure imgf000074_0002
[0277] Referring to Scheme 6, to a solution of 2-bromo-5-fluoro-benzaldehyde (960 mg, 5 mmol), and cyano-acetic acid ethyl ester (600mg, 5.4 mmol) in EtOH (4mL) was added three drops of 10% aqueous KOH. After stirring for 15 min and standing at room temperature for 30 min, the mixture was filtered to give Compound AB. [0278] Compound AB (300 mg) and 6-amino- 1 ,3-dimethyl uracil (500 mg) in propanol (5 mL) was refluxed overnight. After general workup and BH3 reduction as described in the synthesis of Example 1, Example 7 was isolated by LC-MS as the TFA salt. 1H NMR (400 MHz, CDCl3-CD3OD 10:1) δ 7.56 (dd, 7=8.8, 5.1 Hz, 1 H) 6.99 (td, 7=8.3, 2.8 Hz, 1 H) 6.92 (dd, 7=8.3, 3.0 Hz, 1 H) 3.79, 3.45 (ABq, 7=13.6, 135.9 Hz, 2 H) 3.59 (s, 3 H), 3.22 (s, 3 H). [M-NH2] calc'd for C16H13BrFN3O3, 393; found, 393. Scheme 7:
Figure imgf000075_0001
AD AE
BH3, THF
HCI in Dixoane, 7OC, 4 hrs
Figure imgf000075_0003
Figure imgf000075_0002
AF Example 8
Compound AE: 2-(2,5-Dichloro-benzylidene)-malononitrile
Figure imgf000075_0004
[0279] To a solution of 2,5-dichlorbenzaldehyde (4.0 g, 0.0228 mole) in ethanol (6 ml) was added malononitrile (1.52g, 0.0228 mole), followed by 100 uL of 10% KOH/H2O. The mixture was stirred at room temperature for 2 hrs and then filtered to give the title compound (4.82 g) in 95% yield. 1H-NMR (400 MHz, d6-DMSO): δ ppm 8.66 (s, IH), 8.07 (d, J= 2.0 Hz, IH), 7.74 (s, IH), 7.74 (s, IH). MS [m+H] calc'd for C10H4Cl2N2, 223.0, 224.8; found 223.0, 224.8.
Compound AF: 7-Amino-5-(2,5-dichloro-phenyl)- 1 ,3-dimethyl-2,4-dioxo- 1 ,2,3 ,4- tetrahydropyrido[2,3-^pyrimidine-6-carbonitrile
Figure imgf000076_0001
[0280] Compound AE (4.82g, 0.0204 mole) and 6- Amino- 1 , 3-dimethyluracil (6.34g, 0.041 mole) were suspended in 6 ml of propanol. The mixture was heated to 12O0C overnight, and then concentrated in vacuo. The residue was dissolved in EtOAc and washed with 10%HCl/H2O and H2O, dried (Na2SO4), filtered, then concentrated in vacuo. The crude product was carried onto the next step without further purification. An amount of 3.3g (43% yield) of the title compound was collected. 1H-NMR (400 MHz, d6-DMSO): δ ppm 8.03 (br s, IH), 7.58(d, J= 8.4 Hz, IH), 7.52 (dd, J1= 2 Hz, J2= 8.4 Hz, 2H), 7.42 (d, J= 2.4 Hz, IH), 3.58 (s, 3H), 3.05(s, 3H). MS [m+H] calc'd for Ci6HnCl2N5O2, 375.9, 377.7; found 375.9, 377.7.
Example 8: 7-Amino-6-aminomethyl-5-(2,5-dichloro-phenyl)- 1 ,3-dimethyl- IH- pyrido[2,3-<i] pyrimidine-2, 4-dione
Figure imgf000076_0002
[0281] To a cold (0 0C - 2 0C) solution of Compound AF (50 mg, 0.1329 mmole) in 500 uL of anhydrous TΗF, was added a IM solution of BH3. THF (531.6 uL, 0.5316 mmole) under nitrogen, followed by 400 uL of IN HCl in Dioxane. The mixture was stirred at room temp, for about lOmin., then heated to 7O0C for 3 hrs. After cooling, to the reaction was added IN HC1/H2O until no more bubbling occurred, followed by MeOH, plus a few drops of TFA. The residue was then dried in vacuo. The product was purified by prep. HPLC and concentrated. The resulting product was washed in EtOAc, and filtered to give 23.0 mg (46%) of the title compound. 1H-NMR (400 MHz, d6-DMSO): δ ppm 8.08 (s, 3H), 7.642 (s, 2H), 7.6195 (d, J= 8.4 Hz, IH), 7.564 (dd, J1= 2.4 Hz, J2= 8.4 Hz, IH), 7.494 (d, J= 2.4 IH), 3.59 (s, 3H), 3.32 (m, IH), 3.31 (d, J= 9.2 IH), 3.23(s, 3H). MS [m+H] calc'd for C16H11Cl2N5O2 , 379.85, 381.87; found 379.85, 381.87.
Example 9: 7-Amino-6-aminomethyl-5- (2-bromo-5-fluoro-phenyl)-l,3-dimethyl-lH- pyrido [2,3-d] pyrimidine-2, 4-dione
Figure imgf000077_0001
[0282] The title compound was prepared using the procedures described in the preparation of Compounds AE and AF, and Example 8. 1H-NMR (400 MHz, d6- DMSO): 6 ppm 7.94 (s, 3H), 7.64 (q, J= 4.8 Hz, IH), 7.50 (s, 2H), 7.16 (m, J= 14.8 Hz, 2H), 3.77(d, J= 7.2 Hz, IH), 3.45 (s, 3H), 3.17 (d, J= 6.4 IH), 3.02 (s, 3H). MS [m+H] calc'd for C16H15BrFN5O2, 407.81, 409.79; found 407.81, 409.79.
Example 10: 7-Amino-6-aminomethyl-5- (2-bromo-phenyl)-l,3-dimethyl-lH-pyrido [2,3-d] pyrimidine-2, 4-dione
Figure imgf000077_0002
[0283] The title compound was prepared using the procedures described in the preparation of Compounds AE and AF, and Example 8. 1H-NMR (400 MHz, d6- DMSO): δ ppm 7.86 (br s, 3H), 7.81(d, J= 8.0 Hz, IH), 7.59 (t, J=7.6 Hz, IH), 7.56 (br s, 2H), 7.48 (td, J1= 1.6 Hz, J2= 7.6 Hz, IH), 7.40 (dd, J1= 1.6 Hz, J2= 7.6 Hz, IH), 3.94 (d, J= 14.8 Hz, IH), 3.66 (s, 3H), 3.51 (d, J=8.4 Hz, IH), 3.21 (s, 3H). MS [m+H] calc'd for Ci6H16BrN5O2, 391.87, 392.78; found 391.87, 392.78.
Example 11: 7-Amino-6-aminomethyl — 1,3-dimethyl- 5- (3-methyl-thiophen-2-yl)-lH- pyrido[2,3-d] pyrimidine-2, 4-dione
Figure imgf000078_0001
[0284] The title compound was prepared using the procedures described in the preparation of Compounds AE and AF, and Example 8. The only difference was that after the synthesis of 2-(3-Methyl-thiophen-2-ylmethylene)-malononitrile, the reaction was carried onto the next step without further work-up or purification, and propanol was used instead of ethanol. Furthermore, after the hydrogenation using BH3 • THF, the reaction mixture was concentrated. An ample amount of MeOH was added until there was no more bubbling. The mixture was dried in vacuo, and purified by prep. HPLC. After washing the product with EtoAc, an amount of 82.4mg (17.1% yield) of the title compound was collected. 1H-NMR (400 MHz, d6-DMSO): δ ppm 7.80 (br s, 3H), 7.53 (d, J= 4.0 Hz, IH), 7.36 (br s, 2H), 6.96 (d, J= 4.0 Hz, IH), 3.80 (m, 2H), 3.51 (s, 3H), 3.10 (s, 3H). MS [m+H] calc'd for Ci5H17N5O2S, 332.0, 333.2; found 332.0, 333.2.
Example 12: 7-Amino-6-aminomethyl-5- (2-chloro-phenyl)-l,3-dimethyl-lH-pyrido [2,3- d] pyrimidine-2, 4-dione
Figure imgf000078_0002
[0285] The title compound was prepared using the procedures described in the preparation of Example 11. 1H-NMR (400 MHz, d6-DMSO): δ ppm 7.79 (br s, 3H), 7.51 (dd, J1= 1.6 Hz, J2= 7.6 Hz, IH), 7.41 (m, 3H), 7.27 (dd, J1= 2.0 Hz, J2= 7.2 Hz, IH), 3.83(d, J= 14.4 Hz, IH), 3.52(s, 3H), 3.24 (m, IH), 3.07 (s, 3H). MS [m+H] calc'd for Ci6H16ClN5O2, 345.90, 347.91; found 345.90, 347.91.
Example 13: 7-Amino-6-aminomethyl-5- (4-fluoro-phenyl)-l,3-dimethyl-lH-pyrido [2,3- d] pyrimidine-2, 4-dione
Figure imgf000079_0001
[0286] The title compound was prepared using the procedures described in the preparation of Example 11. 1H-NMR (400 MHz, d6-DMSO): δ ppm 7.40 (br s, 3H), 7.16 (m, 6H), 3.51 (s, 3H), 3.23 (s, 2H), 3.06 (s, 3H). MS [m+H] calc'd for C16H16FN5O2, 329.93, 330.91; found 329.93, 330.91.
Example 14: 7-Amino-6-aminomethyl-5- (5-chloro-thiophen-2-yl)-l,3-dimethyl-lH- pyrido [2,3-d] pyrimidine-2, 4-dione
Figure imgf000079_0002
[0287] The title compound was prepared using the procedures described in the preparation of Example 11. 1H-NMR (400 MHz, d6-DMSO): δ ppm 7.49 (br s, 2H), 7.08 (d, J= 3.6 Hz, IH), 6.77 (d, J= 3.6 Hz, IH), 3.50(s, 3H), 3.38 (s, 2H), 3.12 (s, 3H). MS [m+H] calc'd for C14H14ClN5O2S, 351.87, 353.82; found 351.87, 353.82345.90, 347.91.
Example 15: 7-Amino-6-aminomethyl-5- (4-bromo-phenyl)-l,3-dimethyl-lH-pyrido [2,3-dj pyrimidine-2, 4-dione
Figure imgf000080_0001
[0288] The title compound was prepared using the procedures described in the preparation of Example 11. 1H-NMR (400 MHz, d6-DMSO): δ ppm 7.54 (d, J= 8.0 Hz, 2H), 7.41 (br s, 2H), 7.08 (d, J= 8.4 Hz, 2H), 3.51(s, 3H), 3.20(s, 2H), 3.06 (s, 3H). MS [m+H] calc'd for C16H16BrN5O2, 391.80, 392.78; found 391.80, 392.78.
Example 16: 7-Amino-6-aminomethyl-5- (2,3-dichloro-phenyl)-l,3-dimethyl-lH-pyrido [2,3-d\ pyrimidine-2, 4-dione
Figure imgf000080_0002
[0289] The title compound was prepared using the procedures described in the preparation of Example 11. 1H-NMR (400 MHz, d6-DMSO): δ ppm 7.62 (d, J= 8.0 Hz, IH), 7.52 (b, 2H), 7.37 (t, J= 8.0 Hz, IH), 7.17 (d, J= 7.6 Hz, IH), 3.52(s, 3H), 3.26 (d, J= 14.0 Hz, IH), 3.15 (d, J= 13.6 Hz, IH), 3.08 (s, 3H). MS [m+H] calc'd for C16H15Cl2N5O2, 379.79, 381.80; found 379.79, 381.80. Example 17: 7-Amino-6-aminomethyl-5- (2-chloro-6-fluoro-phenyl)-l,3-dimefhyl-lH- pyrido [2,3-d] pyrimidine-2, 4-dione
Figure imgf000081_0001
[0290] The title compound was prepared using the procedures described in the preparation of Example 11. 1H-NMR (400 MHz, d6-DMSO): δ ppm 7.84 (br s, 3H), 7.56 (br s, 2H), 7.52 (m, IH), 7.42 (d, J= 8.0 Hz, IH), 7.32 (t, J= 8.4 Hz, IH), 3.72 (d, J= 14.4 Hz, IH), 3.54 (s, 3H), 3.49 (d, J= 14.8 Hz, IH), 3.1 (s, 3H). MS [m+H] calc'd for C16Hi5ClFN5O2, 363.88, 365.89, and 366.87; found 363.88, 365.89, and 366.87.
Example 18: 7-Amino-6-aminomethyl-5- (3-methoxy-phenyl)-l,3-dimethyl-lH-pyrido [2,3-d] pyrimidine-2, 4-dione
Figure imgf000081_0002
[0291] The title compound was prepared using the procedures described in the preparation of Example 11. 1H-NMR (400 MHz, d6-DMSO): δ ppm 7.88 (br s, 3H), 7.50 (br s, 2H), 7.44 (m, J= 8.0 Hz, IH), 7.07 (dd, J1= 2.8 Hz, J2= 8.4 Hz, IH), 6.88 (s, IH), 6.82 (d, J= 7.6 Hz, IH), 3.88 (s, 3H), 3.72 (d, J= 14.4 Hz, IH), 3.65 (d, J= 14.4 Hz, IH), 3.65 (s, 3H). MS [m+H] calc'd for C17H19N5O3, 342.2, 343.2; found 342.2, 343.2.
Example 19: 7-Amino-6-aminomethyl-5- (2-methoxy-phenyl)-l,3-dimethyl-lH-pyrido [2,3-d] pyrimidine-2, 4-dione
Figure imgf000082_0001
[0292] The title compound was prepared using the procedures described in the preparation of Example 11. 1H-NMR (400 MHz, d6-DMSO): δ ppm 7.69 (br s, 3H), 7.38 (td, J1= 1.6 Hz, J2= 8.8 Hz, IH), 7.27 (br s, 2H), 7.02 (m, 3H), 3.74 (d, J= 16.8 Hz, IH), 3.63 (s, 3H), 3.40 (d, J= 14.4 Hz, IH), 3.51 (s, 3H). MS [m+H] calc'd for C17H19N5O3, 342.0, 343.1, and 344.2; found 342.0, 343.1, and 344.2.
Example 20: 7-Amino-6-aminomethyl-5- (2-chloro-3, 6-difluoro-phenyl)-l,3-dimethyl- lH-pyrido [2,3-J] pyrimidine-2, 4-dione
Figure imgf000082_0002
[0293] The title compound was prepared using the procedures described in the preparation of Example 11. 1H-NMR (400 MHz, d6-DMSO): δ ppm 7.64 (br s, 3H), 7.51 (td, J1= 4.8 Hz, J2= 8.8 Hz, IH), 7.34 (td, J1= 4.0 Hz, J2= 8.8 Hz, IH), 3.53 (s, 3H), 3.29 (d, J= 8.4 Hz, 2H), 3.10 (s, 3H). MS [m+H] calc'd for C16H14ClF2N5O2, 381.80, 383.81 and 384.85; found 381.80, 383.81 and 384.85.
Example 21: 7-Amino-6-aminomethyl-5-phenyl-l,3-dimethyl-lH-pyrido [2,3-d] pyrimidine-2, 4-dione
Figure imgf000083_0001
[0294] The title compound was prepared using the procedures described in the preparation of Example 11. 1H-NMR (400 MHz, d6-DMSO): δ ppm 7.34 (m, 5H), 7.10 (dd, J1= 1.6 Hz, J2= 7.2 Hz, 2H), 3.52 (s, 3H), 3.19 (s, 2H), 3.06 (s, 3H). MS [m+H] calc'd for C16H17N5O2, 311.96, 312.93; found 311.96, 312.93.
Example 22: 7-Amino-6-aminomethyl-5- (3-bromo-thiophen-2-yl)-l,3-dimethyl-lH- pyrido [2,3-d] pyrimidine-2, 4-dione
Figure imgf000083_0002
[0295] The title compound was prepared using the procedures described in the preparation of Example 11. 1H-NMR (400 MHz, d6-DMSO): δ ppm 7.88 (s, 3H), 7.80 (d, J= 5.2 Hz, IH), 7.48 (s, 2H), 7.17 (d, J= 5.2 Hz, IH), 3.87 (d, J= 14.4 Hz, IH), 3.51 (s, 3H), 3.47 (d, J= 14.4 Hz, IH), 3.06 (s, 3H). MS [m+H] calc'd for C14H14BrN5O2S, 397.8; found 397.8.
Example 23: 7-Amino-6-aminomethyl-5- (2-chloro-5-fluoro-phenyl)-l,3-dimethyl-lH- pyrido [2,3-J] pyrimidine-2, 4-dione
Figure imgf000083_0003
[0296] The title compound was prepared using the procedures described in the preparation of Example 11. 1H-NMR (400 MHz, d6-DMSO): δ ppm 7.75 (br s, 3H), 7.58(dd, Ji= 5.2 Hz, J2= 9.2 Hz, IH), 7.53 (br s, 2H), 7.33 (td, J1= 2.8 Hz, J2= 8.4 Hz, IH), 7.20 (dd, J1= 2.8 Hz, J2= 8.8 Hz, IH), 3.84 (d, J= 14.4 Hz, IH), 3.53 (s, 3H), 3.23 (d, J= 14.4 Hz, IH), 3.09 (s, 3H). MS [m+H] calc'd for C16H15ClFN5O2, 363.88, 365.83, and 366.87; found 363.88, 365.83, and 366.87.
Example 24: 7-Amino-6-aminomethyl-5- (2-bromo-5-fluoro-phenyl)-l,3-dimethyl-lH- pyrido [2,3-d] pyrimidine-2, 4-dione
Figure imgf000084_0001
[0297] The title compound was prepared using the procedures described in the preparation of Example 11. 1H-NMR (400 MHz, d6-DMSO): δ ppm 8.11 (s, 3H), 7.70 (dd, J1= 5.2 Hz, J2= 8.4 Hz, IH), 7.61 (s, 2H), 7.23 (m, 2H), 3.83 (d, J= 14.4 Hz, IH), 3.51 (s, 3H), 3.22 (d, J= 14.4 Hz, IH), 3.08 (s, 3H). MS m+H] calc'd for C16H15BrFN5O2, 409.8, 411.0, and 412.0; found 409.8, 411.0, and 412.0.
Example 25: 7-Amino-6-aminomethyl-5-(2-chloro-4-fluoro-phenyl)-l,3-dimethyl-lH- pyrido [2,3-d] pyrimidine-2, 4-dione
Figure imgf000084_0002
[0298] The title compound was prepared using the procedures described in the preparation of Example 11. 1H-NMR (400 MHz, d6-DMSO): δ ppm 7.80 (br s, 2H), 7.74 (d, J= 2.0 Hz, IH), 7.52 (m, 2H), 7.32 (m, 2H), 3.79 (d, J= 8.8 Hz, IH), 3.49 (s, 3H), 3.28 (d, J= 8.8 Hz, IH), 3.08 (s, 3H). MS m+H] calc'd for C16H15ClFN5O2, 363.88, 365.83; found 363.88, 365.83.
Example 26: 7-Amino-6-aminomethyl-5-cyclopentyl-l,3-diinethyl-lH-pyrido [2,3-d] pyrimidine-2, 4-dione
Figure imgf000085_0001
[0299] The title compound was prepared using the procedures described in the preparation of Example 11, with the exception that it was extracted with saturated NaHCO3 and EtOAc, instead of IN HCl. 1H-NMR (400 MHz, d6-DMSO): δ ppm 7.22 (br s, 2H), 3.68 (s, 2H), 3.47 (s, 3H), 3.22 (s, 3H), 1.92 (m, 8H), 1.74 (m, IH). MS m+H] calc'd for C15H21N5O2, 304.1, 305.2; found 304.1, 305.2.
Example 27: 7-Amino-6-aminomethyl-l,3-dimethyl-5-pyridin-3-yl-lH-pyrido [2,3-d] pyrimidine-2, 4-dione
Figure imgf000085_0002
[0300] The title compound was prepared using the procedures described in the preparation of Example 26. 1H-NMR (400 MHz, d6-DMSO): δ ppm 8.63 (d, J= 5.2, IH), 8.41 (br s, IH), 7.77 (br s, 3H), 7.68 (d, J= 8.4 Hz, IH), 7.53 (m, 3H), 3.57 (d, J= 5.6, 2H), 3.52 (s, 3H), 3.05 (s, 3H). MS [m+H] calc'd for C15H16N6O2, 313.2, 314.3; found 313.2, 314.3.
Example 28: 7-Amino-6-aminomethyl-5-(4,5-dimethyl-thiophen-2-yl)-l,3-dimethyl-lH- pyrido [2,3-d] pyrimidine-2, 4-dione
Figure imgf000086_0001
[0301] The title compound was prepared using the procedures described in the preparation of Example 26. 1H-NMR (400 MHz, d6-DMSO): δ ppm 7.78 (br s, 3H), 7.41 (br s, 2H), 6.67 (s, IH), 3.75 (br s, IH), 3.65 (br s, IH), 3.51 (s, 3H), 3.12 (s, 3H), 2.34 (s, 3H), 2.12 (s, 3H). MS [m+H] calc'd for C16H19N5O2S, 346.1, 347.3; found 346.1, 347.3.
Example 29: 7-Amino-6-aminomethyl-5- (5-fluoro-2-nitro-phenyl)-l,3-dimethyl-lH- pyrido [2,3-d] pyrimidine-2, 4-dione
Figure imgf000086_0002
[0302] The title compound was prepared using the procedures described in the preparation of Example 26. 1H-NMR (400 MHz, d6-DMSO): δ ppm 8.40 (dd, Jl= 5.2 Hz, J2= 9.2 Hz, IH), 7.68 (br s, 4H), 7.57 (m, IH), 7.25 (dd, Jl= 2.8 Hz, J2= 8.8 Hz, IH), 3.69 (d, J= 14.8 Hz, IH), 3.53 (s, 3H), 3.49 (d, J= 13.6 Hz, IH), 3.04 (s, 3H). MS [m+H] calc'd for C16H15FN6O4, 375.04, 376.21; found 375.04, 376.21. Example 30: 7-Amino-6-aminomethyl- 1 ,3-dimethyl-5-(3-methyl-3H-imidazol-4-yl)- IH- pyrido [2,3-d] pyrimidine-2, 4-dione
Figure imgf000087_0001
[0303] The title compound was prepared using the procedures described in the preparation of Example 26. 1H-NMR (400 MHz, d6-DMSO): δ ppm 9.09 (bs, IH), 7.92 (bs, 3H), 7.69 (bs, 2H), 7.59 (s, IH), 3.90 (d, J= 15.2 Hz, IH), 3.51 (s, 4H), 3.41 (s, 3H), 3.11 (s, 3H). MS [m+H] calc'd for C14HnN7O2, 316.1, 317.3; found 316.1, 317.3.
Example 31: 7-Amino-6-aminomethyl-5-benzo [b] thiophen-2-yl-l,3-dimethyl-lH-pyrido [2,3-d] pyrimidine-2, 4-dione
Figure imgf000087_0002
[0304] The title compound was prepared using the procedures described in the preparation of Example 26. 1H-NMR (400 MHz, d6-DMSO): 5 ppm 8.0 (d, J= 8.4 Hz,
IH), 7.85 (m, 4H), 7.53 (br s, 2H), 7.42 (m, 2H), 7.33 (s, IH), 3.84 (d, J= 14.4 Hz, IH), 3.62 (d, J= 14.4 Hz, IH), 3.53 (s, 3H), 3.09 (s, 3H). MS [m+H] calc'd for C18H17N5O2S, 368.08, 369.25; found 368.08, 369.25. Example 32: 7-Amino-6-aminomethyl-l, 3- dimethyl-5- (3-methyl-benzo [b] thiophen-2- yl)-lH-pyrido [2,3-d] pyrimidine-2, 4-dione
Figure imgf000088_0001
[0305] The title compound was prepared using the procedures described in the preparation of Example 26. 1H-NMR (400 MHz, d6-DMSO): δ ppm 7.96 (d, J= 8.0 Hz,
IH), 7.82 (br s, 3H), 7.77 (d, J= 7.2 Hz, IH), 7.43 (m, 4H), 3.65 (b, 2H), 3.53 (s, 3H), 3.07 (s, 3H), 2.02 (s, 3H). MS [m+H] calc'd for C19H19N5O2S, 382.1, 383.2; found 382.1, 383.2.
Example 33: 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-hydroxy-l,3- dimethylpyrido[2,3-d]pyrimidine-2,4(lH,3H)-dione
Figure imgf000088_0002
Example 34: 6-(aminomethyl)-7-chloro-5-(2,4-dichlorophenyl)- 1 ,3-dimethylpyrido[2,3- d]pyrimidine-2,4( lH,3H)-dione
Figure imgf000089_0001
[0306] To a solution of Compound IB (200 mg, 1.3 mmol) in a mixture of AcOH and concentrated HCl (2:1, 3 mL) was added a solution Of NaNO2 (400 mg) in water (0.5mL). After 30 minutes, the mixture was concentrated, diluted with water and extracted with DCM 3 times. The organic phase was washed with water and dried over Na2SO4. The crude residue was treated with IM BH3-THF (7.8 mL, 7.8 mmol) at rt for 5 min, and then at reflux for Ih. The mixture was concentrated in vacuo, co-evaporated with MeOH, and purified by LC-MS to give Example 33 and Example 34.
[0307] Example 33: 1H-NMR (400 MHz, CDCl3-CD3OD 10: 1) δ 7.40 (d, 7=2.0 Hz, 1 H) 7.24 - 7.28 (dd, 7=1.7 and 8.4 Hz, 1 H) 7.05 (d, /=8.1 Hz, 1 H) 3.72 (d, 7=13.9 Hz, 1 H) 3.55 (s, 3 H) 3.42 (d, 7=13.9 Hz, 1 H) 3.16 (s, 3 H). [M-H] calc'd for C16H15Cl2N4O3, 382; found, 382. [M-NH2] calc'd for C16H12Cl2N3O3, 364; found, 364. [0308] Example 34: 1H-NMR (400 MHz, CDCl3-CD3OD 10: 1) δ 7.44 (d, 7=1.5 Hz, 1 H) 7.31 (dd, 7=8.1, 1.5 Hz, 1 H) 7.11 (d, 7=8.1 Hz, 1 H) 3.96 (d, 7=13.4 Hz, 1 H) 3.62 (s, 3 H) 3.26 (d, 7=13.4 Hz, 1 H) 3.20 (s, 3 H).
Example 35: 7-amino-6-(aminomethyl)-5-(2-chloro-5-fluorophenyl)-3-methylpyrido[2,3- d]pyrimidine-2,4( lH,3H)-dione
Figure imgf000089_0002
[0309] The title compound was synthesized using the procedure described in the synthesis of Example 1. 1H-NMR (400 MHz, CDCl3-CD3OD 10:1) δ 7.55 (d, 7=13.9 Hz, 1 H) 7.24 (td, 7=8.5, 2.9 Hz, 1 H) 7.08 (dd, 7=8.6, 3.0 Hz, 1 H) 3.91 (d, 7=14.9 Hz, 1 H) 3.62 (d, /=14.7 Hz, 1 H) 3.17 (s, 3 H). [M-H] calc'd for C15Hi6ClFN5O2, 350; found, 350. [M-NH2] calc'd for C15H11ClFN4O2, 333; found, 333.
Example 36: 7-amino-6-(aminomethyl)-5-(2-(aminomethyl)phenyl)-l,3- dimethylpyrido[2,3-d]pyrimidine-2,4(lH,3H)-dione
Figure imgf000090_0001
Example 37: 2-(7-amino-6-(aminomethyl)-l,3-dimethyl-2,4-dioxo-l,2,3,4- tetrahydropyrido[2,3-d]pyrimidin-5-yl)benzonitrile
Figure imgf000090_0002
Example 38: 7-amino-5-(2-(aminomethyl)phenyl)- 1 ,3-dimethyl-2,4-dioxo- 1 ,2,3,4- tetrahydropyrido[2,3-d]pyrimidine-6-carbonitrile
Figure imgf000090_0003
[0310] Examples 36, 37 and 38 were synthesized using the procedures described in the synthesis of Example 1. The three compounds were isolated by LC-MS. [0311] Example 36: 1H-NMR (400 MHz, CDCl3-CD3OD 10: 1) δ 7.37 - 7.44 (m, 2 H) 7.33 (td, 7=7.1, 2.0 Hz, 1 H) 6.82 - 6.88 (d, 7=7.1 Hz, 1 H) 3.82 (d, 7=14.4 Hz, 2 H) 3.73 (d, 7=14.4 Hz, 2 H) 3.60 (d, J=I.5 Hz, 2 H) 3.52 (s, 3 H) 3.11 (s, 3 H). [M-H] calc'd for C17H21N6O2, 341; found, 341. [M-NH2] calc'd for C17Hi8N5O2, 324; found, 324. [0312] Example 37: 1H-NMR (400 MHz, CDCl3-CD3OD 10: 1) δ 7.70 (dd, 7=7.4, 1.1 Hz, 1 H) 7.62 (td, 7=7.7, 1.3 Hz, 1 H) 7.47 (td, 7=7.8, 1.1 Hz, 1 H) 7.21 (d, 7=7.3 Hz, 1 H) 3.68 (d, 7=14.9 Hz, 1 H) 3.54 (d, 7=14.9 Hz, 1 H) 3.53 (s, 3 H) 3.12 (s, 3 H). [M-H] calc'd for CnH17N6O2, 336; found, 336. [M-NH2] calc'd for C17H14N5O2, 320; found, 320.
[0313] Example 38: 1H-NMR (400 MHz, CDCl3-CD3OD 10: 1) δ 7.46 - 7.52 (m, 2 H) 7.43 (td, 7=7.1, 2.1 Hz, 1 H) 7.03 (dd, 7=7.2, 1.1 Hz, 1 H) 3.92 (d, 7=13.9 Hz, 1 H) 3.75 (d, 7=13.9 Hz, 1 H) 3.56 - 3.59 (s, 3 H) 3.18 (s, 3 H). [M-H] calc'd for CnH17N6O2, 336; found, 336. [M-NH2] calc'd for C17H14N5O2, 320; found, 320.
Example 39: 6-(arninomethyl)-7-(cyclopropylmethylamino)-5-(2,4-dichlorophenyl)- 1 ,3- dimethylpyrido[2,3-d]pyrimidine-2,4(lH,3H)-dione
Figure imgf000091_0001
[0314] The title compound was synthesized using the procedures described in the synthesis of Example 4. Example 39: 1H-NMR (400 MHz, CDCl3-CD3OD 10:1) δ 7.48 (d, 7=2.0 Hz, 1 H) 7.32 (dd, 7=8.2, 1.9 Hz, 1 H) 7.04 (d, 7=8.3 Hz, 1 H) 3.75 (d, 7=14.6 Hz, 1 H) 3.61 (s, 3 H) 3.59 d, 7=14.6 Hz, 1 H) 3.36 (d, 7=7.1 Hz, 2 H) 3.20 (s, 3 H) 1.12 - 1.22 (m, 1 H) 0.45 - 0.51 (m, 2 H) 0.22 - 0.27 (m, 2 H). [M-H] calc'd for C20H22 Cl2N5O2, 434; found, 434. [M-NH2] calc'd for C20H19 Cl2N4O2, 417; found, 417. Example 40: 2-(7-amino-6-(aminomethyl)-l-isobutyl-3-methyl-2,4-dioxo-l,2,3,4- tetrahydropyrido[2,3-d]pyrimidin-5-yl)benzonitrile
Figure imgf000092_0001
[0315] The title compound was synthesized using the procedures described in the preparation of Example 1. 1H-NMR (400 MHz, CDCl3-CD3OD 10:1) δ 7.74 (dd, J=7.8, 1.0Hz, 1 H) 7.67 (td, 7=7.7, 1.3 Hz, 1 H) 7.52 (td, /=7.7, 1.0Hz, 1 H) 7.23 - 7.26 (m, 1 H) 4.07 (dd, /=7.5, 2.1 Hz, 2 H) 3.69 (d, /=15.0 Hz, 1 H) 3.60 (d, /=15.0 Hz, 1 H) 3.17 (s, 3 H) 2.13 - 2.25 (m, 1 H) 0.89 (dd, /=6.8, 2.3 Hz, 6 H). [M-H] calc'd for C20H23N6O2, 379; found, 379. [M-NH2] calc'd for C20H20N5O2, 362; found, 362.
Example 41: 6-(aminomemyl)-5-(2,4-dichlorophenyl)-l,3-dimethylpyrido[2,3- d]pyrimidine-2,4(lH,3H)-dione
Figure imgf000092_0002
[0316] Example 34 (70 mg, 0.19 mmol) in a mixture of THF (5mL) and DIPEA (0.2mL) was stirred with 10% Pd/C (20 mg) under H2 atmosphere for 4 h, and then filtered and concentrated. The residue was purified by LC-MS to give the title compound. 1H- NMR (400 MHz, CDCl3-CD3OD 10:1) 6 8.83 (s, IH) 7.49 (d, /=1.5 Hz, IH) 7.35 (dd, /=8.2, 1.6 Hz, IH) 7.10 (d, /=8.1 Hz, IH) 3.85 (d, /=14.1 Hz, IH) 3.69 (s, 3 H) 3.64 (d, /=14.4 Hz, IH) 3.26 (s, 3 H). [M-H] calc'd for C16H15 Cl2N4O2, 365; found, 365. [M- NH2] calc'd for C16H15Cl2N3O2, 348; found, 348. Example 42: 7-Amino-6- (aminomethyl)-5-(2-chloro-5- (trifluoromethyl) phenyl)- 1,3- dimethylpyrido [2,3-d] pyrimidine-2, 4(iH, 3H)-dione
Figure imgf000093_0001
[0317] The title compound was prepared using the procedures described in the preparation of Example 11. 1H-NMR (400 MHz, d6-DMSO): δ ppm 7.81 (m, 4H), 7.73 (bs, IH), 7.56 (bs, 2H), 3.82 (d, J= 14.4 Hz, IH), 3.53 (s, 3H), 3.24 (d, J= 16.8 Hz, IH), 3.08 (s, 3H). MS [m+H] calc'd for C17Hi5ClF3N5O2, 414.0, 415.8 ; found 414.0, 415.8.
Example 43: 7-Amino-6- (aminomethyl)-5-(2-chloro-5-fluorophenyl)-l-methylpyrido [2,3-d] pyrimidine-2, 4(iH, 3H)-dione
Figure imgf000093_0002
[0318] The title compound was prepared using the procedures described in the preparation of Compounds N and P, and Example 8. 1H-NMR (400 MHz, d6-DMSO): δ ppm 11.07 (s, IH), 7.82 (bs, 3H), 7.57 (dd, Ji= 5.2, J2= 9.2, IH), 7.51 (bs, 2H), 7.31(td, J1= 2.8, J2= 8.0, IH), 7.21 (dd, J1= 2.8, J2= 8.8, IH), 3.83 (d, J= 22.4, IH), 3.43 (s, 3H), 3.23 (d, J= 20.0, IH). MS [m+H] calc'd for C15Hi3ClFN5O2, 350.1, 352.0; found 350.1, 352.0.
Example 44: 7-Amino-6-(aminomethyl)-5-(2-bromo-5-fluorophenyl)-l- methyrpyrido[2,3-d] pyrimidine-2, 4(iH,5H)-dione
Figure imgf000094_0001
[0319] The title compound was prepared using the procedures described in the preparation of Compounds N and P, and Example 8. 1H-NMR (400 MHz, d6-DMSO): δ ppm 11.07 (s, IH), 7.82 (bs, 3H), 7.70 (dd, J1= 5.2, J2= 8.8, IH), 7.50 (bs, 2H), 7.21 (m, 2H), 3.57 (dd, Jχ=4.8, J2= 14.4, IH), 3.43 (s, 3H), 3.20 (dd, J1= 6.0, J2= 14.8, IH). MS [m+H] calc'd for C15H13BrFN5O2, 395.83, 396.80; found 395.83, 396.80.
4. Examples Of In vitro Assays
[0320] The protease inhibitory activities of DPP-IV inhibitors can be readily determined by methods known to those of ordinary skill in the art since suitable in vitro assays for measuring protease activity and the inhibition thereof by test compounds are known. Examples of assays that may be used for measuring protease inhibitory activity and selectivity are set forth below.
DPP-IV Assay
[0321] Solutions of test compounds in varying concentrations (≤lOmM final concentration) were prepared in Dimethyl Sulfoxide (DMSO) and then diluted into assay buffer comprising: 2OmM Tris, pH 7.4; 2OmM KCl; and O.lmg/mL BSA. Human DPP-IV (0.1 nM final concentration) was added to the dilutions and pre-incubated for 10 minutes at ambient temperature before the reaction was initiated with A-P-7-amido-4- trifluoromethylcoumarin (AP-AFC; 10 μM final concentration). The total volume of the reaction mixture was 10-100 μL depending on assay formats used (384 or 96 well plates). The reaction was followed kinetically (excitation λ=400 nm; emission λ=505 nm) for 5-10 minutes or an end-point was measured after 10 minutes. Inhibition constants (IC50) were calculated from the enzyme progress curves using standard mathematical models.
FAPα Assay [0322] Solutions of test compounds in varying concentrations (≤lOmM final concentration) were prepared in Dimethyl Sulfoxide (DMSO) and then diluted into assay buffer comprising: 2OmM Tris, pH 7.4; 2OmM KCl; and O.lmg/mL BSA. Human FAPα (2 nM final concentration) was added to the dilutions and pre-incubated for 10 minutes at ambient temperature before the reaction was initiated with A-P-7-amido-4- trifluoromethylcoumarin (AP-AFC; 40 μM final concentration). The total volume of the reaction mixture was 10-100μL depending on assay formats used (384 or 96 well plates). The reaction was followed kinetically (excitation λ=400 nm; emission λ=5O5 nm) for 5-10 minutes or an end-point was measured after 10 minutes. Inhibition constants (IC50) were calculated from the enzyme progress curves using standard mathematical models.
PREP Assay
[0323] Solutions of test compounds in varying concentrations (≤lOmM final concentration) were prepared in Dimethyl Sulfoxide (DMSO) and then diluted into assay buffer comprising: 2OmM Sodium Phosphate, pH 7.4; 0.5mM EDTA; 0.5mM DTT; and 0.1mg/mL BSA. PREP (EC3.4.21.26 from Flavobacterium meningosepticum; 0.2 nM final concentration) was added to the dilutions. The PREP and compound were pre- incubated for 10 minutes at ambient temperature before the reaction was initiated with Z- G-P-AMC (10 μM final concentration). The total volume of the reaction mixture was 10- 100 μL depending on assay formats used (384 or 96 well plates). The reaction was followed kinetically (excitation λ=375 nm; emission λ=460 nm) for 10 minutes or an end- point was measured after 10 minutes. Inhibition constants (IC50) were calculated from the enzyme progress curves using standard mathematical models.
Tryptase Assay
[0324] Solutions of test compounds in varying concentrations (≤lOmM final concentration) were prepared in Dimethyl Sulfoxide (DMSO) and then diluted into assay buffer comprising: 10OmM Hepes, pH 7.4; 0.01% Brij35; and 10% glycerol. Tryptase (rhLung beta; 0.1 nM final concentration) was added to the dilutions and pre-incubated with compound for 10 minutes at ambient temperature. The enzymatic reaction was initiated with 25 μM Z-lys-SBzl and 400μM DTNB. The total volume of the reaction mixture was lOOμL in Costar A/2 96 well plates. The reaction was followed colorimetrically (λ^405 nm) for 10 minutes. Inhibition constants (IC50) were calculated from the enzyme progress curves using standard mathematical models. [0325] Compounds of the invention were tested according to the above-described assays for protease inhibition and observed to exhibit selective DPP-IV inhibitory activity. For example, compounds of the invention were found to inhibit DPP-IV activity at concentrations that are at least 50 fold less than those concentrations required to produce an equiactive inhibition of protease activity for FAPα. The apparent inhibition constants (Ki) for compounds of the invention, against DPP-IV, were in the range from about 10"9M to about 10"5M.
[0326] It will be apparent to those skilled in the art that various modifications and variations can be made to the compounds, compositions, kits, and methods of the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents. [0327] While the present invention is disclosed with reference to certain embodiments and examples detailed above, it is to be understood that these embodiments and examples are intended to be illustrative rather than limiting. As such, it is contemplated that various modifications and variations will be apparent to those skilled in the art and intended that those modifications and variations fall within the scope of the invention and the appended claims. AU patents, patent applications, papers, and books cited in this application are incorporated by reference herein in their entirety.

Claims

What is claimed is: 1. A compound comprising the formula:
Figure imgf000097_0001
wherein:
W is selected from the group consisting of CR3 and N;
X is selected from the group consisting of CR4 and N;
Y is selected from the group consisting of CO, CS, SO, SO2, CR6R6' and C=NR6;
Z is selected from the group consisting of CO, CS, SO, SO2, and C=NR6;
R1 is selected from the group consisting of (C1-Io)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-10)alkyl, heteroaryl(Cr5)alkyl, (C^^bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (Ci-3)alkyl, amino, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkenyl, alkynyl, carbonyl group, cyano, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted;
R2 is selected from the group consisting of amino (C1-6)alkyl, hetero(C3-12)cycloalkyl, hetero(C4-12)bicycloaryl, heteroaryl, and cyano, each substituted or unsubstituted;
R3 is selected from the group consisting of hydrogen, halo, perhalo(C1-1o)alkyl, amino, nitro, cyano, thio, sulfonamide, (CriO)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(Ci-1o)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, (C1-10)alkylamino, amino (Q-^alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or R2 and R3 are taken together to form a ring;
R4 is selected from the group consisting of hydrogen, halo, perhalo(Crio)alkyl, amino, nitro, cyano, thio, sulfonamide, (C1-Io)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-io)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl(Ci-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, sulfonylamino, imino(Ci-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or R3 and R4 are taken together to form a ring;
R5 and R7 are independently selected from the group consisting of hydrogen, halo(Crl0)alkyl, amino, nitro, thio, sulfonamide, (Cπo)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-10)alkyl, heteroaryl(Cr5)alkyl, (Cg.i^bicycloaryl, hetero(C4-12)bicycloaryl, (C3-12)cycloalkyl(C1-1o)alkyl, carbonyl(C1-3)alkyl, thiocarbony^Q. 3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or R5 is absent when the N to which it is bound forms part of a double bond; and
R6 and R6' are each independently selected from the group consisting of hydrogen, amino, alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted, or R5 and R6 are taken together to form a ring, with the proviso that R6' is absent when Y forms part of a double bond.
2. The compound according to claim 1, comprising the formula:
Figure imgf000098_0001
wherein:
Ri is selected from the group consisting of (Cπo)alkyl, (C3-i2)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(Cπo)alkyl, heteroaryl(C1-5)alkyl,
Figure imgf000099_0001
hetero(C4.12)bicycloaryl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1.3)alkyl, imino (C1-3)alkyl, amino, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkenyl, alkynyl, carbonyl group, cyano, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted;
R2 is selected from the group consisting of amino (Ci-6)alkyl, hetero(C3-i2)cycloalkyl, hetero(C4-i2)bicycloaryl, heteroaryl, and cyano, each substituted or unsubstituted;
R3 is selected from the group consisting of hydrogen, halo, perhalo(Ci-i0)alkyl, amino, nitro, cyano, thio, sulfonamide, (Cπo)alkyl, (C3-i2)cycloalkyl, hetero(C3-i2)cycloalkyl, aryl(Ci-io)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl(Ci-3)alkyl, thiocarbonyl(Ci.3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(Ci-3)alkyl, imino(Ci.3)alkyl, (C1-i0)alkylamino, amino (Ci-io)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or R2 and R3 are taken together to form a ring; and
R5 and R7 are independently selected from the group consisting of hydrogen, halo(Ci-io)alkyl, amino, nitro, thio, sulfonamide, (CπO)alkyl, (C3-i2)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(CriO)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl, hetero(C4-i2)bicycloaryl, (C3-i2)cycloalkyl(Ci-i0)alkyl, carbonyl(C1-3)alkyl, thiocarbony^Q. 3)alkyl, sulfonyl(Ci-3)alkyl, sulfinyl(C1-3)alkyl, imino(Ci-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted.
3. The compound according to claim 1, comprising the formula:
Figure imgf000100_0001
wherein:
R1 is selected from the group consisting of (Cπo)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(Cπo)alkyl, heteroaryl(Ci-5)alkyl, (C9-12)bicycloaryl, hetero(C4_12)bicycloaryl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (Ci.3)alkyl, imino (Ci_3)alkyl, amino, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkenyl, alkynyl, carbonyl group, cyano, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted;
R2 is selected from the group consisting of amino (C1-6)alkyl, hetero(C3-12)cycloalkyl, hetero(C4-12)bicycloaryl, heteroaryl, and cyano, each substituted or unsubstituted;
R3 is selected from the group consisting of hydrogen, halo, perhalo(Cr10)alkyl, amino, nitro, cyano, thio, sulfonamide, (Cr^alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-10)alkyl, heteroaryl(Cr5)alkyl, (C9-12)bicycloaryl, hetero(C4.12)bicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, (C1-10)alkylamino, amino (C1-10)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or R2 and R3 are taken together to form a ring;
R6 and R6' are each independently selected from the group consisting of hydrogen, amino, alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and
R7 is selected from the group consisting of hydrogen, halo(Crl0)alkyl, amino, nitro, thio, sulfonamide, (Crlo)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(Crio)alkyl, heteroaryl(C1-5)alkyl, (Cg^bicycloaryl, hetero(C4-12)bicycloaryl, (C3-12)cycloalkyl(Cr10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1.3)alkyl, imino(C1.3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted.
4. The compound according to any one of claims 1-3, wherein: R2 is -CR8R9NR10RH;
R8 and R9 are each independently selected from the group consisting of hydrogen, halogen, perhalo(Cr10)alkyl, cyano, nitro, alkyl, cycloalkyl, alkene, alkyne, aryl, and heteroaryl, each substituted or unsubstituted, or where R8 and R9 are taken together to form a substituted or unsubstituted ring; and
R1O and R11 are independently selected from the group consisting of hydrogen, perhalo(C1-1o)alkyl, amino, thio, (Cri0)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-1o)alkyl, heteroaryl(Ci-5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1_3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, and imino group, each substituted or unsubstituted, or R10 and R11 are taken together to form a ring.
5. The compound according to any one of claims 1-3, wherein R2 and R3 are taken together to form a ring.
6. The compound according to claim 5, wherein the ring formed by taking R2 and R3 together is a substituted or unsubstituted 5 or 6 membered ring.
7. The compound according to claim 5, wherein the ring formed by taking R2 and R3 together is a substituted or unsubstituted cycloalkyl, bicycloalkyl, heterocycloalkyl, aryl, heteroaryl, (C9-12)bicycloaryl, or hetero(C8-12)bicycloaryl.
8. The compound according to any one of claims 1-7, wherein: R3 is -NR12R13; and
R12 and R13 are each independently selected from the group consisting of hydrogen, perhalo(C1-1o)alkyl, amino, thio, (Crlo)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(Crlo)alkyl, heteroaryl(Cr5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, and imino group, each substituted or unsubstituted, or R12 and R13 are taken together to form a ring.
9. The compound according to claim 8, wherein R12 and R13 are taken together to form a ring.
10. The compound according to claim 9, wherein the ring formed by taking R12 and R13 together is a substituted or unsubstituted 3, 4, 5 or 6 membered ring.
11. The compound according to claim 9, wherein the ring formed by taking R12 and R13 together is a substituted or unsubstituted heterocycloalkyl, heterobicycloalkyl, aryl, heteroaryl, or hetero(C8-12)bicycloaryl.
12. The compound according to any one of claims 1 and 4-7, wherein R3 and R4 are taken together to form a ring.
13. The compound according to claim 12, wherein the ring formed by taking R3 and R4 together is a substituted or unsubstituted 5 or 6 membered ring.
14. The compound according to claim 12, wherein the ring formed by taking R3 and R4 together is a substituted or unsubstituted cycloalkyl, bicycloalkyl, heterocycloalkyl, aryl, heteroaryl, (Cg-I2)WCyClOaTyI, or hetero(C8_12)bicycloaryl.
15. The compound according to any one of claims 1-14, wherein R1 is a substituted or unsubstituted (C3-7)cycloalkyl.
16. The compound according to any one of claims 1-14, wherein R1 is a substituted or unsubstituted (C3-7)heterocycloalkyl.
17. The compound according to any one of claims 1-14, wherein R1 is a substituted or unsubstituted aryl.
18. The compound according to any one of claims 1-14, wherein R1 is a substituted or unsubstituted phenyl.
19. The compound according to any one of claims 1-14, wherein R1 is a substituted or unsubstituted heteroaryl.
20. The compound according to any one of claims 1-14, wherein R1 is
Figure imgf000103_0001
wherein: a is O, 1, 2, 3, 4, or 5; and
R14 is selected from the group consisting of hydrogen, halo, perhalo(Ci-io)alkyl, amino, nitro, cyano, thio, sulfonamide, (Ci-10)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(Ci-10)alkyl, heteroaryl(Cr5)alkyl, (C9-12)bicycloaryl, hetero(C4.12)bicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1.3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted.
21. The compound according to any one of claims 1-14, wherein R1 is a cyclic substituent having a ring with a non-hydrogen substituent at a 2 or 3 position of the ring.
22. The compound according to any one of claims 1-14, wherein R1 is a cyclic substituent having a ring with a non-hydrogen substituent at a 2 or 3 position of the ring selected from the group consisting of (Cr10)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-10)alkyl, heteroaryl(Cr5)alkyl, (Cg-^bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (Ci-3)alkyl, amino, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, cyano, nitro, halo, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted.
23. The compound according to any one of claims 1-14, wherein R1 is selected from the group consisting of:
Figure imgf000104_0001
wherein:
V is selected from the group consisting of S, O, and NR16;
R15 is selected from the group consisting of hydrogen, halo, perhalo(Crio)alkyl, amino, nitro, cyano, thio, sulfonamide, (C1-10)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-1o)alkyl, heteroaryl(Cr5)alkyl, (C9..12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted; and
R16 is selected from the group consisting of hydrogen, perhalo(Ci-10)alkyl, amino, (C1- 10)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-10)alkyl, heteroaryl (Cr5)alkyl, (C9-12)bicycloaryl, hetero(Cg-12)bicycloaryl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, imino group, carbonyl group, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, and sulfinyl group, each substituted or unsubstituted.
24. The compound according to any one of claims 1-14, wherein R1 is a substituted or unsubstituted halophenyl or dihalophenyl.
25. The compound according to any one of claims 1-14, wherein R1 is a substituted or unsubstituted haloaryl, haloheteroaryl, dihaloaryl or dihaloheteroaryl.
26. The compound according to any one of claims 1-14, wherein R1 is selected from the group consisting of (2-cyano)phenyl; (3-cyano)phenyl; (2-hydroxy)phenyl; (3-hydroxy)phenyl; (2-alkenyl)phenyl; (3-alkenyl)phenyl; (2-alkynyl)phenyl; (3-alkynyl)phenyl; (2- methoxy)phenyl; (3-methoxy)phenyl; (2-nitro)phenyl; (3-nitro)phenyl; (2-carboxy)phenyl; (3- carboxy)phenyl; -(CH2)-(2-carboxamido)phenyl; (3-carboxamido)phenyl; (2- sulfonamido)phenyl; (3-sulfonamido)phenyl; (2-tetrazolyl)phenyl; (3-tetrazolyl)phenyl; (2-aminomethyl)phenyl; (3-aminomethyl)phenyl; (2-hydroxymethyl)phenyl; (3-hydroxymethyl)phenyl; (2-phenyl)phenyl; (3-phenyl)phenyl; (2-halo)phenyl; (3- halo)phenyl; (2-CONH2)phenyl; (3-CONH2)ρhenyl; (2-CONH(Cr7)alkyl)phenyl; (3-CONH(Ci-7)alkyl)phenyl; (2-CO2(Cr7)alkyl)phenyl; (3-CO2(Cr7)alkyl)phenyl; (2- NH2)phenyl; (3-NH2)phenyl; (2-(C3-7)alkyl)phenyl; (3-(C3-7)alkyl)phenyl; (2-(C3-7)cycloalkyl)phenyl; (3-(C3-7)cycloalkyl)phenyl; (2-aryl)phenyl; (3-aryl)phenyl; (2-heteroaryl)phenyl; (3-heteroaryl)phenyl; 2-bromo-5-fluoro phenyl; 2-chloro-5-fluoro phenyl; 2-cyano-5-fluoro phenyl; 2,5-dichloro phenyl; 2,5-difluoro phenyl; 2,5-dibromo phenyl; 2-bromo-3,5-difluoro phenyl; 2-chloro-3,5-difluoro phenyl; 2,3,5-trifluoro phenyl; 2,3,5,6-tetrafluorophenyl; 2-bromo-3,5,6-trifluoro phenyl; 2-chloro-3,5,6-trifluoro phenyl; 2- cyano-3,5-difluoro phenyl; 2-cyano-3,5,6-trifluoro phenyl; (2-heterocycloalkyl)phenyl; and (3-heterocycloalkyl)phenyl, each substituted or unsubstituted.
27. The compound according to any one of claims 1-14, wherein R1 is selected from the group consisting of:
Figure imgf000105_0001
wherein:
A is S, O or NR17; B is CR18 or N;
R17 is independently selected from the group consisting of hydrogen, perhalo(C1-1o)alkyl, amino, (C1-Io)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(Cr 10)alkyl, heteroaryl (Cr5)alkyl, (Cg.^bicycloaryl, hetero(C8-12)bicycloaryl, carbonyl (C1- 3)alkyl, thiocarbonyl (C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, imino group, carbonyl group, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, and sulfinyl group, each substituted or unsubstituted; and
R18 is independently selected from the group consisting of hydrogen, halo, perhalo(C1-io)alkyl, amino, thio, cyano, CF3, nitro, (C1-10)alkyl, (C3-12)cycloalkyl, hetero(C3-i2)cycloalkyl, aryl(C1-i0)alkyl, heteroaryl (Cr5)alkyl, (C9_12)bicycloaryl, hetero(C8-i2)bicycloaryl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, imino group, carbonyl group, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, and sulfinyl group, each substituted or unsubstituted, or R17 and R18, or two R18 are taken together to form an unsubstituted or substituted ring.
28. The compound according to any one of claims 1-14, wherein R1 is selected from the group consisting of:
Figure imgf000106_0001
wherein: t is O, 1, 2, 3, 4 or 5; and each R^ is independently selected from the group consisting of halo, perhalo(C1-1o)alkyl, CF3, (C1-10)alkyl, alkenyl, alkynyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, cyano, nitro, hydroxy, alkoxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or two R^ are taken together to form an unsubstituted or substituted ring.
29. The compound according to any one of claims 1-14, wherein Ri is selected from the group consisting of:
Figure imgf000107_0001
wherein: s is O, 1, 2, or 3; and each R20 is independently selected from the group consisting of halo, perhalo(d-io)alkyl, CF3, (Ci.io)alkyl, alkenyl, alkynyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, cyano, nitro, hydroxy, alkoxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or two R20 are taken together to an unsubstituted or substituted form a ring.
30. The compound according to any of claims 1-14, wherein Ri is an aryl substituted with one or more substituents selected from the group consisting of halo; hydroxy (Ci-6)alkyl; amino (Ci-6)alkyl; and (Ci-6)alkoxy.
31. A compound selected from the group consisting of:
7-Amino-6-aminomethyl-5-(2,4-dichloro-phenyl)-l,3-dimethyl-lH-pyrido[2,3- d]pyrimidine-2,4-dione;
7-Amino-6-aminomethyl-5-(2-bromo-4-fluoro-phenyl)-l,3-dimethyl-lH-pyrido[2,3- d]pyrimidine-2,4-dione;
7-Amino-6-aminomethyl-5-(2-bromo-phenyl)-l,3-dimethyl-lH-pyrido[2,3- d]pyrimidine-2,4-dione; -Aminomethyl-5-(2,4-dichloro-phenyl)-7-ethylamino- 1 ,3-dimethyl- 1 H-pyrido [2,3- d]pyrimidine-2,4-dione; -Aminomethyl-5-(2,4-dichloro-phenyl)-l,3-dimethyl-7-methylamino-lH-pyrido[2,3- d]pyrimidine-2,4-dione; -Aminomethyl-5-(2,4-dichloro-phenyl)-7-dimethylamino-l,3-dimethyl-lH- pyrido[2,3-d]pyrimidine-2,4-dione; -Hydroxy-5-(2-bromo-5-fluoro-phenyl)-l,3-dimethyl-2,4-dioxo-l,2,3,4- tetrahydropyrido[2,3-d]pyrimidine-6-carbonitrile; -Aminomethyl-5-(2-bromo-5-fluoro-phenyl)-7-hydroxy-l,3-dimethyl-lH-pyrido[2,3- d]pyrimidine-2,4-dione; -Amino-5-(2,5-dichloro-phenyl)-l,3-dimethyl-2,4-dioxo-l,2,3,4- tetrahydropyrido[2,3-rf]pyrimidine-6-carbonitrile; -Amino-6-aminomethyl-5-(2,5-dichloro-phenyl)-l,3-dimethyl-lH-pyrido[2,3-<f| pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (2-bromo-5-fluoro-phenyl)-l ,3-dimethyl-lH-pyrido [2,3- d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl — 1 ,3-dimethyl- 5- (3-methyl-thiophen-2-yl)-lH-pyrido[2,3- d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (2-chloro-phenyl)-l,3-dimethyl-lH-pyrido [2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (4-fluoro-phenyl)-l ,3-dimethyl- lH-pyrido [2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (5-chloro-thiophen-2-yl)-l,3-dimethyl-lH-pyrido [2,3-d\ pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (4-bromo-phenyl)-l,3-dimethyl-lH-pyrido [2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (2,3-dichloro-phenyl)-l ,3-dimethyl- lH-pyrido [2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (2-chloro-6-fluoro-phenyl)-l,3-dimethyl-lH-pyrido [2,3- d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (3-methoxy-phenyl)-l,3-dimethyl-lH-pyrido [2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (2-methoxy-phenyl)-l,3-dimethyl-lH-pyrido [2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (2-chloro-3, 6-difluoro-phenyl)-l,3-dimethyl-lH-pyrido [2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5-phenyl-l,3-dimethyl-lH-pyrido [2,3-d] pyrimidine-2, A- dione; -Amino-6-aminomethyl-5- (3-bromo-thiophen-2-yl)- 1 ,3-dimethyl- lH-pyrido [2,3-d] pyrimidine-2, 4-dione; -Amino-6-atninomethyl-5- (2-chloro-5-fluoro-phenyl)- 1 ,3-dimethyl- lH-pyrido [2,3- d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (2-bromo-5-fluoro-phenyl)- 1 ,3-dimethyl- lH-pyrido [2,3- d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5-(2-chloro-4-fluoro-phenyl)-l,3-dimethyl-lH-pyrido [2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5-cyclopentyl-l,3-dimethyl-lΗ-pyrido [2,3-d] pyrimidine-2,
4-dione; -Amino-6-aminomethyl-l,3-dimethyl-5-pyridin-3-yl-lH-pyrido [2,3-d] pyrimidine-2,
4-dione; -Amino-6-aminomethyl-5-(4,5-dimethyl-thiophen-2-yl)-l,3-dimethyl-lH-pyrido [2,3- d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5- (5-fluoro-2-nitro-phenyl)-l ,3-dimethyl- lH-pyrido [2,3-d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-l ,3-dimethyl-5-(3-methyl-3H-imidazol-4-yl)- lH-pyrido [2,3- d] pyrimidine-2, 4-dione; -Amino-6-aminomethyl-5-benzo [b] thiophen-2-yl-l,3-dimethyl-lH-pyrido [2,3-d] pyrimidine-2, 4-dione; -Arnino-6-aminomethyl~l, 3- dimethyl-5- (3-methyl-benzo [b] thiophen-2-yl)-lH- pyrido [2,3-d] pyrimidine-2, 4-dione; -(aminomethyl)-5-(2,4-dichlorophenyl)-7-hydroxy-l,3-dimethylpyrido[2,3- d]pyrimidine-2,4(lH,3H)-dione; -(aminomethyl)-7-chloro-5-(2,4-dichlorophenyl)-l,3-dimethylpyrido[2,3- d]pyrimidine-2,4(lH,3H)-dione; -amino-6-(aminomethyl)-5-(2-chloro-5-fluorophenyl)-3-methylpyrido[2,3- d]pyrimidine-2,4(lH,3H)-dione; -amino-6-(aminomethyl)-5-(2-(aminomethyl)phenyl)-l,3-dimethylpyrido[2,3- d]pyrimidine-2,4(lH,3H)-dione; -(7-amino-6-(aminomethyl)-l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydropyrido[2,3- d]pyrimidin-5-yl)benzonitrile; -amino-5-(2-(aminomethyl)phenyl)-l,3-dimethyl-2,4-dioxo-l,2,3,4- tetrahydropyrido[2,3-d]pyrimidine-6-carbonitrile; -(aminomethyl)-7-(cyclopropylmethylamino)-5-(2,4-dichlorophenyl)-l,3- dimethylpyrido[2,3-d]pyrimidine-2,4(lH,3H)-dione; -(7-amino-6-(aminomethyl)- 1 -isobutyl-3 -methyl-2,4-dioxo- 1 ,2,3 ,4- tetrahydropyrido[2,3-d]pyrimidin-5-yl)benzonitrile; -(aminomethyl)-5-(2,4-dichlorophenyl)-l,3-dimethylpyrido[2,3-d]pyrimidine- 2,4(lH,3H)-dione; -Amino-6- (aminomethyl)-5-(2-chloro-5- (trifluoromethyl) phenyl)- 1,3- dimethylpyrido [2,3-J] pyrimidine-2, 4(iH, 5H)-dione; -Amino-6- (ammomethyl)-5-(2-chloro-5-fluorophenyl)- 1 -methylpyrido [2,3-J] pyrimidine-2, 4(iH 3H)-dione; -Amino-6-(aminomethyl)-5-(2-bromo-5-fluorophenyl)- 1 -methylpyrido [2,3-d] pyrimidine-2, 4(iH,3H)-dione; -(7-amino-6-(aminomethyl)-l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydropyrido[2,3- d]pyrimidin-5-yl)-4-fluorobenzonitrile; -(6-(aminomethyl)-7-chloro-l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydropyrido[2,3- J]pyrimidin-5-yl)-4-fluorobenzonitrile; -(6-(aminomethyl)- 1 ,3 ,7-trimethyl-2,4-dioxo- 1 ,2,3 ,4-tetrahydropyrido [2,3- <i]pyrimidin-5-yl)-4-fluorobenzonitrile; -(6-(aπύnomethyl)-l,3-dimethyl-2,4-dioxo-7-(trifluoromethyl)-l,2,3,4- tetrahydropyrido[2,3-rf]pyrimidin-5-yl)-4-fluorobenzonitrile; -(6-(aminomethyl)- 1 ,3-dimethyl-2,4-dioxo- 1 ,2,3,4-tetrahydropyrido [2,3-J]pyrimidin- 5-yl)-4-fluorobenzonitrile; -(6-(aminomethyl)-l,3-dimethyl-2,4-dioxo-7-(2,2,2-trifluoroethylamino)-l,2,3,4- tetrahydropyrido[2,3-J]pyrimidin-5-yl)-4-fluorobenzonitrile; -(6-(aminomethyl)-l,3-dimethyl-7-(methyl(2,2,2-trifluoroethyl)amino)-2,4-dioxo- l,2,3,4-tetrahydropyrido[2,3-(f]pyrimidin-5-yl)-4-fluorobenzonitrile; -(6-(aminomethyl)-7-(bis(txifluoromethyl)amino)-l,3-dimethyl-2,4-dioxo-l,2,3,4- tetrahydropyrido[2,3-d]pyrimidin-5-yl)-4-fluorobenzonitrile; -(6-(aminomethyl)-l,3-dimethyl-2,4-dioxo-7,8-imidazo-[l,2-a]-l,2,3,4,7,8- hexahydropyrido[2,3-d]pyrimidin-5-yl)-5-chlorobenzonitrile; -(6-(aminomethyl)-3-(cyclopropylmethyl)- 1 ,7-dimethyl-2,4-dioxo- 1 ,2,3,4- tetrahydropyrido[2,3-(i]pyrimidin-5-yl)-5-chlorobenzonitrile; -(aminomethyl)-5-(4-chloro-2-methoxyphenyl)-l,3,7-trimethylpyrido[2,3- <f]pyrimidine-2,4( lΗ,3Η)-dione; 2-(6-(aminomethyl)-7-methoxy- 1 ,3-dimethyl-2,4-dioxo- 1 ,2,3,4-tetrahydropyrido[2,3- d]pyrimidin-5-yl)-5-chlorobenzonitrile;
2-(6-(aminomethyl)- 1 ,3-dimethyl-2,4-dioxo-7-(pyrrolidin- 1 -yl)- 1 ,2,3 ,4- tetrahydropyrido[2,3-ώT|pyrimidin-5-yl)-5-chlorobenzonitrile;
6-(aminomethyl)-5-(5-fluoro-2-methoxyphenyl)-l,3-dimethyl-7- morpholinopyrido[2,3-(i]pyrimidine-2,4(lH,3H)-dione;
N-(6-(aminomethyl)-5-(4-chloro-2-methoxyphenyl)- 1 ,3-dimethyl-2,4-dioxo- 1 ,2,3 ,4- tetrahydropyrido[2,3-<i]pyrimidin-7-yl)methanesulfonamide;
2-(6-(aminomethyl)-3-benzyl-7-methoxy-l-methyl-2,4-dioxo-l, 2,3,4- tetrahydropyrido[2,3-<i]pyrimidin-5-yl)-5-chlorobenzonitrile;
6-(aminomethyl)-3-benzyl-5-(4-chloro-2-methoxyphenyl)-l-methyl-7- (trifluoromethyl)pyrido[2,3-(i]pyrimidme-2,4(lH,3H)-dione;
6-(aminomethyl)-5-(3 ,5-difluoro-2-methoxyphenyl)- 1 ,3-dimethyl-7- (trifluoromethyl)pyrido[2,3-(i]pyrimidine-2,4(lH,3H)-dione;
6-(aminomethyl)-3-benzyl-5-(2-chloro-3 ,5-difluorophenyl)- 1 -methyl-7- (txifluoromethyl)pyrido[2,3-cT|pyrimidine-2,4(lH,3H)-dione;
6-(aminomethyl)-5-(2-bromo-3,5-difluorophenyl)- 1 ,3-dimethyl-7- (trifluoromethyl)pyrido[2,3-(i]pyrimidine-2,4(lH,3H)-dione;
6-(aminomethyl)-5-(3,5-difluoro-2-methoxyphenyl)-l,2-imidazo-[l,2-a]-3-methyl-7- (trifluoromethyl)-2,3-dihydropyrido[2,3-d]pyrimidin-4(lH)-one;
6-(aminomethyl)-5-(3,5-difluoro-2-methoxyphenyl)-3-methyl-2-(methylamino)-7- (trifluoromethyl)pyrido[2,3-J]pyrimidin-4(3H)-one;
2-amino-6-(aminomethyl)-5-(2-chloro-3,5-difluorophenyl)-3-methyl-7- (trifluoromethyl)pyrido[2,3-J]pyrimidin-4(3H)-one;
2,7-diamino-6-(l-aminoethyl)-5-(2-chloro-5-fluorophenyl)-3-methylpyrido[2,3- <f]pyrimidin-4(3H)-one; 2-(6-(aminomethyl)-7-ethoxy- 1 ,3-dimethyl-2,4-dioxo- 1 ,2,3,4-tetrahydropyrido[2,3- d]pyrimidin-5-yl)-5-chlorobenzonitrile; and
6-(aminomethyl)-5-(3,5-difluoro-2-methoxyphenyl)-2-(dimethylamino)-3-methyl-7- (txifluoromethyl)pyrido[2,3-d]pyrimidin-4(3H)-one.
32. The compound according to any one of claims 1-31, wherein the compound is in the form of a pharmaceutically acceptable salt.
33. The compound according to any one of claims 1-31, wherein the compound is present in a mixture of stereoisomers.
34. The compound according to any one of claims 1-31, wherein the compound comprises a single stereoisomer.
35. A pharmaceutical composition comprising, as an active ingredient, a compound according to any one of claims 1-31.
36. The pharmaceutical composition according to claim 35, wherein the composition is a solid formulation adapted for oral administration.
37. The pharmaceutical composition according to claim 35, wherein the composition is a tablet.
38. The pharmaceutical composition according to claim 35, wherein the composition is a liquid formulation adapted for oral administration.
39. The pharmaceutical composition according to claim 35, wherein the composition is a liquid formulation adapted for parenteral administration.
40. The pharmaceutical composition comprising a compound according to any one of claims 1-31, wherein the composition is adapted for administration by a route selected from the group consisting of orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, and intrathecally.
41. A kit comprising: a compound according to any one of claims 1-31; and instructions which comprise one or more forms of information selected from the group consisting of indicating a disease state for which the compound is to be administered, storage information for the compound, dosing information and instructions regarding how to administer the compound.
42. The kit according to claim 41, wherein the kit comprises the compound in a multiple dose form.
43. An article of manufacture comprising: a compound according to any one of claims 1-31; and packaging materials.
44. The article of manufacture of claim 43, wherein the packaging material comprises a container for housing the compound.
45. The article of manufacture of claim 43, wherein the container comprises a label indicating one or more members of the group consisting of a disease state for which the compound is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition.
46. The article of manufacture of claim 43, wherein the article of manufacture comprises the compound in a multiple dose form.
47. A method of inhibiting DPP-IV comprising: contacting DPP-IV with a compound according to any one of claims 1-31.
48. A method of inhibiting DPP-IV comprising: causing a compound according to any one of claims 1-31 to be present in a subject in order to inhibit DPP-IV in vivo.
49. A method of inhibiting DPP-IV comprising: administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits DPP-IV in vivo, the second compound being a compound according to any one of claims 1-31.
50. A therapeutic method comprising: administering a compound according to any one of claims 1-31 to a subject.
51. A method of treating a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state, the method comprising causing a compound according to any one of claims 1-31 to be present in a subject in a therapeutically effective amount for the disease state.
52. The method according to claim 51 , wherein the disease is type I or type II diabetes.
53. A method of treating cancer in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to any one of claims 1-31.
54. The method of claim 53, wherein the cancer treated is colorectal, prostate, breast, thyroid, skin, lung, or head and neck.
55. A method of treating autoimmune disorders such as, but not limited to, rheumatoid arthritis, psoriasis, and multiple sclerosis in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to any one of claims 1-31.
56. A method of treating a condition characterized by inadequate lymphocyte or hemapoietic cell activation or concentration in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to any one of claims 1-31.
57. The method of claim 56, wherein said condition is a side effect of chemotherapy or radiation therapy.
58. The method of claim 56, wherein said condition is a result of kidney failure.
59. The method of claim 56, wherein said condition is a result of a bone marrow disorder.
60. A method of treating HTV infection in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to any one of claims 1-31.
61. A method of treating a condition characterized by immunodeficiency symptoms in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to any one of claims 1-31.
PCT/US2005/025070 2004-07-16 2005-07-14 Dipeptidyl peptidase inhibitors WO2006019965A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58857704P 2004-07-16 2004-07-16
US60/588,577 2004-07-16

Publications (2)

Publication Number Publication Date
WO2006019965A2 true WO2006019965A2 (en) 2006-02-23
WO2006019965A3 WO2006019965A3 (en) 2006-04-06

Family

ID=35505925

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/025070 WO2006019965A2 (en) 2004-07-16 2005-07-14 Dipeptidyl peptidase inhibitors
PCT/US2005/025153 WO2006020017A2 (en) 2004-07-16 2005-07-15 Dipeptidyl peptidase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025153 WO2006020017A2 (en) 2004-07-16 2005-07-15 Dipeptidyl peptidase inhibitors

Country Status (4)

Country Link
US (1) US7825242B2 (en)
EP (1) EP1773832A2 (en)
JP (1) JP4945443B2 (en)
WO (2) WO2006019965A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007112347A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2008064107A3 (en) * 2006-11-20 2008-07-10 Bristol Myers Squibb Co 7,8-dihydro-1,6-naphthyridin-5(6h)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase iv and methods
WO2008121506A2 (en) * 2007-03-30 2008-10-09 Takeda Pharmaceutical Company Limited Renin inhibitors
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000008A (en) * 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
KR20080104351A (en) * 2006-03-31 2008-12-02 노파르티스 아게 Organic compounds
SG10201404220TA (en) 2006-04-11 2014-10-30 Arena Pharm Inc Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
WO2008073958A2 (en) * 2006-12-12 2008-06-19 Wyeth Substituted benzothiadiazinedioxide derivatives and methods of their use
WO2008133753A2 (en) * 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds
DE102007061764A1 (en) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellated cyanopyridines and their use
EP2108960A1 (en) * 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
WO2011143521A2 (en) * 2010-05-13 2011-11-17 Dara Biosciences, Inc. Enhanced homing and engraftment of hematopoietic stem cells using cd26 inhibitors
CN103003241B (en) * 2010-06-15 2014-07-30 拜耳知识产权有限责任公司 Process for preparing 2,2-difluoroethylamine derivatives by alkylation with 2,2-difluoro-1-haloethanes
EP2680851B1 (en) 2011-03-03 2016-08-17 Merck Sharp & Dohme Corp. Fused bicyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
MX2017011586A (en) 2015-03-09 2017-10-26 Intekrin Therapeutics Inc Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy.
TWI741155B (en) * 2017-02-27 2021-10-01 大陸商貝達藥業股份有限公司 FGFR inhibitor and its application
CN110996951A (en) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 PPAR gamma agonists for the treatment of progressive supranuclear palsy
US10100054B1 (en) 2018-04-03 2018-10-16 King Saud University Pyrido[2,3-d]pyrimidines as anticancer agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004018467A2 (en) * 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Phenacyl xanthine derivatives as dpp-iv inhibitor
WO2004050658A1 (en) * 2002-12-03 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel substituted imidazo-pyridinones and imidazo-pyridazeiones, the production and use thereof as medicaments

Family Cites Families (253)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2961377A (en) 1957-08-05 1960-11-22 Us Vitamin Pharm Corp Oral anti-diabetic compositions and methods
US3947442A (en) * 1969-11-20 1976-03-30 The Sherwin-Williams Company Method for producing heterocyclic acid anhydrides and pyrimidinediones
US3960949A (en) 1971-04-02 1976-06-01 Schering Aktiengesellschaft 1,2-Biguanides
US4113859A (en) * 1972-10-12 1978-09-12 Burroughs Wellcome Co. Certain pyrido-pyrimidines for treating mammalian and avian infections
US3922275A (en) * 1972-11-09 1975-11-25 Hisamitsu Pharmaceutical Co Pyrido{8 2,3-D{9 {0 pyrimidine-2,4(1H,3H)-diones
US4494978A (en) 1976-12-30 1985-01-22 Chevron Research Company Herbicidal N-(N'-hydrocarbyloxycarbamylalkyl)-2,6-dialkyl-alpha-haloacetanilides
US4808587A (en) * 1986-04-16 1989-02-28 Nippon Zoki Pharmaceutical Co., Ltd. 5-substituted pyrido[2,3-d]pyrimidine-2,4-diones
EP0260817B1 (en) * 1986-08-21 1991-05-15 Pfizer Inc. Quinazolinediones and pyridopyrimidinediones
US4935493A (en) 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
AU618158B2 (en) * 1989-01-07 1991-12-12 Bayer Aktiengesellschaft New substituted pyrido(2,3-d)pyrimidines
US5433955A (en) 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
US5366862A (en) 1990-02-14 1994-11-22 Receptor Laboratories, Inc. Method for generating and screening useful peptides
US5814460A (en) 1990-02-14 1998-09-29 Diatide, Inc. Method for generating and screening useful peptides
US5462928A (en) 1990-04-14 1995-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type IV
DE4110019C2 (en) 1991-03-27 2000-04-13 Merck Patent Gmbh Imidazopyridines, processes for their production and pharmaceutical preparations containing them
US5387512A (en) 1991-06-07 1995-02-07 Merck & Co. Inc. Preparation of 3-[z-benzoxazol-2-yl)ethyl]-5-(1-hydroxyethyl)-6-methyl-2-(1H)-pyridinone by biotransformation
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
ATE349461T1 (en) 1991-10-22 2007-01-15 New England Medical Center Inc TYPE IV DIPEPTIDYL-AMINOPEPTIDASE INHIBITORS
WO1993012116A1 (en) 1991-12-12 1993-06-24 Kyowa Hakko Kogyo Co., Ltd. Thienoimidazopyridone derivative
DE4141788A1 (en) 1991-12-18 1993-06-24 Merck Patent Gmbh imidazopyridines
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
DE4305602A1 (en) 1992-06-17 1993-12-23 Merck Patent Gmbh imidazopyridines
IL106998A0 (en) 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
TW299333B (en) * 1992-12-29 1997-03-01 Takeda Pharm Industry Co Ltd
US5811281A (en) 1993-07-12 1998-09-22 Cornell Research Foundation, Inc. Immortalized intestinal epithelial cell lines
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
DE4341453A1 (en) 1993-12-06 1995-06-08 Merck Patent Gmbh imidazopyridines
ATE202567T1 (en) 1994-03-08 2001-07-15 Otsuka Pharma Co Ltd PHOSPHORIC ACID DIESTER DERIVATIVES
US5580979A (en) 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US5543396A (en) 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
US6090786A (en) 1994-06-10 2000-07-18 Fondatech Benelux N.V. Serine proteases, their activity and their synthetic inhibitors
US5589437A (en) 1994-06-13 1996-12-31 Vichnevetskaia; Klara D. Method of using 5-hydroxybenzimidazole compounds for reducing transpiration in plants
US5601986A (en) 1994-07-14 1997-02-11 Amgen Inc. Assays and devices for the detection of extrahepatic biliary atresia
DE4432860A1 (en) 1994-09-15 1996-03-21 Merck Patent Gmbh imidazopyridines
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5614379A (en) 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
JP2002515724A (en) 1995-06-01 2002-05-28 ダナ−ファーバー キャンサー インスティテュート インコーポレイテッド Novel form of dipeptidyl peptidase IV (CD26) found in human serum, antibodies and uses thereof
US6325989B1 (en) 1995-06-01 2001-12-04 Dana-Farber Cancer Institute, Inc. Form of dipeptidylpeptidase IV (CD26) found in human serum
JPH0928376A (en) 1995-07-21 1997-02-04 Ajinomoto Co Inc New dipeptidyl peptidase iv and its production
DE122010000020I1 (en) 1996-04-25 2010-07-08 Prosidion Ltd Method for lowering the blood glucose level in mammals
US20020006899A1 (en) 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
US6875769B2 (en) * 1996-05-23 2005-04-05 Pfizer Inc. Substituted6,6-hetero-bicyclicderivatives
US5965532A (en) 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US5885997A (en) 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
BR9711098B1 (en) 1996-07-01 2011-10-04 heterocyclic compounds, processes for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (en) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
US6011155A (en) 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US6100234A (en) 1997-05-07 2000-08-08 Tufts University Treatment of HIV
WO1998051803A1 (en) 1997-05-16 1998-11-19 Novo Nordisk Biotech, Inc. Polypeptides having prolyl pipeptidyl aminopeptidase activity and nucleic acids encoding same
EP0897012A1 (en) 1997-07-05 1999-02-17 Societe Des Produits Nestle S.A. Cloning of the prolyl-dipeptidyl-peptidase from aspergillus oryzae
US6235493B1 (en) 1997-08-06 2001-05-22 The Regents Of The University Of California Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue
TR200000815T2 (en) 1997-09-29 2000-12-21 Point Therapeutics Inc. Stimulation of hematopoietic cells in vitro.
US6485955B1 (en) 1997-10-06 2002-11-26 The Trustees Of Tufts University Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease
US6342611B1 (en) 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
SI1028950T1 (en) * 1997-10-28 2003-08-31 Warner-Lambert Company Llc 7-substituted quinazolin-2,4-diones useful as antibacterial agents
EP1042457B1 (en) 1997-12-16 2006-03-08 Novozymes A/S Polypeptides having aminopeptidase activity and nucleic acids encoding same
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
EP2583675A1 (en) 1998-02-02 2013-04-24 Trustees Of Tufts College Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
US20020061839A1 (en) 1998-03-09 2002-05-23 Scharpe Simon Lodewijk Serine peptidase modulators
FR2777283B1 (en) 1998-04-10 2000-11-24 Adir NOVEL GLUCAGON-PEPTIDE- 1 (7-37) ANALOGUE PEPTIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
BR9910251A (en) 1998-05-04 2001-01-02 Point Therapeutics Inc Hematopoietic stimulation
DE19823831A1 (en) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
BR9910907A (en) 1998-06-05 2002-02-13 Point Therapeutics Inc Boroproline cyclic compounds
DE19828114A1 (en) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs of unstable inhibitors of dipeptidyl peptidase IV
DE19828113A1 (en) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs of Dipeptidyl Peptidase IV Inhibitors
US6129911A (en) 1998-07-10 2000-10-10 Rhode Island Hospital, A Lifespan Partner Liver stem cell
DE19834591A1 (en) 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Use of substances that decrease the activity of dipeptidyl peptidase IV to increase blood sugar levels, e.g. for treating hypoglycemia
US20030176357A1 (en) 1998-10-06 2003-09-18 Pospisilik Andrew J. Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
JP2000119272A (en) * 1998-10-15 2000-04-25 Nippon Zoki Pharmaceut Co Ltd New 7-aminopyrido[2,3-d]pyrimidine derivative
DE19847690A1 (en) 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Diagnosing sepsis and severe infections, useful for assessing severity and progress of treatment, by measuring content of peptide prohormone or their derived fragments
CO5150173A1 (en) 1998-12-10 2002-04-29 Novartis Ag COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
GB9906715D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
EP1171438A1 (en) 1999-04-20 2002-01-16 Novo Nordisk A/S Compounds, their preparation and use
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6613879B1 (en) 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
DE19926233C1 (en) 1999-06-10 2000-10-19 Probiodrug Ges Fuer Arzneim Production of thiazolidine, useful as pharmaceutical intermediate, comprises reacting hexamethylenetetramine with cysteamine
PT1133312E (en) 1999-06-21 2007-11-30 Lilly Co Eli Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes
US6172081B1 (en) 1999-06-24 2001-01-09 Novartis Ag Tetrahydroisoquinoline 3-carboxamide derivatives
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6107317A (en) 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6617340B1 (en) 1999-07-29 2003-09-09 Novartis Ag N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
DE19940130A1 (en) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim New effectors of Dipeptidyl Peptidase IV for topical use
ES2269178T3 (en) 1999-09-10 2007-04-01 The University Of Sydney DIPEPTIDIL PEPTIDASAS.
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6251391B1 (en) 1999-10-01 2001-06-26 Klaire Laboratories, Inc. Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons
US6261794B1 (en) 1999-10-14 2001-07-17 Saint Louis University Methods for identifying inhibitors of methionine aminopeptidases
US20040152745A1 (en) 1999-11-12 2004-08-05 Guilford Pharmaceuticals, Inc. Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
EP1228061A4 (en) 1999-11-12 2004-12-15 Guilford Pharm Inc Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
US6380398B2 (en) 2000-01-04 2002-04-30 Novo Nordisk A/S Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
EP1248604B2 (en) 2000-01-21 2012-02-29 Novartis AG Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
EA005585B1 (en) * 2000-01-24 2005-04-28 Уорнер-Ламберт Компани 3-aminoquinazolin-2,4-dione antibacterial agents
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
US7064145B2 (en) 2000-02-25 2006-06-20 Novo Nordisk A/S Inhibition of beta cell degeneration
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6608038B2 (en) 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
WO2001072290A2 (en) 2000-03-31 2001-10-04 Probiodrug Ag Method for the improvement of islet signaling in diabetes mellitus and for its prevention
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6545170B2 (en) 2000-04-13 2003-04-08 Pharmacia Corporation 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
US20030166050A1 (en) 2000-05-26 2003-09-04 Rosana Kapeller-Libermann 21956 and 25856, novel human aminiopeptidases and uses thereof
GB0010183D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0010188D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
DE10025464A1 (en) 2000-05-23 2001-12-06 Inst Medizintechnologie Magdeb Combined use of enzyme inhibitors for the therapy of autoimmune diseases, in transplants and tumor diseases, as well as combinations of pharmaceutical preparations comprising enzyme inhibitors
US6783757B2 (en) 2000-06-01 2004-08-31 Kirkman Group, Inc. Composition and method for increasing exorphin catabolism to treat autism
US6432969B1 (en) 2000-06-13 2002-08-13 Novartis Ag N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW583185B (en) 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
US6627636B2 (en) 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
PL360856A1 (en) 2000-07-04 2004-09-20 Novo Nordisk A/S Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
ZA200300255B (en) 2000-07-20 2004-09-28 Bristol Myers Squibb Pharma Co Tricyclic 2-pyridone compounds useful as HIV reverse transcriptase inhibitors.
CA2415851A1 (en) 2000-08-01 2002-02-07 Pharmacia Corporation Hexahydro-7-1h-azepin-2-yl-haxanoic acid derivatives as inhibitors of inducible nitric oxide synthase
EP1307450B1 (en) 2000-08-04 2008-09-17 Warner-Lambert Company LLC 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3-d)pyrimidin-7-ones
EP1930319B1 (en) 2000-08-10 2012-05-02 Mitsubishi Tanabe Pharma Corporation Proline derivatives and use thereof as drugs
US20020165237A1 (en) 2000-08-11 2002-11-07 Fryburg David Albert Treatment of the insulin resistance syndrome
US20020037829A1 (en) 2000-08-23 2002-03-28 Aronson Peter S. Use of DPPIV inhibitors as diuretic and anti-hypertensive agents
US7785810B2 (en) 2000-09-09 2010-08-31 The Research Foundation Of State University Of New York Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof
DE60135862D1 (en) 2000-10-06 2008-10-30 Mitsubishi Tanabe Pharma Corp ALIPHATIC NITROGEN-CONTAINING FIVE-GLASS RING COMPOUNDS
MXPA03003191A (en) 2000-10-12 2004-12-03 Ferring Bv Novel serine protease genes related to dppiv.
AUPR107800A0 (en) 2000-10-27 2000-11-23 University Of Sydney, The Peptide and nucleic acid molecule ii
ZA200302394B (en) 2000-10-27 2004-03-29 Probiodrug Ag Method for the treatment of neurological and neuropsychological disorders.
AU2002253838B2 (en) 2000-10-30 2006-11-09 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising anti-diabetic and anticonvulsant agents
WO2002059343A2 (en) 2000-10-31 2002-08-01 Vanderbilt University Biological markers and diagnostic tests for angiotensin converting enzyme inhibitor- and vasopeptidase inhibitor-associated angioedema
AU2002225954A1 (en) 2000-11-08 2002-05-21 The University Of Georgia Research Foundation, Inc. Dipeptidylpeptidases and methods of use
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
US20020155565A1 (en) 2000-11-10 2002-10-24 Pilar Garin-Chesa FAP-activated anti-tumor compounds
US20030055052A1 (en) 2000-11-10 2003-03-20 Stefan Peters FAP-activated anti-tumor compounds
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
US6670380B2 (en) 2000-11-20 2003-12-30 Bristol-Myers Squibb Co. Pyridone inhibitors of fatty acid binding protein and method
HUP0500880A2 (en) 2000-12-11 2006-05-29 Tularik Inc Cxcr3 antagonists and pharmaceutical compositions thereof
JPWO2002051836A1 (en) 2000-12-27 2004-04-22 協和醗酵工業株式会社 Dipeptidyl peptidase-IV inhibitor
AU2002233288B9 (en) 2001-01-02 2007-08-09 Imtm Gmbh Combined use of Enzyme Inhibitors and Pharmaceutical Preparations thereof for the Treatment and Prophylaxis of Arteriosclerosis, for the Treatment and Prevention of Allergic Reactions of Type I According to the Gell and Coombs Classification, and for the Treatment and Prevention of Dermatological Diseases Associated with FO
DE10100053A1 (en) 2001-01-02 2002-08-22 Keyneurotek Ag I G Use of enzyme inhibitors of dipeptidyl peptidase IV and aminopeptidase N and pharmaceutical preparations therefrom for the prevention and / or therapy of ischemia-related acute and chronic neurodegenerative processes and diseases
GB0101760D0 (en) 2001-01-23 2001-03-07 Glaxo Group Ltd Novel protein
HUP0400058A2 (en) 2001-02-02 2004-04-28 Takeda Chemical Industries, Ltd. Fused heterocyclic compounds, pharmaceutical compositions containing them and their use
TWI255817B (en) 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
DK1368349T3 (en) 2001-02-24 2007-05-21 Boehringer Ingelheim Pharma Xanthine derivatives, their preparation and their use as pharmaceuticals
US6337069B1 (en) 2001-02-28 2002-01-08 B.M.R.A. Corporation B.V. Method of treating rhinitis or sinusitis by intranasally administering a peptidase
AU2002251067B2 (en) 2001-03-19 2005-05-26 Novartis Ag Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
SK11952003A3 (en) * 2001-03-26 2004-03-02 Novartis Ag Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain
ATE395912T1 (en) 2001-03-27 2008-06-15 Merck & Co Inc DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
FR2822826B1 (en) 2001-03-28 2003-05-09 Servier Lab NOVEL ALPHA-AMINO ACID SULPHONYL DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
DE10115921A1 (en) 2001-03-30 2002-10-02 Boehringer Ingelheim Pharma Process for the preparation of 4,6-diaminopyrimido [5,4-d] pyrimidines
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
GB0109146D0 (en) 2001-04-11 2001-05-30 Ferring Bv Treatment of type 2 diabetes
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
PE20021080A1 (en) 2001-04-12 2003-02-12 Boehringer Ingelheim Int A SPECIFIC ANTIBODY FAPO BIBH1 IN THE TREATMENT OF CANCER
DE60231868D1 (en) 2001-04-24 2009-05-20 Purdue Research Foundation FOLAT MIMETICS AND THEIR FOLAT RECEPTOR BINDING CONJUGATES
FR2824825B1 (en) 2001-05-15 2005-05-06 Servier Lab NOVEL ALPHA-AMINOACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
US20030060494A1 (en) 2001-05-18 2003-03-27 Nobuyuki Yasuda Pharmaceutical use of N-carbamoylazole derivatives
US7105556B2 (en) 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
WO2003000180A2 (en) 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
CA2450475A1 (en) 2001-06-20 2003-01-03 Linda Brockunier Dipeptidyl peptidase inhibitors for the treatment of diabetes
RU2003105463A (en) 2001-06-27 2004-11-27 Пробиодруг Аг (De) PEPTIDE STRUCTURES SUITABLE FOR COMPETITIVE MODULATION OF CATALYSIS BY DIPEPTIDYLPEPTIDASE IV
DE10154689A1 (en) 2001-11-09 2003-05-22 Probiodrug Ag Substituted amino ketone compounds
ATE385238T1 (en) 2001-06-27 2008-02-15 Probiodrug Ag USE OF DPIV INHIBITORS AS THERAPEUTICS FOR MEDICAL NEUROLOGICAL CONDITIONS
DE60221983T2 (en) 2001-06-27 2008-05-15 Smithkline Beecham Corp. FLUORPYRROLIDINES AS DIPEPTIDYL-PEPTIDASE INHIBITORS
DE10150203A1 (en) 2001-10-12 2003-04-17 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitor in treatment of cancer
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
AU2002322344C1 (en) 2001-06-27 2006-02-16 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
ATE380175T1 (en) 2001-06-27 2007-12-15 Smithkline Beecham Corp PYRROLIDINE AS DIPEPTIDYL PEPTIDASE INHIBITORS
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US20030135023A1 (en) 2001-06-27 2003-07-17 Hans-Ulrich Demuth Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis
US6869947B2 (en) 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
AU2002322585A1 (en) 2001-07-20 2003-03-03 Adipogenix, Inc. Fat accumulation-modulating compounds
WO2003016335A2 (en) 2001-08-13 2003-02-27 Probiodrug Ag Irreversible cysteine protease inhibitors of legumain
US9048965B2 (en) 2001-08-24 2015-06-02 Mark Henrik Sandstrom Input-controllable dynamic cross-connect
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
DE10143840A1 (en) 2001-09-06 2003-03-27 Probiodrug Ag New acylated hydroxamates useful for the treatment of e.g. wound healing
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
US20040259883A1 (en) 2001-09-14 2004-12-23 Hiroshi Sakashita Thiazolidine derivative and medicinal use thereof
JP2005509603A (en) 2001-09-19 2005-04-14 ノボ　ノルディスク　アクティーゼルスカブ Heterocyclic compounds that are inhibitors of the DPP-IV enzyme
KR100908176B1 (en) 2001-09-21 2009-07-16 브리스톨-마이어스스퀴브컴파니 Lactam-containing Compounds and Derivatives thereof as Factor Jaa Inhibitors
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
EP1432700B1 (en) 2001-10-01 2009-11-04 Bristol-Myers Squibb Company Spiro-hydantoin compounds useful as anti-inflammatory agents
WO2003030946A1 (en) 2001-10-09 2003-04-17 Novartis Ag Regulation of insulin production
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
GB0125445D0 (en) 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
US6673815B2 (en) 2001-11-06 2004-01-06 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US20030125304A1 (en) 2001-11-09 2003-07-03 Hans-Ulrich Demuth Substituted amino ketone compounds
EP2769715A3 (en) 2001-11-26 2014-09-17 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
EP1469873A4 (en) 2001-11-26 2007-10-03 Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
CA2468413A1 (en) 2001-12-14 2003-06-26 Novo Nordisk A/S Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
EP1458382A1 (en) 2001-12-21 2004-09-22 Novo Nordisk A/S Amide derivatives as gk activators
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
AU2002351753A1 (en) 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and a modulator of diabetic late complications
DE60323823D1 (en) 2002-01-11 2008-11-13 Novo Nordisk As METHOD AND COMPOSITION FOR THE TREATMENT OF DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND LIQUID RETENTION CONDITIONS
US7101898B2 (en) 2002-02-01 2006-09-05 Novo Nordisk A/S Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
WO2003063903A2 (en) 2002-02-01 2003-08-07 Probiodrug Ag Modulation of t lymphocytes using dp iv inhibitors
WO2003068748A1 (en) 2002-02-13 2003-08-21 F. Hoffmann-La Roche Ag Novel pyridine- and quinoline-derivatives
AU2003206833B2 (en) 2002-02-13 2006-07-20 F. Hoffmann-La Roche Ag Novel pyridin- and pyrimidin-derivatives
AU2003248354A1 (en) 2002-02-27 2003-09-09 Pfizer Products Inc. Acc inhibitors
UA76309C2 (en) 2002-02-28 2006-07-17 Prosidion Ltd Dpiv inhibitors based on glutaminyl
AU2003228283A1 (en) 2002-03-07 2003-09-22 X-Ceptor Therapeutics, Inc. Quinazolinone modulators of nuclear receptors
US6947847B2 (en) 2002-03-08 2005-09-20 Wisconsin Alumni Research Foundation Method to design therapeutically important compounds
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
WO2003084940A1 (en) 2002-04-08 2003-10-16 Alangudi Sankaranarayanan Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
US20040106802A1 (en) 2002-04-08 2004-06-03 Torrent Pharmaceuticals Ltd. Novel compounds and therapeutic uses thereof
EP1499336A4 (en) 2002-04-30 2005-06-01 Tufts College Protease inhibitors
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
AU2003245325A1 (en) 2002-05-23 2003-12-12 Chiron Corporation Substituted quinazolinone compounds
GB0212412D0 (en) 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
AU2003233010A1 (en) 2002-06-04 2003-12-19 Pfizer Products Inc. Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
US6710040B1 (en) 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
KR100985160B1 (en) 2002-06-06 2010-10-05 에자이 알앤드디 매니지먼트 가부시키가이샤 Novel condensed imidazole derivatives
US20040009972A1 (en) 2002-06-17 2004-01-15 Ding Charles Z. Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase
US20040054171A1 (en) 2002-07-04 2004-03-18 Jensen Anette Frost Polymorphic forms of a 4H-thieno[3,2-E]-1,2,4-thiadiazine 1,1-dioxide derivative
JP2005538118A (en) 2002-08-06 2005-12-15 アストラゼネカ アクチボラグ Condensed pyridine and pyrimidine with TIE2 (TEK) activity
PT1528931E (en) 2002-08-09 2008-08-13 Prosidion Ltd Dipeptidyl peptidase iv inhibitors for decreasing the rate of chronic weight gain
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US20040058876A1 (en) 2002-09-18 2004-03-25 Torsten Hoffmann Secondary binding site of dipeptidyl peptidase IV (DP IV)
ATE461212T1 (en) 2002-09-18 2010-04-15 Prosidion Ltd SECONDARY BINDING SITE OF DIPEPTIDYLPEPTIDASE IV (DP IV)
US7262207B2 (en) 2002-09-19 2007-08-28 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US6869966B2 (en) 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives
EP1556362B1 (en) 2002-10-18 2008-03-26 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004037176A2 (en) 2002-10-21 2004-05-06 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
DE60332856D1 (en) 2002-10-23 2010-07-15 Bristol Myers Squibb Co GLYCINNITRIL BASED DIPEPTIDYLPEPTIDASE IV INHIBITORS
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
BR0316327A (en) 2002-11-18 2005-09-27 Pfizer Prod Inc Dipeptidylpeptidase inhibiting cyclic fluorinated amides iv
DE10254304A1 (en) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg New xanthine derivatives, their production and their use as medicines
US7109192B2 (en) 2002-12-03 2006-09-19 Boehringer Ingelheim Pharma Gmbh & Co Kg Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
CL2004000234A1 (en) 2003-02-12 2005-04-15 Biogen Idec Inc DERIVATIVE COMPOUNDS 3- (PIRIDIN-2-IL) -4-HETEROARIL-PIRAZOL SUBSTITUTED, ANTAGONISTS OF AIK5 AND / OR AIK4; PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND IN THE TREATMENT OF FIBROTIC DISORDERS AS SCLERODERMIA, LUPUS NEFRITICO, CICATRIZACION DE HERID
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
US20050014732A1 (en) 2003-03-14 2005-01-20 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-diabetic agent
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2004099134A2 (en) 2003-05-05 2004-11-18 Prosidion Ltd. Glutaminyl based dp iv-inhibitors
PT1620082E (en) 2003-05-05 2010-06-11 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases for treating alzheimer`s disease and down syndrome
US7638638B2 (en) 2003-05-14 2009-12-29 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
ATE489387T1 (en) 2003-06-20 2010-12-15 Hoffmann La Roche PYRIDOÄ2,1-AÜ-ISOCHINOLINE DERIVATIVES AS DPP-IV INHIBITORS
ATE437876T1 (en) 2003-06-20 2009-08-15 Hoffmann La Roche HEXAHYDROPYRIDOISOCHINOLINES AS DPP-IV INHIBITORS
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
WO2005019168A2 (en) 2003-08-20 2005-03-03 Pfizer Products Inc. Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004018467A2 (en) * 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Phenacyl xanthine derivatives as dpp-iv inhibitor
WO2004050658A1 (en) * 2002-12-03 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel substituted imidazo-pyridinones and imidazo-pyridazeiones, the production and use thereof as medicaments

Non-Patent Citations (31)

* Cited by examiner, † Cited by third party
Title
ABD EL-WARETH A. O. SARHAN, ZEINAB A. HOZIEN, HOSNEY A. H. EL-SHERIEF: "Synthesis, Characterization and Reactions of 2-Deoxo-5-deazaalloxazines" BIOORGANIC & MEDICINAL CHEMISTRY, vol. 9, 2001, pages 2993-2998, XP002362916 *
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1991, SEADA, M. ET AL: "Reactions with 2-amino-3,5-dicyanopyridines" XP002362976 retrieved from STN Database accession no. 1991:81740 & ORIENTAL JOURNAL OF CHEMISTRY , 5(4), 273-80 CODEN: OJCHEG; ISSN: 0970-020X, 1989, *
DATABASE CROSSFIRE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; 1993, XP002362983 Database accession no. 4598493 (BRN) *
DATABASE CROSSFIRE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; 1993, XP002362984 Database accession no. 8353231 (BRN) *
DATABASE CROSSFIRE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; 1994, XP002362978 Database accession no. 6875211 (BRN) *
DATABASE CROSSFIRE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; 2000, XP002362979 Database accession no. 8349174 (BRN) *
DATABASE CROSSFIRE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; 2000, XP002362985 Database accession no. 8360481 (BRN) *
DATABASE CROSSFIRE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; 2000, XP002362986 Database accession no. 8345402 (BRN) *
DATABASE CROSSFIRE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; 2002, XP002362981 Database accession no. 9010879 (BRN) *
DATABASE CROSSFIRE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; 2005, XP002362982 Database accession no. 9955126 (BRN) *
DATABASE CROSSFIRE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DEcr; 1988, XP002362980 Database accession no. 1231932 (BRN) *
DATABASE ZCAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1985, GOGOI, MUKTI ET AL: "Arylidenemalononitriles in heterocyclic syntheses: a novel synthesis of pyrido[2,3-dÜpyrimidines" XP002362977 retrieved from STN Database accession no. 1985:131988 & JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS , (23), 1549-50 CODEN: JCCCAT; ISSN: 0022-4936, 1984, *
DATABASE ZCAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1998, ELNEAIRY, MOHAMED A. A. ET AL: "2-(2-Benzothiazolyl)ethanethioamides in heterocyclic synthesis: novel synthesis of pyridine, pyrido[2,3-dÜpyrimidine, coumarin, thiazolone and triazole derivatives" XP002362975 retrieved from STN Database accession no. 1998:756479 & JOURNAL OF CHEMICAL RESEARCH, SYNOPSES , (11), 684-685 CODEN: JRPSDC; ISSN: 0308-2342, 1998, *
DATABASE ZCAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1999, GEIES, AHMED A.: "Synthesis of pyrido[2,3-dÜpyrimidines via the reaction of activated nitriles with aminopyrimidines" XP002362974 retrieved from STN Database accession no. 1999:158849 & JOURNAL OF THE CHINESE CHEMICAL SOCIETY (TAIPEI) , 46(1), 69-75 CODEN: JCCTAC; ISSN: 0009-4536, 1999, *
DATABASE ZCAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1999, YOUSSIF, SHAKER ET AL: "A facile one-pot synthesis of pyrido[2,3-dÜpyrimidines and pyrido[2,3-d:6,5-d'Üdipyrimidines" XP002362973 retrieved from STN Database accession no. 1999:177044 & JOURNAL OF CHEMICAL RESEARCH, SYNOPSES , (2), 112-113 CODEN: JRPSDC; ISSN: 0308-2342, 1999, *
DATABASE ZCAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2003, YOUSSIF, SHAKER ET AL: "Novel uracil and pyrido[2,3-dÜpyrimidine-2,4(1H, 3H)-dione derivatives: synthesis and antimicrobial activity" XP002362972 retrieved from STN Database accession no. 2003:911230 & MANSOURA JOURNAL OF PHARMACEUTICAL SCIENCES , 18(1), 41-47 CODEN: MJPSEO; ISSN: 1110-1318, 2002, *
E. DIAZ, H. BARRIOS, D. CORONA, A. GUZMAN, R. DIAZ, A. FUENTES: "2D 1H and 13C NMR evidences of the [2+2] autodimerization of 2-benzyl-5-benzylidene cyclopentanone yielding two different diphenyl, dispiro cyclobutane derivatives" SPECTROCHIMICA ACTA PART A, vol. 58, 2002, pages 2079-2087, XP002362915 *
EDWARD C. TAYLOR, EDWARD E. GARCIA: "The Synthesis of 4-Aminoisoxazolo[5,4-dÜpyrimidines" J. ORG. CHEM., vol. 29, 1964, pages 2116-2120, XP002362919 *
IPITSA DEVI, B. S. D. KUMAR, PULAK J. BHUYAN: "A novel three-component one-pot synthesis of pyrano[2,3-dÜpyrimidines and pyrido[2,3-dÜpyrimidines using microwave heating in the solid state" TETRAHEDRON LETTERS, vol. 44, 2003, pages 8307-8310, XP002362953 *
J. R. PIPER, G. S. MCCALEB, J. A. MONTGOMERY, R. L. KISLIUK, Y. GAUMONT, F. M. SIROTNAK: "Syntheses and Antifolate Activity of 5-Methyl-5-deaza Analogues of Aminopterin, Methotrexate, Folic Acid and N10-Methylfolic Acid" J. MED. CHEM., vol. 29, 1986, pages 1080-1087, XP002362909 *
JOHN B. HYNES, SHYAM K. SINGH, OLIVER FETZER, BARRY SHANE: "Inhibition of Hog Liver Folylpolyglutamate Synthetase by 5-Substituted 5,8-Deaza Analogues of Folic Acid Bearing a Terminal L-Ornithine Residue" J. MED. CHEM., vol. 35, 1992, pages 4078-4085, XP002362910 *
KAMALJIT SINGH, JASBIR SINGH, HARJIT SINGH: "Carbon Transfer Reactions of Functionalized Oxazolidines and their Open Chain Enamine Tautomers to Enamine Nucleophiles. A Facile Synthesis of Substituted Pyridines and Ring Annulated Derivatives" TETRAHEDRON, vol. 54, 1998, pages 935-942, XP002362911 *
MAGDA N. NASR, MAGDY M. GINEINAH: "Pyrido[2,3-dÜpyrimidines and Pyrimido[5',4':5,6Üpyrido[2,3-dÜpyrimidine s as New Antiviral Agents: Synthesis and Biological Activity" ARCH. PHARM. PHARM. MED. CHEM., vol. 6, 2002, pages 289-295, XP002362918 *
PULAKJYOTI BHUYAN, ROSMEH CHANDRA BORUAH, JAGIR SINGH SANDHU: "Studies on Uracils. 10. A Facile One-Pot Synthesis of Pyrido[2,3-dÜ- and Pyrazolo[3,4-dÜpyrimidines" J. ORG. CHEM., vol. 55, 1990, pages 568-571, XP002362920 *
ROBB NICEWONGER, APRIL FOWKE, KATHY NGUYEN, LORI DITTO, JUSTIN CASERTA, MICHELE HARRIS, CARMEN M. BALDINO: "Microwave-assisted acylation of 7-amino-5-aryl-6-cyanopyrido[2,3-dÜpyrimid ines" MOLECULAR DIVERSITY, vol. 7, 2003, pages 247-252, XP002362954 *
ROBERT B. NICEWONGER, LORI DITTO, DOUG KERR, LASZLO VARADY: "Synthesis of a Novel, Recyclable" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 12, 2002, pages 1799-1802, XP002362921 *
RUMEN RADINOV, CHRISTO CHANEV, MARIETTA HAIMOVA: "Lithiation of Polychloropyrimidines and Dichloropyridines" J. ORG. CHEM., vol. 56, 1991, pages 4793-4796, XP002362914 *
SHYAM K. SINGH, MELEDATH GOVINDAN, JOHN B. HYNES: "Synthesis of 5-Trifluoromethyl-5,8-dideazafolic Acid and 5-Trifluoromethyl-5,8-dideazaisofolic Acid" J. HETEROCYCL. CHEM., vol. 27, 1990, pages 2101-2105, XP002362917 *
STANLEY WAWZONEK: "Synthesis of Pyrido[2,3-dÜpyrimidine-2,4-diones" J. ORG. CHEM., vol. 41, no. 19, 1976, pages 3149-3151, XP002362913 *
TSANN-LONG SU, JAI-TUNG HUANG, JOSEPH H. BURCHENAL, KYOICHI A. WATANABE, JACK J. FOX: "Synthesis and Biological Activities of 5-Deaza Analogues of Aminopterin and Folic Acid" J. MED. CHEM., vol. 29, 1986, pages 709-715, XP002362908 *
YOSHINORI TOMINAGA, HIROTO OKUDA, SHINYA KOHRA, HISAKO MAZUME: "Reaction of Enaminones with Carbon Disulfide: Synthesis of Heterocycles Using Enamino Dithiocarboxylates" J. HETEROCYCL. CHEM., vol. 28, 1991, pages 1245-1255, XP002362912 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007112347A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US7723355B2 (en) 2006-11-20 2010-05-25 Bristol-Myers Squibb Company 7,8-dihydro-1,6-naphthyridin-5(6H)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase IV and methods
WO2008064107A3 (en) * 2006-11-20 2008-07-10 Bristol Myers Squibb Co 7,8-dihydro-1,6-naphthyridin-5(6h)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase iv and methods
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2008121506A2 (en) * 2007-03-30 2008-10-09 Takeda Pharmaceutical Company Limited Renin inhibitors
WO2008121506A3 (en) * 2007-03-30 2009-02-19 Takeda Pharmaceutical Renin inhibitors
US8133898B2 (en) 2007-03-30 2012-03-13 Takeda Pharmaceutical Company Limited Renin inhibitors
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase

Also Published As

Publication number Publication date
US7825242B2 (en) 2010-11-02
EP1773832A2 (en) 2007-04-18
JP2008506708A (en) 2008-03-06
US20060014764A1 (en) 2006-01-19
JP4945443B2 (en) 2012-06-06
WO2006020017A2 (en) 2006-02-23
WO2006020017A3 (en) 2006-07-27
WO2006019965A3 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
EP2805953B1 (en) Dipeptidyl peptidase inhibitors
EP1586571B1 (en) Dipeptidyl peptidase inhibitors
US7825242B2 (en) Dipeptidyl peptidase inhibitors
US7790736B2 (en) Dipeptidyl peptidase inhibitors
US7790734B2 (en) Dipeptidyl peptidase inhibitors
US7687638B2 (en) Dipeptidyl peptidase inhibitors
EP1608317B1 (en) Dipeptidyl peptidase inhibitors
US20050065144A1 (en) Dipeptidyl peptidase inhibitors
US7169926B1 (en) Dipeptidyl peptidase inhibitors
US7678909B1 (en) Dipeptidyl peptidase inhibitors
AU2011203217B2 (en) Dipeptidyl peptidase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase